Wound healing methods and compositions

A nanoscale polymer layer with bioactive agents and a sacrificial support addresses the limitations of current wound healing methods by modulating the wound bed's chemistry and structure, enhancing healing efficacy and reducing bacterial resistance.

JP7586654B2Active Publication Date: 2024-11-19IMBED BIOSCIENCES INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2020089038
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2012-11-06
Filing Date
2020-05-21
Publication Date
2024-11-19
Estimated Expiration
2033-11-05

AI Technical Summary

Technical Problem

Current wound healing methods, including dressings and drug therapies, are inadequate for promoting optimal healing in complex wounds such as diabetic ulcers and bedsores, as they fail to address the heterogeneous chemistry and structure of the wound bed, leading to prolonged symptoms and increased healthcare costs.

Method used

The use of a nanoscale polymer layer containing a bioactive agent, supported by a sacrificial polymer layer, to modulate the wound bed's chemical composition and physical attributes, incorporating antimicrobial compounds and extracellular matrix components, and employing polyelectrolyte layers with wound active agents like silver nanoparticles for sustained release.

Benefits of technology

This approach enhances wound healing by promoting cellular growth and viability, reducing bacterial resistance, and providing a stable, effective treatment that adapts to various wound types and patient populations, minimizing logistical burdens and toxic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586654000012
    Figure 0007586654000012
  • Figure 0007586654000013
    Figure 0007586654000013
  • Figure 0007586654000014
    Figure 0007586654000014
Patent Text Reader

Abstract

To provide methods and compositions for wound healing.SOLUTION: The present invention relates to promoting and improving wound healing by binding a wound activator to a wound using a cross-linking covalent modifying molecule and delivering it. In addition, a method and composition for forming a polymer electrolyte layer on the wound surface using oppositely charged polymer electrolytes are provided. Furthermore, the invention relates to incorporating a wound activator into a polymeric electrolyte layer for delivery to the wound. Provided is a wound active nanoscale polymer matrix micro sheet, which comprises: a wound active nanoscale polymer layer having a thickness of about 0.5 nm to 1,000 nm, into which a wound activator is incorporated; and a sacrificial polymer layer that is adjacent to the wound active nanoscale polymer layer and is soluble when exposed to a moisture surface, in the embodiment.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to methods and compositions for modulating wound healing. In particular, the present invention relates to a nanoscale polymer layer comprising a bioactive agent and a microsheet comprising the nanoscale polymer layer supported on a sacrificial polymer layer. [Background technology]

[0002] The primary goal of wound treatment is to complete wound closure. Open skin wounds constitute one major category of wounds, including, for example, thermal wounds, wounds resulting from chemical (especially alkaline) burns, wounds resulting from physical trauma, neuropathic ulcers, pressure ulcers, venous stasis ulcers, and diabetic ulcers. Open skin wounds normally heal by a process that includes six major components: i) inflammation, ii) fibroblast proliferation, iii) vascular proliferation, iv) connective tissue synthesis, v) epithelialization, and vi) wound contraction. Wound healing is impaired when these components, either individually or collectively, do not function properly. Many factors can affect wound healing, including, but not limited to, malnutrition, general debilitation from various causes, wound infection, localized deficiency of progenitor cells, local and / or systemic drugs (e.g., many chemotherapeutic agents, actinomycin, and steroids), repeated local trauma, diabetes and other endocrine / metabolic diseases (e.g., Cushing's disease), and advanced age (Hunt and Goodson, 1988, Current Surgical Diagnosis & Treatment, Appleton & Lange, pp. 86-98). In addition, regardless of the cause, wounds of large size present special challenges due to the large surface area that must be re-epithelialized to restore surface integrity.

[0003] Delayed wound healing causes considerable morbidity in subjects with diabetes. Diabetes is a chronic disease of glucose metabolism and homeostasis that damages many organs. It is the eighth leading cause of death in the United States (Harris et al., 1987, Diabetes 36:523). Individuals with diabetes are predisposed to pathological changes in the extremities, especially the feet, due to vascular disease, neuropathy, infection, and repetitive trauma. These pathological changes may eventually lead to chronic ulcers and require amputation. Chronic wounds, and wounds with pathological or dysregulated healing, represent a significant health burden and drain on healthcare resources. Chronic wounds have a significant impact on the physical and mental health of patients, productivity, morbidity, mortality, and costs of care. The most common types of chronic wounds are caused by systemic diseases, e.g., diabetes, vascular disorders such as venous hypertension, and immobility-induced bedsores, which account for 70% of all chronic wounds. Statistics regarding the prevalence of chronic wounds vary, but studies report that 0.2%-1% of the population suffers from venous ulcers, 0.5% from pressure ulcers, and 5%-10% of people with diabetes experience neuropathic ulcers. The economic impact of chronic wounds in the United States is estimated to be well over $15 billion annually for this condition alone. As the population ages, the incidence of diabetes will increase, and so will the severity of the problems associated with chronic wounds in these patients.

[0004] Normal wound healing is a highly complex process involving coordinated interactions between fibroblasts, vascular cells, extracellular matrix, and epithelial cells, resulting in a seamless progression through inflammatory responses, wound repair, contracture, and epithelial barrier coverage. However, in many patients, either due to the local wound environment or systemic disease or other factors, the wound healing process can become asynchronous (i.e., loss of connectivity with the triggering mechanisms associated with previous cellular events) and fail to progress to closure, resulting in chronic ulcers.

[0005] Wounds that do not heal easily cause considerable physical, emotional, and social distress to subjects, as well as significant financial costs (Richey et al., 1989, Annals of Plastic Surgery 23:159). Wounds that do not heal properly and become infected may actually require excision of the affected tissue. As scientists have gained a basic understanding of wounds and wound healing mechanisms, many treatments have been developed.

[0006] The most commonly used traditional method to aid in wound healing involves the use of wound dressings. A major breakthrough in wound care occurred in the 1960s when it was discovered that wound healing with moist occlusive dressings was generally more effective than dry non-occlusive dressings (Winter, 1962, Nature 193:293). Today, many types of dressings are routinely used, including films (e.g., polyurethane films), hydrocolloids (hydrophilic colloidal particles bound to polyurethane foam), hydrogels (crosslinked polymers containing at least about 60% water), foams (hydrophilic or hydrophobic), calcium alginate (nonwoven composites of calcium alginate-derived fibers), and cellophane (cellulose with plasticizers) (Kannon and Garrett, 1995, Dermatol. Surg. 21:583; Davies, 1983, Burns 10:94). Unfortunately, some wounds (e.g., diabetic ulcers, pressure ulcers) and wounds in some subjects (e.g., users of exogenous corticosteroids) do not heal in a timely manner (or at all) with the use of such dressings.

[0007] Also, several pharmacologic therapies have been utilized in an attempt to improve wound healing. For example, some physicians have utilized treatment regimens involving zinc sulfate. However, the effectiveness of these treatment regimens has been attributed primarily to their reversal of the effects of subnormal serum zinc levels (e.g., decreased host resistance and altered intracellular bactericidal activity) (Riley, 1981, Am. Fam. Physician 24:107). Although other vitamin and mineral deficiency conditions have also been associated with impaired wound healing (e.g., deficiencies of vitamins A, C, D, and calcium, magnesium, copper, and iron), there is no compelling evidence that increasing serum levels of these substances above their normal levels actually improves wound healing. Thus, except in very limited circumstances, attempts to promote wound healing with these agents have met with little success.

[0008] Current clinical methods used to promote healing of dysregulated wounds include protection of the wound bed from mechanical trauma (e.g., splinting, bandaging), fine regulation of the surface microbial load (antibiotics that broadly inhibit wound pathogens (e.g., silver sulfadiazine), antimicrobial peptides, bacteriophages, antiseptics, and other antimicrobial compounds) in combination with topical application of soluble cell activating factors (growth factors such as epidermal growth factor-EGF, exogenous extracellular matrix components such as fibronectin, but not limited to), surgical excision of the wound edge or entire wound bed, and surgical placement of tissue flaps and / or autografts, allografts, and xenografts. All of these methods fall short of promoting optimal healing conditions in many of the most challenging wounds. A major factor contributing to the failure of these traditional methods is the fact that they do not alter the endogenous chemistry / structure of the wound bed itself, which has been shown to be a major contributor to the prolonged symptoms in many cases. In addition, traditional approaches that use a single factor or set of factors to treat all wounds are often inadequate due to the great heterogeneity found in the wound bed itself and the complex environment of the wound itself, which contains a host of signaling molecules that frequently regulate the activity of individual molecules.

[0009] Among broad-spectrum bactericides, silver is considered to be particularly advantageous since it is believed to be highly unlikely to develop bacterial resistance to silver and therefore can be used continuously as a bactericide. However, currently available methods of applying silver as a bactericide in wound treatment are not satisfactory. For example, 0.5% silver nitrate solution is a standard and popular agent for topical burn wound treatment, which provides the beneficial effect of reducing wound surface inflammation. However, such formulations have high concentrations of silver, have no residual activity, and require frequent applications (e.g., up to 12 times per day), which impose a severe logistical burden in clinical settings. Silver ions released through the use of 0.5% silver nitrate solution are chemically complexed with chloride within 2 hours and are rapidly inactivated. Frequent dressing applications also result in large amounts of excess silver being delivered to the wound, causing wound discoloration and toxic effects (Dunn et al., 2004, Burns 30(supplement 1):S1; which is incorporated herein by reference in its entirety). In addition, nitric acid is toxic to wounds and mammalian cells. Reduction of nitric acid to nitrite further causes oxidant-induced damage to cells, which is cited as the most likely cause of impaired re-epithelialization associated with the use of silver nitrate solutions in partial thickness burns or donor sites.

[0010] Silver compounds, such as silver sulfadiazine in cream formulations (e.g., Flammazine®, Silvadene®), have also been used to treat wounds. However, such formulations have also had limited residual efficacy and must be applied twice daily. Bacterial resistance to such formulations has developed and impaired re-epithelialization has also been observed. Myelotoxicity has been observed with silver sulfadiazine, primarily due to its propylene glycol content.

[0011] In addition, in some methods, the silver itself is incorporated into the dressing rather than being applied as a separate formulation. The controlled and sustained release of silver to the wound allows for less frequent dressing changes. However, the dressing must be impregnated with large amounts of silver, which results in cytotoxicity to mammalian cells. Silver released from a commercially available wound dressing containing nanocrystalline silver (Acticoat™) (Dunn et al. al., 2004, Burns 30(supplement 1):S1, which is incorporated herein by reference in its entirety), is toxic to in vitro monolayer cell cultures of keratinocytes and fibroblasts (Poon et al., 2004, Burns 30:140; Trop et al., 2006, J. Trauma 60:648, which are incorporated herein by reference in their entireties).

[0012] The complex nature of pathologic wounds and the lack of meaningful clinical progress based on current treatments demonstrate an urgent need for new and unconventional approaches. What is needed are safe, effective and interactive means to improve the healing of chronic severe wounds. The approaches should be adaptable regardless of the type of wound or the nature of the patient population to which they are addressed. Summary of the Invention

[0013] The present invention relates to methods and compositions for modulating wound healing, modulating the surface properties of biomedical devices, and modulating the surface properties of tissues, including skin. In particular, the present invention relates to promoting and improving wound healing by altering the endogenous chemical composition and / or physical attributes of the wound bed. Thus, in some embodiments, the present invention provides formulations that alter the physical attributes (compliance, tissue distribution, charge) and crosslinked covalently modified molecules that bind and deliver antimicrobial compounds and extracellular matrix and other scaffolding materials and cellular active agents to the wound. Additionally, the present invention provides methods and compositions that utilize oppositely charged polyelectrolytes that form polyelectrolyte layers (e.g., multilayers) on the wound surface. The present invention further relates to incorporating uncharged polymers into the wound bed through interactions such as, but not limited to, hydrogen bonding. The scope of the present invention includes incorporating nanoparticles and microparticles into the wound bed to manipulate the physical properties and chemical composition of the wound bed. The present invention further relates to incorporating wound active agents into polyelectrolyte layers (e.g., multilayers), nanoparticles, or microparticles for delivery to the wound. In some embodiments, the present invention provides formulations that promote favorable and stable pH, surface charge, surface energy, osmotic environment, surface functionality that enhances favorable electro-magnetic effects on wound healing, supply of nitric oxide, provide an energy source to cells, and / or provide balance of MMP / other peptidase / protease activity.

[0014] The present invention further relates to providing compositions, methods, and kits comprising a highly bactericidal, yet selectively toxic wound active agent that supports the growth and viability of mammalian cells (keratinocytes, neurons, endothelial cells, and fibroblasts). In a preferred embodiment, the wound active agent is silver, such as, but not limited to, silver nanoparticles. In a particularly preferred embodiment, the silver loading of some embodiments of the present invention is between 0.35 and 0.4 μg / cm. 2 The polyelectrolyte multilayer thin films of the invention containing silver (e.g., silver nanoparticles) find use in wound care and infection prevention, including, but not limited to, as coatings on devices that partially, directly, indirectly, or completely contact the body of a subject (e.g., a human patient). In one embodiment, the compositions and methods of the present invention provide a way to promote healing of pathological wounds by altering the surface chemistry and structure of the pathological wound bed itself, ultimately allowing for differential regulation of key cellular elements that can be customized to a particular patient's healthy wound type and anatomical location in a subject.

[0015] In one embodiment, the invention allows for the covalent immobilization of factors to a wound bed. In some embodiments, the invention provides a method of treatment comprising providing at least one covalent modifying agent and at least one wound active agent to a subject having a wound, and contacting the wound with the at least one covalent modifying agent and at least one wound active agent under conditions such that the at least one wound active agent covalently binds to the wound. In some embodiments, the invention provides a method of treatment in which the subject is a human. In some embodiments, the subject is a non-human vertebrate. In some embodiments, the at least one covalent modifying agent is a homobifunctional crosslinker. In other embodiments, the at least one covalent modifying agent is a heterobifunctional crosslinker. For example, in some embodiments, the homogeneous bifunctional crosslinker is an N-hydroxysuccinimidyl ester (e.g., including, but not limited to, disuccinimidyl ester, dithiobis(succinimidyl propionate), 3,3′-dithiobis(sulfosuccinimidyl propionate), disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, disuccinimidyl tartarate, disulfosuccinimidyl tartarate, bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfone, bis[2-(sulfosuccinimidyloxycarbonyloxy)ethyl]sulfone, ethylene glycol bis(succinimidyl succinate), ethylene glycol bis(sulfosuccinimidyl-succinate), disuccinimidyl glutarate, and N,N′-disuccinimidyl carbonate). In some embodiments, the homogeneous bifunctional crosslinker is at a concentration of 1 nanomolar to 10 millimolar, hi some preferred embodiments, the homogeneous bifunctional crosslinker is at a concentration of 10 micromolar to 1 millimolar.In other embodiments, the at least one covalent modifying agent is a heterobifunctional crosslinker (e.g., N-succinimidyl 3-(2-pyridyldithio)propionate, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate, sulfosuccinimidyl 6-(3′-[2-pyridyldithio]-propionamido)hexanoate, succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio)toluene ... Succinimidyl-6-[α-methyl-α-(2-pyridyldithio)toluamido]hexanoate, Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, N-Succinimidyl (4-iodoacetyl)aminobenzoate, sulfo-succinimidyl (4-iodoacetyl)aminobenzoate, succinimidyl-4-(p-maleimidophenyl)butyrate, sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, N-(γ-maleimidobutyryloxy)succinimide ester, N-(γ-maleimidobutyryloxy)sulfosuccinimide ester, succinimidyl 6-((iodoacetyl)amino)hexadecyl Succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoyl)amino)hexanoate, succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate, succinimidyl 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate, and p-nitrophenyl iodoacetate). In some embodiments, the heterobifunctional crosslinkers are modified with functional groups to be soluble in aqueous solvents and deliverable as an aqueous solution. Additionally, in some embodiments, the aqueous solution contains additives, such as, but not limited to, surfactants and block copolymers.In other embodiments, many heterobifunctional crosslinkers can be attached to molecules, polymers, or particles and used as crosslinkers. In other embodiments, the heterobifunctional crosslinkers are soluble in organic solvents, such as, but not limited to, dimethylsulfoxide. In some embodiments, the at least one wound active agent includes, but is not limited to, nutrients, extracellular matrices, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infective agents, buffers, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anti-cancer agents. In some embodiments, the at least one wound active agent contains one or more free -SH groups.

[0016] The invention also provides a kit for treating a subject having a wound, the kit comprising at least one covalent modifying agent, at least one wound active agent, and instructions for use of the kit to covalently attach the at least one wound active agent to a wound, in some embodiments, the at least one covalent modifying agent is a homogeneous bifunctional crosslinker. In some embodiments, the homogeneous bifunctional crosslinker is an N-hydroxysuccinimidyl ester (e.g., including but not limited to, disuccinimidyl ester, dithiobis(succinimidyl propionate), 3,3′-dithiobis(sulfosuccinimidyl propionate), disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, disuccinimidyl tartarate, disulfosuccinimidyl tartarate, bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfone, bis[2-(sulfosuccinimidyloxycarbonyloxy)ethyl]sulfone, ethylene glycol bis(succinimidyl succinate), ethylene glycol bis(sulfosuccinimidyl-succinate), disuccinimidyl glutarate, and N,N′-disuccinimidyl carbonate).In some embodiments, the at least one covalent modifying agent is a heterobifunctional crosslinker (e.g., N-succinimidyl 3-(2-pyridyldithio)propionate, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate, sulfosuccinimidyl 6-(3′-[2-pyridyldithio]-propionamido)hexanoate, succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio)toluene ... Fosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio)toluamido]hexanoate, Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, N-Succinimidyl succinimidyl (4-iodoacetyl)aminobenzoate, sulfo-succinimidyl (4-iodoacetyl)aminobenzoate, succinimidyl-4-(p-maleimidophenyl)butyrate, sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, N-(γ-maleimidobutyryloxy)succinimide ester, N-(γ-maleimidobutyryloxy)sulfosuccinimide ester, succinimidyl 6-((iodoacetyl)amino)hetero succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoyl)amino)hexanoate, succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate, succinimidyl 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate, and p-nitrophenyl iodoacetate).In some embodiments, the at least one wound active agent may be, for example, but not limited to, nutrients (e.g., polypeptide growth factors, neuropeptides, neurotrophins, extracellular matrices and their respective natural components (e.g., but not limited to, laminin, fibronectin, vitronectin, collagen, as well as selected amino acid sequences found in these proteins known to promote cellular behaviors favorable to wound healing, such as integrin binding sequences, for example, but not limited to, RGD, EILDV, VCAM-1, and recombinant or synthetic analogs thereof, enzymes, enzyme inhibitors, polypeptides, antimicrobial peptides (e.g., but not limited to, defensins, magaignins, cathelicidins, These include anti-infective agents, including silver-containing compounds (e.g., ionic silver, elemental silver, silver nanoparticles, and formulations thereof), buffering agents, vitamins and minerals, compounds that promote nitric oxide production / stabilization, cellular energy sources, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anti-cancer agents. In other embodiments, the kits include small interfering RNAs (siRNAs, also referred to as microRNAs) that can promote cellular behaviors conducive to the wound healing process. In other embodiments, the kits include compounds that promote / stabilize favorable pH, osmotic environment, surface energy, surface charge, surface functionality that enhances favorable current electromagnetic effects on wound healing, or balance of MMP / other peptidase / protease activity.

[0017] In some embodiments, the present invention provides a method of treatment comprising providing to a subject having a wound at least one cationic polyelectrolyte, at least one anionic polyelectrolyte, at least one covalent modifying agent, and at least one wound active agent, and contacting the wound with the at least one cationic polyelectrolyte and at least one anionic polyelectrolyte, the at least one covalent modifying agent, and the at least one wound active agent such that the at least one wound active agent is covalently attached to the wound by being incorporated into the polyelectrolyte layer formed by the at least one cationic polyelectrolyte and the at least one anionic polyelectrolyte. In some preferred embodiments, the polyelectrolyte is applied in a continuous and repeated layer on the wound, and then the at least one covalent modifying agent and the at least one wound active agent are added. In some embodiments, at least one cationic polyelectrolyte (e.g., but not limited to, poly(L-lysine), poly(ethyleneimine), and poly(allylamine hydrochloride), as well as dendrimers and branched polymers providing various amine groups) is the top layer of the polyelectrolyte layer. Further, in some embodiments, the at least one cationic polyelectrolyte comprises primary amine groups that allow for at least one covalent modifier to be attached to the at least one cationic polyelectrolyte. For example, in some preferred embodiments, at least one cationic polyelectrolyte comprises a primary amine group that allows for at least one covalent modifier to be attached to the at least one cationic polyelectrolyte. The thionic polyelectrolyte is polylysine, and the at least one anionic polyelectrolyte is polyglutamic acid. In some embodiments, the at least one anionic polyelectrolyte (e.g., including but not limited to, poly(L-glutamic acid), poly(sodium 4-styrenesulfonate), poly(acrylic acid), poly(maleic acid-co-propylene), hyaluronic acid, chondroitin, and poly(vinyl sulfate)) is the top layer of the polyelectrolyte layer. In one preferred embodiment, the at least one anionic polyelectrolyte is polyglutamic acid.In some embodiments, the at least one covalent modifying agent is a heterobifunctional crosslinker (e.g., N-succinimidyl 3-(2-pyridyldithio)propionate, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate, sulfosuccinimidyl 6-(3′-[2-pyridyldithio]-propionamido)hexanoate, succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio)toluene ... Fosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio)toluamido]hexanoate, Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, N-Succinimidyl succinimidyl (4-iodoacetyl)aminobenzoate, sulfo-succinimidyl (4-iodoacetyl)aminobenzoate, succinimidyl-4-(p-maleimidophenyl)butyrate, sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, N-(γ-maleimidobutyryloxy)succinimide ester, N-(γ-maleimidobutyryloxy)sulfosuccinimide ester, succinimidyl 6-((iodoacetyl)amino)hetero succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoyl)amino)hexanoate, succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate, succinimidyl 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate, and p-nitrophenyl iodoacetate). In some embodiments, at least one covalent modifying agent is a homogeneous bifunctional crosslinker.In some embodiments, the homogeneous bifunctional crosslinker is an N-hydroxysuccinimidyl ester (e.g., including but not limited to, disuccinimidyl ester, dithiobis(succinimidyl propionate), 3,3′-dithiobis(sulfosuccinimidyl-propionate), disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, disuccinimidyl tartarate, disulfosuccinimidyl tartarate, bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfone, bis[2-(sulfosuccinimidyloxycarbonyloxy)ethyl]sulfone, ethylene glycol bis(succinimidyl succinate), ethylene glycol bis(sulfosuccinimidyl succinate), disuccinimidyl glutarate, and N,N′-disuccinimidyl carbonate). In some embodiments, the at least one covalent modifying agent may be at a concentration of 1 nanomolar to 10 millimolar. In some preferred embodiments, the at least one covalent modifying agent is at a concentration of 10 micromolar to 1 millimolar. In some preferred embodiments, the at least one covalent modifying agent is bis(sulfosuccinimidyl) suberate (e.g., in an aqueous solution at a concentration of 1 nM to 10 mM). In some embodiments, the at least one modifying agent comprises an N-hydroxysuccinimidyl ester. In some preferred embodiments, the at least one wound active agent contains the peptide sequence gly-arg-gly-asp-ser-pro-lys.

[0018] In some embodiments, the first at least one anionic or cationic polyelectrolyte is contacted with at least one covalent modifier and at least one wound active agent before contacting the wound bed and the oppositely charged at least one cationic or anionic polyelectrolyte. In some preferred embodiments, the first at least one anionic polyelectrolyte is polyglutamic acid, the at least one covalent modifier is an N-hydroxysuccinimidyl ester, and the at least one wound active agent contains a primary amine (e.g., including but not limited to, the peptide sequence gly-arg-gly-asp-ser-pro-lys). In some preferred embodiments, the first at least one cationic polyelectrolyte is polylysine, the at least one covalent modifier is N-succinimidyl 3-(2-pyridyldithio)propionate, and the at least one wound active agent contains the peptide sequence gly-arg-gly-asp-ser-pro-cys.

[0019] The present invention further provides a kit for treating a subject having a wound, the kit comprising at least one cationic polyelectrolyte, at least one anionic polyelectrolyte, at least one covalent modifying agent, at least one wound active agent, and instructions for using the kit to covalently bind at least one wound active agent to a wound by incorporating it into a polyelectrolyte layer formed by at least one cationic polyelectrolyte and an anionic polyelectrolyte. In some embodiments, the incorporation of at least one wound active agent is achieved by forming successive and repeated layers of polyelectrolyte, followed by the addition of at least one covalent modifying agent and at least one wound active agent. In other embodiments, the first at least one anionic or cationic polyelectrolyte is contacted with at least one covalent modifying agent and at least one wound active agent before contacting the wound bed and the oppositely charged at least one cationic or anionic polyelectrolyte. In some embodiments, the at least one cationic polyelectrolyte includes, but is not limited to, poly(L-lysine), poly(ethyleneimine), and poly(allylamine hydrochloride). In some embodiments, the at least one anionic polyelectrolyte includes, but is not limited to, poly(L-glutamic acid), poly(sodium 4-styrenesulfonate), poly(acrylic acid), poly(maleic acid-co-propylene), and poly(vinyl sulfate). In some embodiments, the at least one covalent modifying agent is a homogeneous bifunctional crosslinker.In some embodiments, the homogeneous bifunctional crosslinker is an N-hydroxysuccinimidyl ester (e.g., including but not limited to, disuccinimidyl ester, dithiobis(succinimidyl propionate), 3,3′-dithiobis(sulfosuccinimidyl propionate), disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, disuccinimidyl tartarate, disulfosuccinimidyl tartarate, bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfone, bis[2-(sulfosuccinimidyloxycarbonyloxy)ethyl]sulfone, ethylene glycol bis(succinimidyl succinate), ethylene glycol bis(sulfosuccinimidyl-succinate), disuccinimidyl glutarate, and N,N′-disuccinimidyl carbonate).In other embodiments, the at least one covalent modifying agent is a heterobifunctional crosslinker (e.g., N-succinimidyl 3-(2-pyridyldithio)propionate, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate, sulfosuccinimidyl 6-(3′-[2-pyridyldithio]-propionamido)hexanoate, succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio)toluene, sulfosuccini ... Succinimidyl-6-[α-methyl-α-(2-pyridyldithio)toluamido]hexanoate, Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, m-Maleimidobenzoyl-N-hydroxysuccinimide ester, N-Succinimidyl (4-iodoacetyl)aminobenzoate, sulfo-succinimidyl (4-iodoacetyl)aminobenzoate, succinimidyl-4-(p-maleimidophenyl)butyrate, sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, N-(γ-maleimidobutyryloxy)succinimide ester, N-(γ-maleimidobutyryloxy)sulfosuccinimide ester, succinimidyl 6-((iodoacetyl)amino)hexadecyl succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoyl)amino)hexanoate, succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate, succinimidyl 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate, and p-nitrophenyl iodoacetate).In some embodiments, the at least one wound active agent includes, but is not limited to, nutrients, extracellular matrices, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infective agents (e.g., including but not limited to, silver (e.g., ionic silver, elemental silver, silver nanoparticles, and formulations thereof)), buffering agents, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anti-cancer agents.

[0020] The present invention also provides a method of treatment comprising providing at least one cationic polyelectrolyte, at least one anionic polyelectrolyte, at least one DNA delivery agent, and at least one DNA species to a subject having a wound, and contacting the wound with at least one cationic polyelectrolyte, at least one anionic polyelectrolyte, at least one DNA delivery agent, and at least one DNA species under conditions such that the at least one DNA species is delivered to the wound. In some preferred embodiments, the at least one DNA species includes, but is not limited to, DNA encoding vascular endothelial growth factor and / or epidermal growth factor. In some preferred embodiments, the at least one cationic polyelectrolyte is polylysine. In some embodiments, the method further comprises contacting the wound with an additional wound active agent, such as, but not limited to, an anti-infective agent (e.g., ionic silver, elemental silver, silver nanoparticles, and formulations thereof).

[0021] The present invention further provides a kit for treating a subject having a wound, the kit comprising at least one cationic polyelectrolyte, at least one anionic polyelectrolyte, at least one DNA delivery agent, at least one DNA species, and instructions for using the kit to deliver at least one DNA species to a wound using the at least one DNA delivery agent and the polyelectrolyte layer formed by the at least one cationic and anionic polyelectrolyte. In some embodiments, the kit further comprises an additional wound active agent, such as, but not limited to, an anti-infective agent (e.g., ionic silver, elemental silver, silver nanoparticles, and formulations thereof).

[0022] The present invention also provides a method of treatment, comprising: providing a subject having a wound with a cationic and anionic polyelectrolyte mixture, a deprotecting agent, at least one covalent modifying agent, and at least one wound active agent; contacting the wound with the polyelectrolyte mixture to form a polyelectrolyte layer on the wound; applying the deprotecting agent to the polyelectrolyte layer to form a deprotected polyelectrolyte layer; applying the at least one covalent modifying agent to the deprotected polyelectrolyte layer to form a deprotected modified polyelectrolyte layer; and applying the at least one wound active agent to the deprotected modified polyelectrolyte layer under conditions such that the at least one wound active agent is covalently bound to the wound. In some preferred embodiments, the anionic and cationic polyelectrolyte mixture comprises a mixture of polylactic acid and poly(epsilon-CBZ-L-lysine) in a ratio of 80:20. In some embodiments, the deprotection occurs by acid hydrolysis. In some embodiments, the at least one covalent modifying agent is SP3. The present invention also provides compositions comprising a deprotected polyelectrolyte functionalized with at least one covalent modifying agent containing an active group that is exposable to at least one wound active agent. In some embodiments, the deprotected polyelectrolyte comprises a mixture of polylactic acid and poly(epsilon-CBZ-L-lysine) in a ratio of 80:20. In one preferred embodiment, the at least one covalent modifying agent is SP3.

[0023] The invention also provides a method of treatment, the method comprising: providing to a subject having a wound a cationic and anionic polyelectrolyte mixture, a deprotecting agent, at least one covalent modifying agent, a first polypeptide, and at least one wound active agent bound to a second polypeptide; contacting the wound with the polyelectrolyte mixture to form a polyelectrolyte layer on the wound; applying the deprotecting agent to the polyelectrolyte layer to form a deprotected polyelectrolyte layer; applying the at least one covalent modifying agent to the deprotected polyelectrolyte layer to form a deprotected modified polyelectrolyte layer; applying a first polypeptide to the deprotected modified polyelectrolyte layer to covalently bond the first polypeptide to the deprotected modified polyelectrolyte layer; and applying the at least one wound active agent bound to the second polypeptide to the deprotected modified polyelectrolyte layer covalently bonded to the first polypeptide under conditions such that the at least one wound active agent binds to the wound by a specific protein bond between the first and second polypeptides. In some preferred embodiments, the specific protein binding occurs between biotin and a polypeptide (such as, but not limited to, avidin, neutravidin, and streptavidin). In other preferred embodiments, the specific protein binding occurs between glutathione-S-transferase and glutathione. In yet other preferred embodiments, the specific protein binding occurs between nickel-nitrilotriacetic acid and polyhistidine. In some embodiments, at least one covalent modifying agent is SP3.

[0024] The present invention further provides a composition comprising a deprotected polyelectrolyte, the polyelectrolyte functionalized with at least one covalent modifying agent, the modifying agent being attached to a first polypeptide, the first polypeptide interacting with a second polypeptide attached to at least one wound active agent through a specific bond. In some preferred embodiments, the specific bond is between biotin and a polypeptide, such as, but not limited to, avidin, neutravidin, and streptavidin. In other preferred embodiments, the specific bond is between glutathione-S-transferase and glutathione. In yet other preferred embodiments, the specific protein bond is between nickel-nitrilotriacetic acid and polyhistidine.

[0025] The invention also provides a method of treatment, the method comprising: providing to a subject having a wound a cationic and anionic polyelectrolyte mixture, a deprotecting agent, at least one covalent modifying agent, at least one molecule containing an azide group, and at least one wound active agent containing an alkyne group; contacting the wound with the polyelectrolyte mixture to form a polyelectrolyte layer on the wound; applying a deprotecting agent to the polyelectrolyte layer to form a deprotected polyelectrolyte layer; applying the at least one covalent modifying agent to the deprotected polyelectrolyte layer to form a deprotected modified polyelectrolyte layer; applying at least one molecule containing an azide group to the deprotected modified polyelectrolyte layer to covalently bond the at least one molecule containing an azide group to the deprotected modified polyelectrolyte layer; and applying at least one wound active agent containing an alkyne group to the deprotected modified polyelectrolyte layer covalently bonded to the at least one molecule containing an azide group, such that the at least one wound active agent is bonded to the wound by click chemistry. In some preferred embodiments, at least one molecule containing an azide group has the formula H 2 N(CH 2 CH 2 O) 2 N 3In some preferred embodiments, the at least one wound active agent is L-propargylglycine. In some preferred embodiments, the reaction is carried out in the presence of Cu(I).

[0026] The present invention further provides a composition comprising a deprotected polyelectrolyte functionalized with at least one covalent modifying agent attached to at least one azide group-containing molecule which is attached by click chemistry to at least one wound active agent containing an alkyne group.

[0027] The present invention further provides a kit for treating a subject having a wound, the kit comprising a cationic and anionic polyelectrolyte mixture, a deprotecting agent, at least one covalent modifying agent, at least one wound active agent, and instructions for using the kit to covalently bind at least one wound active agent to a wound by deprotecting the polyelectrolyte mixture in contact with the wound, followed by adding at least one covalent modifying agent and at least one wound active agent. In some preferred embodiments, the polyelectrolyte mixture comprises polylactic acid and poly(epsilon-CBZ-L-lysine). In some preferred embodiments, the deprotecting agent causes deprotection by acid hydrolysis of the polyelectrolyte mixture. In some preferred embodiments, the at least one covalent modifying agent is SP3. In some embodiments, the kit also contains a first and a second polypeptide that interact with each other by specific protein binding. In some preferred embodiments, the first polypeptide binds to either the at least one covalent modifying agent or the at least one wound active agent, and the second polypeptide binds to the other at least one covalent modifying agent or the at least one wound active agent. In some preferred embodiments, the first polypeptide is biotin and the second polypeptide is avidin, neutravidin, or streptavidin. In some other preferred embodiments, the first polypeptide is glutathione-S-transferase and the second polypeptide is glutathione. In yet other preferred embodiments, the first polypeptide is nickel-nitrilotriacetic acid and the second polypeptide is polyhistidine. In some embodiments, the kit contains at least one molecule containing an azide group that is attached to the polyelectrolyte mixture after deprotection so that at least one wound active agent containing an alkyne group can be attached to the wound by click chemistry.

[0028] The present invention further provides a method of treatment, comprising: providing to a subject having a wound at least one cationic polyelectrolyte, at least one anionic polyelectrolyte, at least one modifying agent, and at least one wound active agent containing an amino-terminal cysteine ​​residue; and contacting the wound with the polyelectrolyte, the at least one modifying agent, and the at least one wound active agent such that the at least one wound active agent is bound to the wound by native chemical ligation. In some preferred embodiments, the polyelectrolyte forms a continuous and repeating layer on the wound. In some embodiments, the at least one anionic polyelectrolyte (e.g., but not limited to, polyglutamic acid) is the top layer of the polyelectrolyte layer. In some embodiments, the at least one modifying agent is selected from the group consisting of ethylene dichloride and HSCH. 2 It is Ph.

[0029] The present invention also provides a composition comprising a polyelectrolyte layer functionalized with at least one modifying agent capable of being subjected to native chemical ligation with at least one wound active agent containing an amino-terminal cysteine ​​residue.

[0030] The present invention also provides a kit for treating a subject having a wound, the kit comprising at least one cationic polyelectrolyte, at least one anionic polyelectrolyte, at least one modifying agent, at least one wound active agent containing an amino-terminal cysteine ​​residue, and instructions for using the kit to form a polyelectrolyte layer on the wound and subsequently treat with the at least one modifying agent and the at least one wound active agent by native chemical ligation. In some preferred embodiments, the at least one anionic polyelectrolyte is polyglutamic acid. In some preferred embodiments, the at least one modifying agent is ethylene dichloride and HSCH. 2 It is Ph.

[0031] In some embodiments, the present invention provides a method of treatment comprising: a) providing at least one wound modifying agent and at least one wound active agent to a subject having a wound; b) contacting the wound with at least one wound modifying agent to provide a modified wound bed; and c) contacting the modified wound bed with at least one wound active agent under conditions such that the at least one wound active agent is incorporated into the modified wound bed to improve wound healing. In some embodiments, the modified wound bed is modified to provide a functionalized surface that is reactive to at least one wound active agent. In some embodiments, a wound active agent is applied to the modified wound bed to form a gradient. In some embodiments, the wound modifying agent alters a property of the wound bed selected from the group consisting of compliance, pH, alkalinity, oxidative or reductive power, net charge, hydrophilicity, osmotic power, nanoscale or submicron topographical features, electrical conductivity, MMP production, phagocytosis, and transglutaminase activity. In some embodiments, the wound modifying agent is applied to the wound by a method selected from the group consisting of coating, sprinkling, seeding, electrospinning, sputtering, stamping, spraying, pumping, painting, smearing, and printing. In some embodiments, the at least one wound modifying agent is at least one crosslinking agent. In some embodiments, the at least one crosslinking agent is selected from the group consisting of homogeneous bifunctional crosslinking agents, heterogeneous bifunctional crosslinking agents, heterogeneous and homogeneous multifunctional crosslinking agents, and photoactivatable crosslinking agents, and combinations thereof. In some embodiments, the heterogeneous bifunctional crosslinking agent comprises an alkyne group. In some embodiments, the wound modifying agent comprises at least one polymer. In some embodiments, the at least one polymer is applied to the wound bed to form a polymeric multilayer. In some embodiments, the at least one polymer is selected from the group consisting of cationic polymers, anionic polymers, nonionic polymers, amphoteric polymers, and combinations thereof. In some embodiments, the method further comprises contacting the polymeric multilayer with a crosslinking agent to form a functionalized surface reactive to at least one wound active agent.In some embodiments, the at least one polymer is a polyelectrolyte multilayer preformed on a carrier such that the polyelectrolyte multilayer can be transferred from the carrier to the wound bed to form the modified wound bed. In some embodiments, the carrier is an elastomeric carrier. In some embodiments, the polymer multilayer is between 1 nm and 250 nm thick. In some embodiments, the polymer multilayer has a compliance between 3 and 500 kPa. In some embodiments, the wound modifying agent is selected from the group consisting of nanoparticles and microparticles. In some embodiments, the nanoparticles and microparticles are functionalized. In some embodiments, the functionalized beads are mesoscopic crosslinkers. In some embodiments, the at least one wound active agent is selected from the group consisting of nutrients, extracellular matrices, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infectives, buffers, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anti-cancer agents.

[0032] In some embodiments, the present invention provides a kit for treating a subject having a wound, the kit comprising: a) at least one wound modifying agent; b) at least one wound active agent; and c) instructions for using the kit to treat a wound bed with the at least one wound modifying agent to provide a modified wound bed and incorporate the wound active agent into the modified wound bed. In some embodiments, the at least one wound modifying agent is selected from the group consisting of a covalent modifying agent, at least one polyelectrolyte, a microparticle, a nanoparticle, and combinations thereof.

[0033] In some embodiments, the invention provides a method of treatment, the method comprising: a) providing to a subject having a wound: i) a cationic and anionic polyelectrolyte mixture; ii) a deprotecting agent; iii) at least one covalent modifying agent; iv) at least one molecule containing an azide group or an alkyne group; and v) at least one wound active agent containing the other of an azide group or an alkyne group; b) contacting the wound with the polyelectrolyte mixture to form a polyelectrolyte layer on the wound; c) applying a deprotecting agent to the polyelectrolyte layer to form a deprotected polyelectrolyte layer; d) applying at least one covalent modifying agent to the deprotected polyelectrolyte layer; e) applying at least one molecule containing an azide group or an alkyne group to the deprotected, modified polyelectrolyte layer to covalently bond the molecule containing the azide or alkyne group to the deprotected, modified polyelectrolyte layer; and f) applying at least one wound active agent containing the other of an azide group or an alkyne group to the deprotected, modified polyelectrolyte layer covalently bonded to the molecule containing the azide group under conditions such that the at least one wound active agent is bonded to the wound by click chemistry.

[0034] In some embodiments, the present invention provides compositions comprising a deprotected polyelectrolyte, the electrolyte functionalized with at least one covalent modifying agent, the modifying agent attached to at least one molecule containing an azide group, the molecule attached to at least one wound active agent containing an alkyne group via click chemistry.

[0035] In some embodiments, the present invention provides a method comprising: a) providing a plurality of functionalized beads and at least one cellular active factor to a subject having a wound; b) contacting the at least one cellular active factor with the at least one functionalized biocompatible bead such that the at least one cellular active factor binds to the at least one functionalized biocompatible bead; and c) applying the at least one functionalized biocompatible bead bound to the at least one cellular active factor to a wound bed of the subject.

[0036] In some embodiments, the present invention provides a method of treatment comprising: a) providing at least one polymer and at least one wound active agent to a subject having a wound; b) applying the at least one polymer to the wound such that a polymer multilayer is formed on the wound; and c) incorporating at least one wound active agent into the polymer multilayer during application of the at least one polymer, wherein the at least one wound active agent forms a gradient in the polymer multilayer.

[0037] In some embodiments, the present invention provides an article comprising a matrix formed from a biocompatible material, the matrix comprising at least one wound active agent, the matrix having a thickness of 1-500 nm and a compliance of 3-500 kPa. In some embodiments, the matrix is ​​functionalized. In some embodiments, the biocompatible material is selected from the group consisting of a protein and a polymer. In some embodiments, the polymer is selected from the group consisting of a polyanionic polymer, a polycationic polymer, an uncharged polymer, an amphoteric polymer, and combinations thereof, and the polymer forms multiple layers. In some embodiments, the protein is an extracellular matrix protein selected from the group consisting of laminin, vitronectin, fibronectin, keratin, collagen, and combinations thereof. In some embodiments, the matrix is ​​supported by a solid support selected from the group consisting of silicone, siloxane elastomer, latex, nylon, nylon mesh, biological tissue, silk, polyurethane, Teflon, polyvinyl alcohol membrane, and polyethylene oxide membrane. In some embodiments, the at least one wound active agent is distributed on the matrix such that a gradient is formed. In some embodiments, the matrix is ​​at least partially PEGylated. In some embodiments, the invention provides a method comprising applying the article described above to a wound in a subject, the article improving wound healing, hi some embodiments, the invention provides a kit comprising the article described above in a sterile package.

[0038] In some embodiments of the invention, the compositions and methods described above improve wound healing. The invention contemplates that wound healing may be improved in a variety of ways. In some embodiments, the compositions and methods minimize wound contracture to best favor function and cosmetology. In some embodiments, the compositions and methods of the invention promote wound contracture to best favor function and cosmetology. In some embodiments, the compositions and methods of the invention promote angiogenesis. In some embodiments, the compositions and methods of the invention inhibit angiogenesis. In some embodiments, the compositions and methods of the invention promote fibrosis. In some embodiments, the compositions and methods of the invention inhibit fibrosis. In some embodiments, the compositions and methods of the invention promote epithelial coverage. In some embodiments, the compositions and methods of the invention inhibit epithelial coverage. In some embodiments, the compositions and methods of the invention modulate one or more properties of cells in the wound environment or in the immediate vicinity of the wound. Properties that are modulated, e.g., enhanced or decreased, include, but are not limited to, adhesion, migration, proliferation, differentiation, extracellular matrix secretion, phagocytosis, MMP activity, contraction, and combinations thereof.

[0039] In some embodiments, the present invention allows for the use of any of the compositions described herein above or elsewhere to improve wound healing or to modulate one or more properties of cells in or near the wound environment. In some embodiments, the present invention allows for the use of a combination of wound modifying agents and wound active agents to improve wound healing or to modulate one or more properties of cells in or near the wound environment. In some embodiments, the present invention allows for the use of the above-mentioned articles to improve wound healing or to modulate one or more properties of cells in or near the wound environment.

[0040] In some embodiments, the present invention provides an article or composition comprising a polymeric multilayer comprising at least one polymer, the polymeric multilayer having associated therewith particles selected from the group consisting of nanoscale particles and microscale particles. In some embodiments, the at least one polymer is selected from the group consisting of cationic polymers, anionic polymers, nonionic polymers, amphoteric polymers, and combinations thereof. In some embodiments, the polymeric multilayer has a thickness of 1 nm to 500 nm, preferably 1 nm to 250 nm. In some embodiments, the polymeric multilayer has a compliance of 3 kPa to 500 kPa, 3 kPa to 10 MPa, or 3 kPa to 5 GPa. In some embodiments, the particles are polymeric particles. In some embodiments, the particles are selected from the group consisting of spherical, ovoid, and cylindrical particles. In some embodiments, the diameter of the particles is greater than the thickness of the polymeric multilayer.

[0041] In some embodiments, the article or composition includes at least one wound active agent associated with the composition. In some embodiments, the wound active agent is selected from the group consisting of antimicrobials, nutrients, extracellular matrices, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infectives, buffers, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anti-cancer agents. In some embodiments, the wound active agent is dispersed within the polymeric multilayer. In some embodiments, the wound active agent is covalently associated with the polymeric multilayer. In some embodiments, the particles are functionalized. In some embodiments, the wound active agent is bound to the particles. In some embodiments, the wound active agent is contained within the particles.

[0042] In some embodiments, the polymeric layer is disposed on a carrier. In some embodiments, the carrier is a polymeric carrier. In some embodiments, the polymeric carrier is a different polymeric composition than the polymeric multilayer. In some embodiments, the polymeric carrier is an elastomeric polymer. In some embodiments, the polymeric carrier and the polymeric multilayer are separated by a water soluble material. In some embodiments, the polymeric carrier is water soluble. In some embodiments, the water soluble carrier comprises polyvinyl alcohol. In some embodiments, the carrier is a wound dressing. In some embodiments, the carrier is a biological wound dressing. In some embodiments, the polymeric multilayer is deposited on the carrier by a method selected from the group consisting of adsorption from solution, spin coating, and spray coating.

[0043] In some embodiments, the particles have an elastic modulus of about 0.5 to about 10 GPa. In some embodiments, the particles are interspersed or dispersed within the polymeric multilayer. In some embodiments, the particles are present on a surface of the polymeric multilayer. In some embodiments, the particles are beneath the polymeric multilayer. In some embodiments, the particles are between the polymeric multilayer and the carrier. In some embodiments, the particles are present on a surface of the polymeric multilayer and have a diameter greater than the thickness of the polymeric multilayer, and the article further comprises an antimicrobial silver composition.

[0044] In some embodiments, the present invention provides a method of modifying a surface, the method comprising contacting a surface with a polymeric multilayer comprising at least one polymer, wherein the polymeric multilayer is associated with particles selected from the group consisting of nanoscale particles and microscale particles under conditions such that the polymeric multilayer is transferred to the surface. In some embodiments, pressure is applied to the polymeric multilayer to effect transfer to the surface. In some embodiments, the pressure is about 10 to about 500 kPa. In some embodiments, the polymeric multilayer is disposed on a support. In some embodiments, the support is about 1 micrometer to about 10 mm thick. In some embodiments, the surface is a wound dressing. In some embodiments, the wound dressing is a biological wound dressing. In some embodiments, the polymeric multilayer is deposited on the support by a method selected from the group consisting of adsorption from a solution, spraying, and spin coating. In some embodiments, the support is an elastomeric support. In some embodiments, the surface is a soft or pliable surface. In some embodiments, the soft surface has an elastic modulus of about 10 to about 100 kPa. In some embodiments, the soft surface is a biological surface. In some embodiments, the biological surface is selected from the group consisting of skin, a wound bed, hair, a tissue surface, and an organ surface. In some embodiments, the biological surface comprises a molecule selected from the group consisting of proteins, lipids, carbohydrates, and combinations thereof. In some embodiments, the surface comprises (e.g., is coated with or exhibits) glycosaminoglycans, collagen, and / or hyaluronic acid. In some embodiments, the surface is a surface on a biomedical device. In some embodiments, the surface is a silicone surface. In some embodiments, the at least one polymer is selected from the group consisting of cationic polymers, anionic polymers, nonionic polymers, amphoteric polymers, and combinations thereof. In some embodiments, the polymeric multilayer is between 1 nm and 500 nm thick. In some embodiments, the polymeric multilayer has a compliance between 3 kPa and 500 kPa, between 3 kPa and 10 MPa, or between 3 kPa and 5 GPa. In some embodiments, the particle is a polymeric particle.In some embodiments, the diameter of the particles is greater than the thickness of the polymeric multilayer. In some embodiments, the particles are selected from the group consisting of spherical, ovoid, and cylindrical particles. In some embodiments, the polymeric multilayer comprises at least one wound active agent. In some embodiments, the wound active agent is selected from the group consisting of nutrients, extracellular matrix, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infectives, buffers, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, antimicrobials, growth factors, oligopeptides, sugars, polysaccharides, synthetic molecules including biological components, metal particles, electrodes, magnetic particles, honey, and anti-cancer agents. In some embodiments, the wound active agent is dispersed within the polymeric multilayer. In some embodiments, the wound active agent is covalently associated with the polymeric multilayer. In some embodiments, the particles are functionalized. In some embodiments, the wound active agent is bound to the particles. In some embodiments, the particles have an elastic modulus of about 0.5 to about 10 GPa. In some embodiments, the particles are dispersed within the polymeric multilayer. In some embodiments, the particles are present on the surface of the polymeric multilayer.

[0045] In some embodiments, the transfer is performed in the substantial absence of a solution or liquid solvent. In some embodiments, the transfer is a substantially or completely dry transfer. In some embodiments, the transfer is performed in the gas phase. In some embodiments, the transfer is performed in an environment where the humidity is less than 100% saturated. In some embodiments, the transfer is performed in the absence of liquid water.

[0046] In some embodiments, the present invention provides a polymer multilayer 1 cm 2 The present invention provides an article or composition comprising a polymeric multilayer loaded with an antimicrobial silver composition in an amount of about 100 to about 500 μg per unit area, or a polymeric multilayer having a releasable antimicrobial silver composition incorporated therein, the releasable antimicrobial silver composition being capable of being absorbed in a volume of about 1 cm per day of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.01 and 100 μg per cm of the polymeric multilayer. 2In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 100 μg per cm of the polymeric multilayer. 2 In some embodiments, the antimicrobial silver composition can be delivered in amounts between about 0.05 and 20 μg per cm of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 5 μg per cm of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 2 μg per cm of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 1 μg per cm of the polymeric multilayer. 2 In some embodiments, the antimicrobial silver composition comprises silver nanoparticles. In some embodiments, the silver nanoparticles are zero-valent silver nanoparticles. In some embodiments, the composition provides at least 99.99% kill of Staphylococcus epidermis. In some embodiments, the article does not substantially impair wound healing. In some embodiments, the antimicrobial silver composition allows at least 90% viability of NIH-3T3 cells. In some embodiments, viability is assessed after 24 hours of incubation of NIH-3T3 cells on the composition in the presence of growth medium. In some embodiments, the article is a film. In some embodiments, the article is a three-dimensional object, at least a portion of which is coated with a polymeric multilayer. In some embodiments, the three-dimensional object is a medical device.

[0047] In some embodiments, the article is selected from the group consisting of a polymeric carrier, an elastomeric carrier, a wound care device, a wound dressing, and a biological wound dressing. In some embodiments, the medical device is partially in contact with the subject. In some embodiments, the medical device is fully implanted in the subject. In some embodiments, at least one of the polymers comprises poly(allylamine hydrochloride). In some embodiments, at least one of the polymers comprises poly(acrylic acid). In some embodiments, the article or composition further comprises at least one additional antimicrobial agent.

[0048] In some embodiments, the present invention provides a method of treating a wound comprising providing a subject having a wound and contacting the wound with an article or composition as described above.

[0049] In some embodiments, the invention provides a kit for treating a wound in a subject, comprising an article or composition as described above and instructions for applying the article to the wound. In some embodiments, the invention provides a kit further comprising an additional wound dressing material. In some embodiments, the wound dressing material is a biological wound dressing.

[0050] In some embodiments, the present invention provides articles or compositions comprising a solid carrier comprising a releasable antimicrobial silver composition, the releasable antimicrobial silver composition being present in an amount greater than 1 cm of the solid carrier. 2 and / or 1 cm of solid carrier per day. 2 The releasable antimicrobial silver composition is releasable in amounts between about 0.01 and 100 μg per solid carrier. In some embodiments, the solid carrier is selected from the group consisting of a polymeric carrier, an elastomeric carrier, a nanoparticle, a microparticle, a wound dressing, and a biological wound dressing. In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.01 and 100 μg per solid carrier per day ... 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 100 μg per cm of solid carrier per day. 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 20 μg per cm of solid carrier per day. 2In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 5 μg per cm of solid carrier per day. 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 2 μg per cm of solid carrier per day. 2 In some embodiments, the releasable antimicrobial silver composition is releasable in amounts between about 0.05 and 1 μg per cm of solid carrier per day. 2 In some embodiments, the antimicrobial silver composition comprises silver nanoparticles. In some embodiments, the silver nanoparticles are zero-valent silver nanoparticles. In some embodiments, the article does not substantially impair wound healing. In some embodiments, the article or composition further comprises at least one additional antimicrobial agent.

[0051] In some embodiments, the present invention provides a method of treating a wound comprising providing a subject having a wound and contacting the wound with an article or composition as described above.

[0052] In some embodiments, the present invention provides a method of synthesizing a wound treating composition, the method comprising: a) assembling alternating layers of polymers to form a film or coating; and b) incorporating an antimicrobial silver composition into the alternating layers of polymer during assembly.

[0053] In some embodiments, the invention provides a method of synthesizing a wound treating composition, the method comprising: a) assembling alternating layers of a polymer to form a film or coating; b) incubating the film or coating in a bulk solution of a silver salt; c) exposing the film or coating to a reducing agent; and d) administering a concentration of 0.01 and 100 μg / cm 2and selecting for use a film or coating having a silver loading level of 0.1 to 0.5%. In some embodiments, at least one of the polymers comprises a solution containing poly(allylamine hydrochloride). In some embodiments, at least one of the polymers comprises a solution containing poly(acrylic acid). In some embodiments, the bulk solution of silver salt comprises silver nitrate. In some embodiments, the Ag in the silver nitrate solution + The concentration of is 0.005 mM to 5 mM. In some embodiments, the pH of the poly(acrylic acid) solution is 2.5 to 7.5.

[0054] In some embodiments, the present invention provides a solid carrier and a polymeric multilayer carried by the solid carrier, the polymeric multilayer comprising at least one wound active agent. In some embodiments, the article further comprises a water-soluble material between the solid carrier and the polymeric multilayer. In some embodiments, the solid carrier comprises a polymer. In some embodiments, the polymer is an elastomeric polymer. In some embodiments, the elastomeric polymer is a silicone polymer. In some embodiments, the silicone polymer is selected from the group consisting of polydimethylsiloxane and medical grade silicone. In some embodiments, the polymeric multilayer has a thickness of about 1 nm to 500 nm. In some embodiments, the polymeric multilayer has a compliance of about 3 kPa to 5 GPa, preferably about 3 kPa to 500 kPa. In some embodiments, the polymeric multilayer comprises nanoscale to microscale particles incorporated therein. In some embodiments, the particles have a diameter greater than the thickness of the polymeric multilayer. In some embodiments, the at least one wound active agent is an antimicrobial silver composition. In some embodiments, the silver loading of the polyelectrolyte multilayer is greater than cm of the antimicrobial silver composition. 2The antimicrobial silver composition may be about 0.01-500 μg per microgram. In some embodiments, the antimicrobial silver composition comprises silver nanoparticles. In some embodiments, the silver nanoparticles are zero-valent silver nanoparticles. In some embodiments, the antimicrobial silver composition comprises multivalent silver ions supported on zirconium phosphate. In some embodiments, the solid support comprises a material selected from the group consisting of foams, transparent films, hydrogels, hydrofibers, hydrocolloids, alginate fibers, and combinations thereof. In some embodiments, the solid support comprises a material selected from the group consisting of superabsorbent polymers (SAPs), silica gels, sodium polyacrylates, potassium polyacrylamides, and combinations thereof. In some embodiments, the solid support comprises an absorbent material. In some embodiments, the polymeric multilayer is transferred to the support in the substantial absence of a solvent. In some embodiments, the absorbent material is selected from the group consisting of woven fabrics, e.g., cotton or nylon gauze, and polymeric foams. In some embodiments, the absorbent material comprises a first surface comprising an anti-adhesive material. In some embodiments, the polymeric multilayer is deposited on a first surface comprising an anti-adhesive material. In some embodiments, the absorbent material comprises a second surface secured to the adhesive material. In some embodiments, the adhesive material is sized to extend from one or more edges of the absorbent material such that the absorbent material is exposed to the skin of the subject. In some embodiments, the article further comprises a removable sheet, and the article is removably affixed to the removable sheet. In some embodiments, the article is packaged in a sterile package. In some embodiments, the polymeric multilayer has a thickness of about 1 nm to 500 nm. In some embodiments, the polymeric multilayer has a compliance of about 3 to 500 kPa. In some embodiments, the polymeric multilayer comprises nanoscale to microscale particles therein. In some embodiments, at least one wound active agent is an antimicrobial silver composition. In some embodiments, the silver loading of the polyelectrolyte multilayer is about 1000 g / cm of the antimicrobial silver composition. 2About 0.01-500 g per gram. In some embodiments, the antimicrobial silver composition comprises silver nanoparticles. In some embodiments, the silver nanoparticles are selected from the group consisting of zerovalent silver nanoparticles and multivalent silver ions (supported on zirconium phosphate).

[0055] In some embodiments, the solid support comprises a biological wound dressing. In some embodiments, the biological wound dressing comprises (e.g., is coated with or exhibits) a biological molecule selected from the group consisting of collagen, hyaluronic acid, glycosaminoglycan, keratin, fibronectin, vitronectin, laminin, and combinations or fragments thereof. In some embodiments, the biopolymer is supported on a silicone film. In some embodiments, the silicone film comprises a woven support. In some embodiments, the woven support is a nylon woven support. In some embodiments, the polymer multilayer is deposited on the silicone film. In some embodiments, the polymer multilayer has a thickness of about 1 nm to 500 nm. In some embodiments, the polymer multilayer has a compliance of about 3 to 500 kPa. In some embodiments, the polymer multilayer comprises nanoscale to microscale particles incorporated therein. In some embodiments, the particles have a diameter greater than the thickness of the polymer multilayer. In some embodiments, at least one wound active agent is an antimicrobial silver composition. In some embodiments, the silver loading of the polyelectrolyte multilayer is greater than cm of the antimicrobial silver composition. 2 About 0.01-500 μg per gram. In some embodiments, the antimicrobial silver composition comprises silver nanoparticles. In some embodiments, the silver nanoparticles are selected from the group consisting of zerovalent and multivalent silver nanoparticles.

[0056] In some embodiments, the present invention provides a method for producing a nanoscale polymer matrix microsheet, the method comprising: a) forming a nanoscale polymer layer on a substrate having a thickness of about 0.5 nm to 1000 nm; b) introducing a bioactive agent into the nanoscale polymer layer to provide a bioactive nanoscale polymer layer; and c) forming a sacrificial polymer layer on the bioactive nanoscale polymer layer, the sacrificial polymer layer being dissolvable. In some embodiments, the present invention provides a method for producing a nanoscale polymer matrix microsheet, the method comprising: a) forming a nanoscale polymer layer on a substrate having a thickness of about 0.5 nm to 1000 nm; b) introducing a bioactive agent into the nanoscale polymer layer to provide a bioactive nanoscale polymer layer; and c) forming a second polymer layer on the bioactive nanoscale polymer layer, the second polymer layer being formed from a different polymer than the nanoscale polymer layer. In some embodiments, the present invention provides a method for producing a nanoscale polymer matrix microsheet, the method comprising: a) forming a nanoscale polymer layer having a thickness of about 0.5 nm to 1000 nm on a substrate; and b) forming a second polymer layer on the nanoscale polymer layer by spin coating, the second polymer layer being formed from a different polymer than the nanoscale polymer layer.

[0057] In some embodiments, the bioactive agent is a wound active agent. In some embodiments, the nanoscale polymer matrix is ​​a polymeric multilayer. In some embodiments, the nanoscale polymer matrix is ​​formed by alternating layers of at least one positively charged electrolyte with at least one negatively charged polyelectrolyte. In some embodiments, the at least one positively charged polyelectrolyte is selected from the group consisting of poly(allylamine hydrochloride) (PAH), poly-L-lysine (PLL), poly(ethyleneimine) (PEI), poly(histidine), poly(N,N-dimethylaminoacrylate), poly(N,N,N-trimethylaminoacrylate chloride), poly(methyacrylamidopropyltrimethylammonium chloride), and natural or synthetic polysaccharides such as chitosan. In some embodiments, the at least one negatively charged polyelectrolyte is selected from the group consisting of poly(acrylic acid) (PAA), poly(styrene sulfonate) (PSS), alginate, hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate, dextran sulfate, poly(methacrylic acid), oxidized cellulose, carboxymethyl cellulose, polyaspartic acid, and polyglutamic acid. In some embodiments, the polymer multilayer is formed by applying the at least one positively charged electrolyte and the at least one negatively charged polyelectrolyte by a method selected from the group consisting of spraying a polymer solution onto a substrate, dip-coating the substrate into the polymer solution, or spin-coating the polymer solution onto a substrate. In some embodiments, the at least one positively charged electrolyte and the at least one negatively charged polyelectrolyte are synthetic polyelectrolytes.

[0058] In some embodiments, the bioactive agent is incorporated into the nanoscale polymer layer such that the bioactive agent is interspersed within the three-dimensional structure of the nanoscale polymer layer. In some embodiments, the bioactive agent is incorporated into the nanoscale polymer multilayer such that the bioactive agent is interspersed within the layer or polymer multilayer. In some embodiments, the bioactive agent is selected from the group consisting of antibacterial agents, antibiofilm agents, growth factors, hemostatic agents, bioactive peptides, bioactive polypeptides, analgesics, anticoagulants, anti-inflammatory agents, and drug molecules or drug compounds. In some embodiments, the antibacterial agent is selected from the group consisting of charged small molecule antibacterial agents, antibacterial polypeptides, metal particles, and metal ion antibacterial agents. In some embodiments, the metal ion antibacterial agent is a metal ion, a metal ion salt, or a metal ion nanoparticle. In some embodiments, the metal ion nanoparticle is a silver nanoparticle. In some embodiments, the charged small molecule antibacterial agent is selected from the group consisting of chlorhexidine, antibiotics, polyhexamethylene biguanide (PHMB), iodine, cadexomer iodine, povidone iodine (PVI), hydrogen peroxide, and vinegar (acetic acid). In some embodiments, the metal ion anti-biofilm agent is a metal ion, a metal ion salt, or a metal ion nanoparticle. In some embodiments, the metal ion anti-biofilm agent is a gallium salt, a gallium nanoparticle, a gallium alloy, or an alloy of gallium and silver. In some embodiments, the bioactive agent is introduced into the nanoscale polymer layer during formation of the nanoscale polymer layer. In some embodiments, the bioactive agent is introduced into the nanoscale polymer layer after formation of the nanoscale polymer layer. In some embodiments, introducing the bioactive agent into the nanoscale polymer layer to provide a bioactive nanoscale polymer multilayer comprises introducing silver ions into the nanoscale polymer multilayer and reducing the silver ions in situ to provide silver nanoparticles. In some embodiments, introducing the bioactive agent into the nanoscale polymer layer to provide a bioactive nanoscale polymer multilayer comprises introducing a charged small molecule antimicrobial agent between differently charged polyelectrolyte layers.In some embodiments, the method includes repeating the loading step 1-20 times, for example, to control and / or increase the amount of bioactive agent loaded into the nanoscale polymer layer. In some embodiments, the method includes controlling the amount of bioactive agent in the nanoscale polymer matrix microsheet by controlling the number of nanoscale polymer layers, controlling the pH at which the nanoscale polymer layers are formed, and / or controlling the number of loading cycles.

[0059] In some embodiments, the sacrificial polymer layer is about 0.1 μm to about 100 μm thick. In some embodiments, the sacrificial polymer layer is about 0.1 μm to about 50 μm thick. In some embodiments, the sacrificial polymer layer is about 1 μm to about 20 μm thick. In some embodiments, the sacrificial polymer layer is about 1 μm to about 10 μm thick. In some embodiments, the sacrificial polymer layer comprises a water soluble polymer. In some embodiments, the water soluble sacrificial polymer layer is made of and / or comprises polyvinyl alcohol (PVA). In some embodiments, the soluble polymer has a molecular weight greater than 22 kDa. In some embodiments, the water soluble polymer is removable by renal filtration.

[0060] In some embodiments, the water-soluble sacrificial polymer layer is made of polyacrylic acid (PAA), polystyrene (PS), polymethyl methacrylate (PMMA), or polyvinyl acetate (PVAc). In some embodiments, the sacrificial polymer layer comprising the water-soluble polymer dissolves when exposed to moisture on the surface such that a bioactive nanoscale polymer multilayer is deposited on the surface. In some embodiments, the method further comprises introducing a bioactive agent to the sacrificial polymer layer. In some embodiments, the method further comprises introducing microparticles or nanoparticles to the sacrificial polymer layer. In some embodiments, the microparticles or nanoparticles of the sacrificial polymer layer are loaded with a bioactive agent. In some embodiments, the method further comprises introducing magnetic microparticles or nanoparticles to the sacrificial polymer layer. In some embodiments, the bioactive agent is selected from the group consisting of antimicrobial agents, growth factors, hemostatic agents, bioactive peptides, bioactive polypeptides, analgesics, anticoagulants, anti-inflammatory agents, and drug molecules or drug compounds. In some embodiments, the antimicrobial agent is selected from the group consisting of charged small molecule antimicrobial agents, antimicrobial polypeptides, metal particles, and metal ion antimicrobial agents. In some embodiments, the metal ion antimicrobial reagent is a metal ion, a metal ion salt, or a metal ion nanoparticle. In some embodiments, the metal ion nanoparticle is a silver nanoparticle. In some embodiments, the small molecule antimicrobial agent is selected from the group consisting of chlorhexidine, an antibiotic, polyhexamethylene biguanide (PHMB), iodine, cadexomer iodine, povidone iodine (PVI), hydrogen peroxide, and vinegar (acetic acid). In some embodiments, the substrate is selected from the group consisting of a polydimethylsiloxane (PDMS) substrate, a glass substrate, a plastic substrate, a metal substrate, and a Teflon substrate. In some embodiments, the substrate is functionalized to provide a low energy surface. In some embodiments, the substrate is functionalized with octadecyltrichlorosilane.

[0061] In some embodiments, the method further comprises removing the nanoscale polymer layer matrix microsheet comprising the bioactive nanoscale polymer layer and the associated sacrificial polymer layer from the substrate. In some embodiments, greater than 90%, greater than 95%, greater than 97%, greater than 98%, or greater than 99% of the nanoscale polymer matrix microsheet comprising the bioactive nanoscale polymer layer and the associated sacrificial polymer layer is removed from said substrate. In some embodiments, the method further comprises incorporating nanoscale or microscale particles or beads into the nanoscale polymer layer. In some embodiments, the method further comprises incorporating magnetic nanoparticles or microparticles into the nanoscale polymer layer.

[0062] In some embodiments, the nanoscale polymer layer comprises a polymer selected from the group consisting of polyelectrolytes, lipids, proteins, collagen, hyaluronic acid, chitosan, keratin, fibronectin, vitronectin, laminin, polysaccharides, polyanhydrides, poly(lactic-co-glycolic acid) (PLGA), poly(L-lactic acid) (PLLA), and combinations or fragments thereof. In some embodiments, the sacrificial polymer layer is applied to the nanoscale polymer layer by spin coating, dip coating, or spray coating. In some embodiments, the nanoscale polymer matrix microsheet has a Young's modulus of about 0.1 GPa to about 10 GPa after removal from the substrate. In some embodiments, forming the nanoscale polymer layer comprises depositing a positively charged electrolyte and a negatively charged polyelectrolyte to form a bilayer. In some embodiments, the method comprises 2 to 50 deposition steps. In some embodiments, forming the nanoscale polymer layer comprises providing solution conditions comprising a pH of 1.5 to 2.5, a pH of 6.5 to 8.5, and / or a pH of 4.5 to 6.5. In some embodiments, the method further comprises drying the nanoscale polymer matrix microsheet. In some embodiments, the method further comprises incorporating a second or more bioactive agents into the nanoscale polymer layer.

[0063] In some embodiments, the present invention provides a nanoscale polymer layer matrix microsheet made by the above-described method.

[0064] In some embodiments, the present invention provides a wound-active nanoscale polymer matrix microsheet comprising a wound-active nanoscale polymer layer having a thickness of about 0.5 nm to 1000 nm, the nanoscale wound-active polymer layer having a wound active agent incorporated therein, and a sacrificial polymer layer adjacent to the wound-active nanoscale polymer layer, the sacrificial polymer layer being dissolvable when exposed to a moisture surface. In some embodiments, the nanoscale polymer layer is a polymer multilayer. In some embodiments, the nanoscale polymer multilayer is formed by alternating layers of at least one positively charged electrolyte and at least one negatively charged polyelectrolyte. In some embodiments, the at least one positively charged polyelectrolyte is selected from the group consisting of poly(allylamine hydrochloride) (PAH), poly-L-lysine (PLL), poly(ethyleneimine) (PEI), poly(histidine), poly(N,N-dimethylaminoacrylate), poly(N,N,N-trimethylaminoacrylate chloride), poly(methacrylamidopropyltrimethylammonium chloride), and natural or synthetic polysaccharides such as chitosan. In some embodiments, the at least one negatively charged polyelectrolyte is selected from the group consisting of poly(acrylic acid) (PAA), poly(styrenesulfonate) (PSS), alginate, hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate, dextran sulfate, poly(meth)acrylic acid, oxidized cellulose, carboxymethylcellulose, polyaspartic acid, and polyglutamic acid. In some embodiments, the at least one positively charged electrolyte and the at least one negatively charged polyelectrolyte are synthetic polyelectrolytes. In some embodiments, the wound active agent is incorporated into the nanoscale polymer layer such that the wound active agent is interspersed within the three-dimensional structure of the nanoscale polymer layer. In some embodiments, the wound active agent is incorporated into the nanoscale polymer multilayer such that the wound active agent is interspersed within each layer of the nanoscale polymer multilayer.

[0065] In some embodiments, the wound active agent is selected from the group consisting of antimicrobial agents, growth factors, hemostatic agents, bioactive peptides, bioactive polypeptides, analgesics, anticoagulants, anti-inflammatory agents, and drug molecules or drug compounds. In some embodiments, the antimicrobial agent is selected from the group consisting of small molecule antimicrobial agents, charged small molecule antimicrobial agents, antimicrobial polypeptides, metal particles, and metal ion antimicrobial agents. In some embodiments, the metal ion antimicrobial agent is a metal ion, a metal ion salt, or a metal ion nanoparticle. In some embodiments, the metal ion nanoparticle is a silver nanoparticle. In some embodiments, the charged small molecule antimicrobial agent or the small molecule antimicrobial agent is selected from the group consisting of chlorhexidine, antibiotics, polyhexamethylene biguanide (PHMB), iodine, cadexomer iodine, povidone iodine (PVI), hydrogen peroxide, and vinegar (acetic acid). In some embodiments, the sacrificial polymer layer is about 0.1 μm to about 100 μm thick. In some embodiments, the sacrificial polymer layer is about 0.1 μm to about 50 μm thick. In some embodiments, the sacrificial polymer layer is about 1 μm to about 20 μm thick. In some embodiments, the sacrificial polymer layer is about 1 μm to about 10 μm thick. In some embodiments, the sacrificial polymer layer comprises a water soluble polymer. In some embodiments, the sacrificial polymer layer comprises a wound active agent. In some embodiments, the wound active agent is selected from the group consisting of antimicrobial agents, growth factors, hemostatic agents, bioactive peptides, bioactive polypeptides, analgesics, anticoagulants, anti-inflammatory agents, and drug molecules or drug compounds. In some embodiments, the antimicrobial agent is selected from the group consisting of small molecule antimicrobial agents, antimicrobial polypeptides, metal particles, and metal ion antimicrobial agents. In some embodiments, the metal ion antimicrobial agent is a metal ion, a metal ion salt, or a metal ion nanoparticle. In some embodiments, the metal ion nanoparticle is a silver nanoparticle. In some embodiments, the small molecule antimicrobial agent is selected from the group consisting of chlorhexidine, antibiotics, polyhexamethylene biguanide (PHMB), iodine, cadexomer iodine, povidone iodine (PVI), hydrogen peroxide, and vinegar (acetic acid).

[0066] In some embodiments, the microsheet further comprises nanoscale or microscale particles incorporated into the nanoscale polymer layer.

[0067] In some embodiments, the nanoscale polymer layer comprises a polymer selected from the group consisting of polyelectrolytes, lipids, proteins, collagen, hyaluronic acid, chitosan, keratin, fibronectin, vitronectin, laminin, polysaccharides, polyanhydrides, poly(lactic-co-glycolic acid) (PLGA), poly(L-lactic acid) (PLLA), and combinations or fragments thereof.

[0068] In some embodiments, the microsheet contains wound active agent at a concentration of about 0.01-100 μg / cm 2 In some embodiments, the bioactive agent is present in a concentration between about 0.01 and 100 μg / cm per day of wound active agent. 2 In some embodiments, the microsheet is provided in an amount such that the microsheet is released at a rate of about 0.2 to 600 cm 2 It has an area of.

[0069] In some embodiments, the sacrificial polymer layer has a uniform thickness, with less than 500, 400, 300, 200, 100, 50, 20, or 10% variation in average thickness when measured in cross section. In some embodiments, the microsheet has a Young's modulus of about 0.1 GPa to about 10 GPa, for example, after removal from the substrate.

[0070] In some embodiments, when the article is applied to a surface, the sacrificial polymer layer dissolves upon exposure to moisture, leaving a nanoscale polymer layer on the surface. In some embodiments, the nanoscale polymer layer forms a barrier to adventitious pathogens when applied to a wet surface. In some embodiments, the microsheet further comprises a second or more wound active agents. In some embodiments, the microsheet is translucent and / or transparent.

[0071] In some embodiments, the present invention provides a medical device comprising the microsheet described above. In some embodiments, the device comprises a surface in contact with the microsheet. In some embodiments, the medical device is selected from the group consisting of a medical device, a wound dressing, an implantable medical device, a medical device in contact with the skin, a catheter, a stent, a membrane, a contact lens, and a surgical mesh. In some embodiments, the wound dressing is selected from the group consisting of a biological wound dressing, a non-biological wound dressing, an absorbent material, a foam, a transparent film, a hydrogel, a hydrofiber, a hydrocolloid, an alginate fiber, a silica gel, a sodium polyacrylate, a potassium polyacrylamide, and combinations thereof.

[0072] In some embodiments, the present invention provides a kit comprising the above-mentioned microsheet and a medical device. In some embodiments, the medical device is selected from the group consisting of a medical device, a wound dressing, an implantable medical device, a medical device that contacts the skin, a catheter, a stent, a membrane, a contact lens, and a surgical mesh. In some embodiments, the wound dressing is selected from the group consisting of a biological wound dressing, a non-biological wound dressing, an absorbent material, a foam, a transparent film, a hydrogel, a hydrofiber, a hydrocolloid, an alginate fiber, a silica gel, a sodium polyacrylate, a potassium polyacrylamide, and combinations thereof.

[0073] In some embodiments, the present invention provides a method of treating a subject comprising applying the microsheet described above to a biological surface of the subject. In some embodiments, the biological surface is a wet surface. In some embodiments, the surface is selected from the group consisting of an exterior surface and an interior surface. In some embodiments, the surface is a wound.

[0074] In some embodiments, the method further comprises applying a wound dressing over the microsheet. In some embodiments, the method further comprises applying a medical device over the microsheet. In some embodiments, the method further comprises applying a surgical mesh over the microsheet. In some embodiments, the sacrificial polymer layer dissolves when the wound active nanoscale polymer layer article is applied to the surface, leaving the wound active nanoscale polymer layer on the surface. In some embodiments, the nanoscale polymer layer acts as a barrier against exogenous pathogens. In some embodiments, the subject has a wound, and application of the microsheet improves wound closure. In some embodiments, the wound active nanoscale polymer layer allows for sustained release of the wound active agent. In some embodiments, the method further comprises conforming the microsheet to the microcontours of the wound bed of the subject. In some embodiments, the method comprises dissolving the sacrificial polymer layer. In some embodiments, the method further comprises conforming the microsheet to the microcontours of the wound bed of the subject within a time period of 30 seconds to 1 hour after dissolving the sacrificial polymer layer. In some embodiments, dissolution dissolves greater than 90%, greater than 95%, greater than 97%, or greater than 98% of the sacrificial polymer layer over a period of time between 30 seconds and 1 hour. In some embodiments, greater than 90%, greater than 95%, greater than 97%, or greater than 98% of the microsheet is transferred to the biological surface of the subject. In some embodiments, greater than 80%, greater than 85%, greater than 90%, or greater than 95% of the microsheet remains applied to the biological surface of the subject after rubbing the microsheet with the dressing. In some embodiments, greater than 80%, greater than 85%, or greater than 90% of the wound bed is covered by the microsheet after 1 day, 2 days, 3 days, 4 days, or 5 days. In some embodiments, applying the microsheet to the biological surface of the subject reduces the bacterial count on the biological surface of the subject by at least 1, 2, 3, 4, 5, or 6 logs. 10In some embodiments, applying the microsheet to the biological surface of the subject reduces the number of gram-negative and / or gram-positive bacteria on the biological surface of the subject by at least 5 log 10 Reduce.

[0075] In some embodiments, the method further comprises observing the wound through the microsheet after applying the microsheet to said biological surface. In some embodiments, the method further comprises testing the subject for wound healing and / or wound infection. In some embodiments, the method further comprises applying a second or more microsheets to said biological surface of the subject. In some embodiments, the second microsheet comprises an amount of wound active agent based on the results of the testing step.

[0076] In some embodiments, applying the microsheet to a biological surface of a subject does not affect normal growth and proliferation of epithelial cells of the subject. In some embodiments, applying the microsheet does not impair wound healing. In some embodiments, applying the microsheet does not cause excessive inflammation of the wound.

[0077] In some embodiments, the present invention provides a process for imparting a desired biological activity to a medical device, the process comprising applying a wound-active nanoscale polymeric article to a surface of the medical device.

[0078] In some embodiments, the present invention provides a nanoscale polymer microsheet comprising a first nanoscale polymer layer having a thickness of about 0.5 nm to 500 nm on a substrate having a bioactive agent incorporated therein, and a second polymer layer on the bioactive nanoscale polymer layer, the second polymer layer being formed from a different polymer than the nanoscale polymer layer. In some embodiments, the present invention provides a nanoscale polymer microsheet comprising a first nanoscale polymer layer having a thickness of about 0.5 nm to 500 nm on a substrate, and the second polymer layer being spin-coated or dip-coated onto the nanoscale polymer matrix layer. [Brief description of the drawings]

[0079] [Figure 1] FIG. 1 is a schematic diagram of a wound bed modified with a polyelectrolyte multilayer. [Diagram 2] FIG. 1 is a schematic diagram of a wound bed modified with a covalent modifying agent. [Diagram 3] 1 is an illustration of covalent protein immobilization to model amine-terminated glass surfaces. [Figure 4] Ex vivo results are shown for multilayer deposition of the polyelectrolytes polystyrene sulfonate (PSS) and FITC-labeled poly(allylamine hydrochloride) (FITC-PAH). [Diagram 5] 1 shows the differences in full thickness skin wound healing in diabetic (db / db) mice compared to control (wild type) mice. [Figure 6] An example of the use of beads for wound bed healing. In this example, carboxylic acid terminated beads are activated on the outside of the wound bed by using NHS and EDC. The activated beads are introduced to the wound bed and immobilized therein via reaction of the activated surface of the beads with amine groups present in the wound bed. Growth factors are introduced to the wound bed and immobilized therein via reaction with the exposed surface of the activated beads. [Figure 7-1] 1 shows a list of antimicrobial polypeptides, identified by name and AMSDb database ID number. [Figure 7-2] This is a continuation of Figure 7-1. [Figure 7-3] This is a continuation of Figure 7-2. [Figure 7-4] This is a continuation of Figure 7-3. [Figure 7-5] This is a continuation of Figure 7-4. [Figure 7-6] This is a continuation of Figure 7-5. [Figure 7-7] This is a continuation of Figure 7-6. [Figure 7-8] This is a continuation of Figure 7-7. [Figure 7-9]This is a continuation of Figure 7-8. [Figure 7-10] This is a continuation of Figure 7-9. [Figure 7-11] This is a continuation of Figure 7-10. [Figure 7-12] This is a continuation of Figure 7-11. [Figure 7-13] This is a continuation of Figure 7-12. [Figure 7-14] This is a continuation of Figure 7-13. [Figure 7-15] This is a continuation of Figure 7-14. [Figure 7-16] This is a continuation of Figure 7-15. [Figure 7-17] This is a continuation of Figure 7-16. [Figure 8] 1 shows the viability of NIH-3T3 mouse fibroblast cells after 24 hours of incubation in growth medium on silver-loaded polyelectrolyte multilayers (PEMs) (Example 13). [Figure 9] Viable bacteria detected on silver-loaded PEMs after 8 hours of incubation with 108 cfu / ml S. epidermidis in buffer. PEMs with various silver loadings were prepared by incubating with serial 10-fold dilutions of bulk Ag+ solution. As shown in this figure, PEMs incubated with 5 mM Ag+ (silver nitrate) solution contained approximately 0.38 μg / cm2 (no cytotoxicity was observed against NIH-3T3 cells in FIG. 8), and the silver loading of the remaining PEMs was below the detection limit of the elemental analysis spectroscopy. [Figure 10] NIH-3T3 cells after 24 h incubation on glass surfaces coated with PEMs (10.5 bilayers of PAH7.5 / PAAX) without (a, c, e) and with silver nanoparticles (concentrations of (b) 0.62, (d) 0.48, or (f) 0.39 μg / cm2). PEMs were prepared in PAA solutions at pH 5.5 (a, b), 6.5 (c, d), or 7.5 (e, f). [Figure 11] FIG. 1 shows a schematic diagram of one embodiment of a polymer multilayer using microscale beads. [Figure 12] 1 shows a graph depicting the migration of a polymeric multilayer containing microscale beads to a soft surface compared to the migration of a polymeric multilayer without microscale beads. [Figure 13] FIG. 1 shows diagrams for the fabrication of microsheets composed of polymer nanofilms and sacrificial casts. [Figure 14] FIG. 1 shows an illustration of the application of the microfilm as a microfilm wound dressing. A sacrificial cast of the microfilm dressing dissolves quickly in a moist wound, anchoring the polymer nanofilm to the wound surface. [Figure 15] Images of a microsheet composed of a sacrificial water-soluble cast of PVA and a nanofilm made from PEM containing silver nanoparticles are shown: (a) the microsheet (1"x1") placed on a glass dish, (b) the polymer nanofilm (1"x1") floating on the water surface after dissolution of the sacrificial cast of the microsheet in solution. [Figure 16] 1 shows a schematic diagram illustrating the assembly of polymer nanofilms deposited on a substrate as PEMs of PAH and PAA. The PEMs are impregnated with silver ions (Ag+) and silver nanoparticles (AgNPs). [Figure 17] 1 shows a schematic representation of the assembly of polymer nanofilms deposited on a substrate as PEMs of PAA and PAH along with chlorhexidine acetate. [Figure 18] FIG. 13 is a graph showing the sustained release of silver ions into PBS from polymer nanofilms assembled as PEMs of PAH and PAA containing 11±2.1 ug / cm2 silver nanoparticles. [Figure 19] FIG. 1 is a graph showing the sustained release of chlorhexidine (CX) into PBS from polymer nanofilms fabricated as PEMs containing chlorhexidine acetate molecules. [Figure 20]Figure 20A and B present images showing the application of silver microfilm wound dressing to an excision wound in a mouse. (A) A 6 mm diameter full thickness splinted wound on the flank of a mouse. (b) Coverage of the wound with silver impregnated microfilm wound dressing. A sacrificial cast was dissolved in the moist wound to immobilize the silver nanofilm on the wound surface. [Figure 21] 1 presents a graph showing the reduction in bacterial colonization of excision wounds in mice 3 days after surgery with silver microfilm wound dressings containing silver nanoparticles. All wounds were inoculated with S. aureus on day 0 and covered with Integra wound dressing or silver microfilm wound dressing together with Integra dressing. [Figure 22-1] Silver microfilm wound dressings inhibit infection and promote closure of contaminated wounds in mice. Two surgical wounds (6 mm diameter) were created in the flank of each BALB / c mouse, inoculated with 2x105 CFU of S. aureus, and either (A) covered with a biosynthetic dressing-Biobrane in group 1, or (B) covered with silver microfilm wound dressing before placing Biobrane on the wound. The figure shows representative wound images in groups A and B on day 9 after surgery. Figure 22C shows wound area (as a percentage of original wound size) on day 9 after surgery (mean±SEM) in wounds from mice treated with either Biobrane dressing only or silver microfilm wound dressing and Biobrane (n=10 mice / group, p<0.05). [Figure 22-2]Figure 22D shows the microbial load of S. aureus (mean ± SEM) in wound biopsies taken from the two groups of mice on day 9 after surgery. Microbial colonization of wounds was significantly less in the group treated with silver microfilm dressing (n = 10 mice / group, p < 0.05; Mann-Whitney U test). Figure 22E shows the percentage of wound closure (as a percentage of the original wound size) on day 9 after surgery (mean ± SEM). Wound closure was significantly higher in the group treated with silver microfilm dressing (n = 10 mice / group, p < 0.05; Mann-Whitney U test). [Diagram 23] Schematic illustration of the application of microsheets for surface modification of medical devices such as surgical meshes, contact lenses, or wound dressings. A sacrificial cast of the microsheet quickly dissolves on a wet surface and anchors a polymer nanofilm thereon. [Figure 24] 13 presents images showing immobilization of a polymer nanofilm by a microsheet on the surface of a wet collagen matrix of an Integra wound dressing. (A) Micrograph of the surface of the collagen matrix of an Integra wound dressing. (B) Micrograph of a fluorescent polymer nanofilm immobilized on the collagen matrix of an Integra wound dressing after sacrificial cast dissolution of the microsheet. Scale bar, 200 um. [Diagram 25] 13 presents images showing immobilization of a microsphere-containing polymer nanofilm by a microsheet onto a wet collagen matrix of an Integra wound dressing. (A) Micrograph of a microsheet with a polymer nanofilm containing fluorescent microspheres of 2 um size assembled onto an elastomer sheet. (B) Micrograph of a polymer nanofilm (with fluorescent microspheres) immobilized onto a wet collagen matrix of an Integra wound dressing after sacrificial cast dissolution of the microsheet. Scale bar, 20 um. [Figure 26]A graph is presented showing the reduction of bacterial colonization in solutions incubated on the surface of Integra wound dressings modified with silver nanofilms (AgNPs) using microsheets with water-soluble sacrificial casts of PVA. The solutions on the test dressings were repeatedly inoculated with 107 CFU / ml of S. aureus every 24 hours. [Figure 27] A stress strain curve is presented, which shows the mechanical strength of the silver microsheet. [Figure 28] 28a shows a schematic diagram according to an embodiment of the technology described herein. FIG. 28a shows the polyelectrolyte used for the multilayer assembly of nanometer-thick PEMs. FIG. 28b is a schematic diagram of the procedure used for the fabrication and application of PEM / PVA microfilms to wound beds; (1) PEMs are assembled on a PDMS sheet, (2) after fabrication, the PEMs are impregnated with silver ions, which are then reduced to silver nanoparticles, (3) a PVA solution is spin-coated onto the silver-loaded PEMs, (4) the PEM / PVA microfilm is peeled off from the PDMS sheet, and (5) placed on a moist wound bed. (6) Dissolution of the PVA layer in the moist wound (7) fixes the PEM onto the wound bed. [Figure 29] Figure 1 shows a plot of the ellipsometric thickness of (FITC-PAH / PAA) PEMs with increasing number of bilayers (n) assembled on a silicon wafer. Data are presented as mean ± SEM (n=12). As shown in the figure, PEMs assembled using PAA solution (pH=2.5) are thicker than those fabricated using PAA solution (pH=5.5). The lower pH of PAA results in fewer ionized carboxyl groups available for electrostatic binding with charged polycations. This weak electrostatic interaction between polymer segments requires the deposition of more polyanions to compensate for the charge on the polycations, thereby forming thicker multilayers. Polymer multilayers at PAA pH 2.5 show a linear growth trend (average thickness of about 1200 Å for 10.5 bilayers), whereas those at PAA pH 5.5 show an exponential growth trend (average thickness of about 800 Å for 10.5 bilayers). [Diagram 30] A series of fluorescence microscopy images showing that the PEM / PVA microfilms peeled uniformly from the PDMS sheet on which they were assembled and retained their silver loading. Figures 30a, 30b, and 30c show representative fluorescence micrographs of 6 mm diameter PEM / PVA microfilms with (FITC-PAH / PAA5.5)10.5 PEM. Figure 30a shows the PEM on the PDMS sheet before peeling; Figure 30b shows the PDMS after peeling; and Figure 30c shows the PEM placed on a glass slide for imaging. [Diagram 31] A series of fluorescence micrographs showing that PEMs of (AF-PAH / PAA5.5)10.5 (assembled with Alexa Fluor 560-labeled PAH) cannot be peeled off from non-OTS-functionalized silicon wafers like PEM / PVA microfilms (FIGS. 31a, 31b, and 31c), but can be peeled off uniformly from OTS-functionalized silicon wafers (FIGS. 31d, 31e, and 31f). FIGS. 31a and 31d show AF-PEMs assembled on Si wafer substrates that are not OTS-functionalized and OTS-functionalized, respectively. Figures 31b and 31e show the PEM / PVA microfilms left on the Si wafer after peeling off, non-OTS-functionalized and OTS-functionalized, respectively, and Figures 31c and 31f show the PEM / PVA microfilms, non-OTS-functionalized and OTS-functionalized, respectively, peeled off from the Si wafer substrate and placed on a glass slide for imaging. [Diagram 32] Plot showing the silver loading of PEM / PVA microfilms before and after peeling the PEM from the PDMS sheet, illustrated with PEMs having different silver loadings. Data are presented as mean ± SEM (n >= 4). [Diagram 33]FIG. 1 is a plot showing that silver loading in PEMs stored at ambient temperature for 3 months is not significantly different from freshly assembled PEMs. Data are presented as mean ± SEM (n≧3). [Diagram 34] 34 is a series of fluorescence microscopy images of immobilized PEMs from PEM / PVA microfilms on human cadaver skin dermis (GammmaGraft) and plots showing the characteristics of the PEMs. FIG. 34a shows a microfilm with PEMs of (FITC-PAH / PAA2.5) 40.5 on a PDMS sheet, FIG. 34b shows a PEM / PVA microfilm placed on the skin dermis with the PEM facing the tissue surface, FIG. 34c shows a PEM immobilized on the skin dermis after being repeatedly rinsed with 1 mL of PBS, and FIG. 34d shows a PEM retained on human skin dermis after being submerged in excess PBS on a shaker plate and continuously incubated for 3 days. The plot in FIG. 34e shows the gradual release of silver ions into PBS from skin dermis modified with PEMs impregnated with various silver loadings. Data are presented as mean ± SEM (n≧4). [Diagram 35] Figure 1 is a plot showing that the PVA cast in the PEM / PVA microfilm completely dissolves in aqueous solution within 10 minutes. The plot represents the absorbance of malachite green dye incorporated into PVA and released as the PVA cast dissolves in 3 mL of PBS buffer at different time points. The absorbance of malachite green dye in PBS was measured with a UV-bis spectrophotometer at a wavelength of 595 nm. Data are presented as mean ± SEM (n > 5). [Diagram 36] 36 is a series of fluorescence microscopy images showing the persistence of FITC-PEM (e.g., (FITC-PAH / PAA2.5)40.5) immobilized on the skin dermis against mechanical pressure and abrasion. FIG. 36a shows FITC-PEM immobilized on the skin dermis, FIG. 36 shows intact FITC-PEM on the skin dermis after vertical application of mechanical pressure of about 8 kPa, and FIG. 36c shows FITC-PEM retained on the skin dermis after lateral abrasion (1 mm / s) with a Telfa dressing after the mechanical pressure treatment described in FIG. 36b. [Figure 37] 37 is a series of fluorescence microscopy images showing the formation of cracks in a PEM with a 40.5 bilayer (PAH / PAA2.5). FIG. 37a is a fluorescence microscopy image of a PEM with a 5.5 bilayer formed on an elastomeric PDMS sheet (FITC-PAH / PAA2.5). FIG. 37b is a fluorescence microscopy image of a PEM with a 10.5 bilayer formed on an elastomeric PDMS sheet (FITC-PAH / PAA2.5). FIG. 37c is a fluorescence microscopy image of a PEM with a 40.5 bilayer formed on an elastomeric PDMS sheet (FITC-PAH / PAA2.5). [Figure 38] 1 is a plot showing antibacterial activity in suspensions of S. aureus incubated for 24 or 48 hours on skin dermis modified with PEM / PVA microfilms with various amounts of silver. The modified skin dermis was incubated in a 96-well plate with 107 CFU of S. aureus in 100 mL of HBSS buffer on a shaking plate (150 rpm) at 37° C. Data are presented as mean ± SEM (n≧4). [Figure 39] FIG. 1 is a plot showing antibacterial activity in suspensions of Ps. aeruginosa incubated for 24 hours on skin dermis modified with Ag / PEM (with a silver loading of 2.9±0.1 μg cm-2) using PEM / PVA microfilm. The modified skin dermis was placed in a 96-well plate and incubated with 107 CFU of Ps. aeruginosa in 100 mL PBS buffer at 37°C for 24 hours with shaking (150 rpm). After incubation, the bacteria were rinsed off and collected from the test wells, serially diluted, and plated on blood agar plates. Data are presented as mean ± SEM (n≧4). [Diagram 40]40a is a series of images showing the modification of a full thickness splinted mouse wound with silver / PEM using microfilm. The photograph in FIG. 40a shows a PEM / PVA microfilm held by tweezers and a splinted mouse wound. FIG. 40b shows a PEM attached to a mouse wound. FIG. 40c, FIG. 40d, and FIG. 40e show the persistence of fluorescently labeled PEM fixed to an excised full thickness surface. FIG. 40c is a fluorescent microscope image showing a PEM / PVA microfilm containing PEM at (FITC-PAH / PAA2.5) 40.5 on a PDMS sheet prior to transfer. FIG. 40d is a fluorescent microscope image showing a PEM / PVA microfilm containing PEM at (FITC-PAH / PAA2.5) 40.5 on a wound bed retrieved from a mouse after 1 hour. FIG. 40e is a fluorescent microscopy image showing a PEM / PVA microfilm containing PEM of (FITC-PAH / PAA2.5) 40.5 on a wound bed harvested from a mouse 3 days after surgery. [Diagram 41] Figure 13 is a plot showing the silver loading in (PAH / PAA2.5)10.5 PEM adjusted to 16.8 ± 0.5 μg cm-2 by three cycles of silver ion exchange and their in situ reduction to silver nanoparticles. Data are presented as mean ± SEM (n > 4). [Diagram 42] Figure 1 shows the sustained release of silver ions from (PAH / PAA2.5)10.5 PEMs with a silver loading of 16.8 ± 0.5 μg cm-2 into PBS. The silver loading in the PEMs was achieved by three cycles of silver ion exchange and reduction. The PEM constructs were used to treat contaminated wounds in mice. Data are presented as mean ± SEM (n=3). [Diagram 43]Figure 1 shows a plot of inhibition of microbial colonization in contaminated mouse wounds treated with PEM / PVA microfilm (with a silver loading of 16.8 ± 0.5 μg cm-2). 6 mm diameter splinted excision wounds topically inoculated with 3.0x106 CFU / cm2 S. aureus were treated with PEM / PVA microfilm and covered with Biobrane® biosynthetic wound dressing. Plots show bacterial counts harvested from wounds harvested (with Biobrane®) and homogenized 3 days after surgery (*, P>0.05; **, P<0.001; ***, P<0.03). Data represent mean ± SEM (n=8 mice (=16 wounds) for each group). [Diagram 44] FIG. 1 is a plot showing inhibition of microbial colonization in contaminated mouse wounds treated with PEM / PVA microfilm (with a silver loading of 17.63±3.13 μg cm-2). 6 mm diameter splinted excision wounds topically inoculated with 2.71×106 CFU / cm2 S. aureus were treated with PEM / PVA microfilm and covered with Biobrane®, a biosynthetic wound dressing. The plot shows bacterial counts harvested from wounds harvested (with Biobrane®) and homogenized 3 days after surgery. Data represent the mean±SEM (n=10 (=20 wounds) for each group) (P<0.001). [Diagram 45]A series of images and plots showing that PEM / PVA microfilms promote normal wound healing in splinted mouse excision wounds. Figure 45a, Figure 45b, and Figure 45c show gross images of wounds modified after surgery with silver / PEM (with a silver loading of 16.8±0.5 μg cm-2) at 0, 7, and 14 days after surgery, respectively. Each line on the scale represents 1 mm. Figure 45d shows the percentage of original wound size 3, 5, 7, 10, and 14 days after surgery in wounds that did not receive PEM treatment and in wounds modified with either non-silver-containing PEM or PEM containing 16.8±0.5 μg cm-2 silver. Each data point represents the mean±SEM of relative wound size. Sample sizes (n) for days 3, 5, and 7 were n=8, 16, and 16 for each group, respectively. Some wounds were harvested for histopathological examination on day 7. Sample sizes for the three groups on days 10 and 14 were n=4, 6, and 6, respectively. [Figure 46] This is a series of images showing that PEM / PVA microfilm promotes normal wound healing in splinted mouse excision wounds. The micrographs in Fig. 46a, Fig. 46b, and Fig. 46c are overall images of wounds without PEM, and the micrographs in Fig. 46d, Fig. 46e, and Fig. 46f are overall images of wounds modified with non-silver-containing PEM, respectively. Fig. 46a and Fig. 46d are images at day 0 after surgery, Fig. 46b and Fig. 46e are images at day 7 after surgery, and Fig. 46c and Fig. 46f are images at day 14 after surgery. Each line on the scale represents 1 mm. [Figure 47]A series of images and plots showing that PEM / PVA microfilms (with 16.8±0.5 μg cm-2 silver) promote epithelialization (measured histopathologically) in splinted mouse excision wounds similar to untreated wounds. Figures 47a and 47b show representative H&E stained sections of wounds 7 and 14 days after surgery in silver / PEM modified wounds, respectively. The original wound margins (arrows), migration of the epithelial apex (arrowheads), granulation tissue (G), and wound matrix (W) are marked. Figure 47c shows the percentage of the original size of wounds not receiving PEM treatment and the size of wounds modified with PEM without silver or PEM containing silver 7 and 4 days after surgery. Each data point represents the mean ± SEM of relative wound size. The sample sizes (n) on day 7 for the groups without PEM, with PEM / PVA without Ag, and with PEM / PVA with Ag were n=4, 9, and 7, respectively. For day 14, n=3 for each group. [Figure 48] PEM / PVA microfilms demonstrate that splinted mouse excision wounds promote epithelialization (as measured histopathologically) similar to untreated wounds. Figures 48a and 48b are photomicrographs of H&E stained sections from wounds without PEM 7 and 14 days after surgery, respectively. Figures 48c and 48d are photomicrographs of H&E stained sections from wounds fixed with PEM without silver 7 and 14 days after surgery, respectively. The original wound margins (arrows), migration of the epithelial apex (arrowheads), granulation tissue (G), and wound matrix (W) are marked. [Figure 49] 49A-49B compare the coverage of a wound with an embodiment of a microfilm silver dressing presented herein with a conventional dressing, with FIG. 49A showing a wound covered with a conventional dressing and FIG. 49B showing a wound covered with a microfilm dressing described herein. [Figure 50]Shown are photomicrographs of hematoxylin and eosin (H&E) stained wounds 12 days after surgery created in the flank of a BALB / c mouse and inoculated with 2x105 CFU of S. aureus. Figure 50A shows the wound covered with a biosynthetic Biobrane dressing. Figure 50B shows the wound covered with a silver microfilm wound dressing prior to placing Biobrane on the wound. In Figure 50, the scale represents 0.5 mm. [Figure 51] FIG. 1 is a plot showing inhibition of P. aeruginosa biofilms on the bottom of 48-well plates in TSB medium with Ga(NO3)3. Data are presented as absorbance of crystal violet stained biofilms (n=4, mean ± SD). [Figure 52] FIG. 1 shows an embodiment of a microfilm dressing containing a water-soluble polymer cast (with anti-biofilm Ga) adhering to a polymeric multilayer nanofilm (PEM) containing silver nanoparticles on a wound bed. [Figure 53] 1 is a plot showing the sustained release of Ga3+ from (PAA / PAH)10 PEM containing 16.1±0.8 μg / cm2 gallium into PBS. [Figure 54] 54A-54B show the sequential transfer of a nanocoating of a PEM containing gallium (Ga) or silver nanoparticles (AgNPs) by stamping onto a silicone film covering: Fig. 54A shows the sequential deposition of the nanocoating onto the silicone film, and Fig. 54B shows the removal of the stamp, leaving the nanocoating on the silicone film. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0080] definition To facilitate understanding of the invention described in the disclosure that follows, several terms are defined below.

[0081] The term "wound" refers broadly to damage to the skin and subcutaneous tissues caused by a variety of conditions (e.g., pressure ulcers from prolonged bed rest, trauma-induced wounds) and with various characteristics. The methods and compositions described herein are useful for treating all types of wounds, including wounds to internal and external tissues. Wounds can be classified into one of four grades based on wound depth: i) Grade I: wounds limited to the epithelium; ii) Grade II: wounds extending into the dermis; iii) Grade III: wounds extending into the subcutaneous tissue; iv) Grade IV (i.e., full thickness wounds): wounds that expose bone (e.g., bony pressure points such as the greater trochanter or sacrum).

[0082] The term "partial thickness wound" refers to wounds that include grades I-III, and examples of partial thickness wounds include burn wounds, pressure ulcers, venous stasis ulcers, and diabetic ulcers. The term "deep wound" is intended to include both grade III and grade IV wounds. The present invention contemplates treating all types of wounds, including deep and chronic wounds.

[0083] The term "chronic wound" refers to a wound that has not healed within 30 days.

[0084] "Promoting wound healing", "improving wound healing" and similar phrases refer to the induction of wound contraction, the formation of granulation tissue, and / or the induction of epithelialization (the production of new cells in the epithelium). Wound healing is conveniently measured by the reduction in wound area.

[0085] The term "wound active agent" refers to a known or potential chemical compound that induces a desired pharmacological or physiological effect useful in the treatment and healing of wounds, the effect may be prophylactic or therapeutic. The term also encompasses pharmacologic acceptable pharmacologically active derivatives of the active agents detailed herein, examples of which include, but are not limited to, nutrients, extracellular matrices, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infective agents (e.g., ionic silver, elemental silver, and silver nanoparticles), buffering agents, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anti-cancer agents.

[0086] The term "polymeric multilayer" refers to a composition formed by successively and repeatedly applying a polymer(s) to form a multilayer structure. For example, a polyelectrolyte multilayer is a polymeric multilayer formed by alternatingly adding an anionic polyelectrolyte and a cationic polyelectrolyte to a wound or support. The term "polymeric multilayer" also refers to a composition formed by successively and repeatedly applying a polymer(s) to a wound or solid support. In addition, the term "polymeric layer" may refer to a monolayer composed of polymer molecules, such as anionic or cationic polyelectrolyte molecules, present as one layer in a multilayer or as a monolayer of only one type of polyelectrolyte molecule on the wound or support. While the delivery of the polymer to the wound bed or support is continuous in the preferred embodiment, the use of the term "polymeric multilayer" is not limiting in terms of the structure of the resulting coating. It is well understood by those skilled in the art that interdiffusion of polymers, such as polyelectrolytes, may occur resulting in a structure that is well mixed in terms of the distribution of anionic and cationic polyelectrolytes. It is also understood that the term polyelectrolyte encompasses polymeric and nanoparticle species and is not intended to be limiting in scope other than to indicate that the species has multiple charged or partially charged groups. It is also well understood by those skilled in the art that multi-layer structures can be formed by a variety of interactions, such as, for example, electrostatic interactions and other hydrogen bonding. Thus, the term "polyelectrolyte" is not limiting in terms of the interactions that result in the formation of a wound bed construct.

[0087] As used herein, the term "crosslinked" refers to a composition containing intermolecular crosslinks and optionally intramolecular crosslinks resulting from the formation of covalent bonds. The covalent bond between two crosslinkable components may be direct, where an atom of one component is directly bonded to an atom of the other component, or the bond may be indirect through a linking group. In addition to covalent bonds, the crosslinked structure may also include intermolecular and / or intramolecular non-covalent bonds, such as hydrogen bonds and electrostatic (ionic) bonds.

[0088] The term "covalent modifier" refers to any molecule that covalently bonds molecules to one another. Covalent modifiers include homobifunctional and heterobifunctional crosslinkers and photoactivatable crosslinkers.

[0089] The term "homogeneous bifunctional crosslinker" refers to a molecule that is used to covalently bond identical or similar molecules to one another. Homogeneous bifunctional crosslinkers have two identical reactive groups, and therefore homogeneous bifunctional crosslinkers can only bond molecules of the same type to one another. Conversely, "heterogeneous bifunctional crosslinkers" refer to a molecule that is used to covalently bond different molecules to one another, since it has two or more different reactive groups that can interact with a variety of different types of molecules. Heterogeneous and homogeneous multifunctional crosslinkers refer to multivalent crosslinkers that have both heterogeneous and homogeneous crosslinking functional groups. Activated dendrimers are an example of a multifunctional crosslinker.

[0090] The term "subject" refers to any animal (e.g., mammal) that is to receive a particular treatment, including, but not limited to, humans, non-human primates, rodents, dogs, cats, and the like. Generally, the terms "subject" and "patient" are used interchangeably herein.

[0091] The term "surfactant" refers to an amphiphilic material that modifies the surface and interfacial properties of a liquid or solid. Surfactants can reduce the surface tension between two liquids. Detergents, wetting agents, emulsifiers, dispersants, and foam suppressors are all surfactants.

[0092] The term "block copolymer" refers to a polymer composed of at least two monomers. In a block copolymer, adjacent blocks are structurally different, i.e., adjacent blocks contain constitutional units derived from different types of monomers or from the same type of monomers but with different composition or sequence distribution of the constitutional units. A block copolymer can be considered as two homopolymers joined at their ends.

[0093] The term "solvent" refers to a liquid capable of dissolving a substance. The term "organic solvent" refers to a solvent derived from a petroleum-based product.

[0094] The term "polyelectrolyte" refers to a water-soluble polymeric material that contains many repeating ionic building blocks, such as cations and anions.

[0095] The term "primary amine" refers to derivatives of ammonia in which a hydrogen has been replaced by a hydrocarbon unit. Primary amines have the general formula RNH 2 Examples include, but are not limited to, aniline, methylamine, and 1-propylamine.

[0096] The term "DNA delivery agent" refers to any molecule capable of contacting DNA with a specific target. In some cases, the DNA delivery agent causes uptake of DNA into one or more cells in vitro or in vivo. The DNA delivery agent may be a virus, including, but not limited to, adenovirus and retrovirus. The DNA delivery agent may also be a non-viral agent, including, but not limited to, plasmids, lipids, liposomes, polymers, and peptides.

[0097] The term "exposable" refers to anything that can be exposed. An exposed surface or molecule is one that is available for interaction with another surface or molecule. For example, in the context of the present invention, a covalent modifier can be exposed to a wound active agent such that the two agents can interact with each other to form a covalent bond.

[0098] The term "functionalization" refers to the modification of an existing molecular segment to generate or introduce a new reactive functional group (e.g., a maleimide or succinimidyl group) that can react with other functional groups (e.g., sulfhydryl groups) to form a covalent bond. For example, a component containing a carboxylic acid (--COOH) group can be functionalized by reaction with N-hydroxy-succinimide or N-hydroxysulfosuccinimide, using known procedures, to form a new reactive functional group in the form of an activated carboxylate (which is a reactive electrophilic group), i.e., an N-hydroxysuccinimide ester or an N-hydroxysulfosuccinimide ester, respectively. In another example, a carboxylic acid group can be functionalized by reaction with an acyl halide, e.g., an acyl chloride, also using known procedures, to obtain a new reactive functional group in the form of an anhydride.

[0099] As used herein, the term "aqueous solution" includes solutions, suspensions, dispersions, colloids, and the like that contain water.

[0100] As used herein, the term "click chemistry" refers to the use of chemical building blocks that incorporate high energy content to drive spontaneous and irreversible conjugation reactions with suitable complementary sites on other components. These chemical reactions (e.g., including but not limited to, the reaction between azide and acetylene groups, which readily combine with each other) are specific and result in a covalent bond between the two molecules.

[0101] The term "native chemical ligation" refers to the chemoselective reaction of two unprotected peptide segments that first generates a thioester-linked species, followed by spontaneous rearrangement of this transient intermediate to yield a full-length product with a native peptide bond at the ligation site.

[0102] The term "specific protein binding" refers to an interaction between two or more proteins that have high affinity and specificity for each other. In order to function, a protein must bind to another protein in vivo that is specific for it. A protein is usually required to bind to only one or a few other proteins among the thousands of proteins present in vivo, and this interaction is used in the present invention to bind a wound active agent to a wound in vitro. In the context of the present invention, specific protein binding interactions include, but are not limited to, those between biotin and avidin, neutravidin, or streptavidin; between glutathione-S-transferase and glutathione; and between nickel-nitrilotriacetic acid and polyhistidine.

[0103] The term "device" refers to an object that contacts a subject's body or bodily fluids for therapeutic or prophylactic purposes. Some devices partially or indirectly contact the subject's body or bodily fluids (e.g., catheters, dialysis tubing, diagnostic sensors, drug delivery devices), while others are completely absorbed or incorporated into the subject's body (e.g., stents, pacemakers, implantable cardioverter defibrillators, angioplasty balloons, orthopedic devices, spinal cages, implantable drug pumps, artificial spinal discs, ear discs).

[0104] The term "selective toxicity" refers to the property of a specific toxic effect experienced by mammalian cells versus microbial cells. For example, a selective toxic agent can effectively kill bacterial cells while simultaneously allowing the growth and survival of mammalian cells.

[0105] The term "toxicity" refers to any toxic or deleterious effect on a subject, cell, or tissue when compared to the same cell or tissue prior to administration of the toxic agent.

[0106] As used herein, the terms "nanoparticle" and "nanoscale particle" are used interchangeably and refer to nanoscale particles having a size measured in nanometers, e.g., nanoscale particles having at least one dimension less than about 1000, less than 500, or less than 100 nm. Examples of nanoparticles include nanobeads, nanofibers, nanohorns, nanoonions, nanorods, and nanoropes.

[0107] As used herein, "microparticle" and "microscale particle" are used interchangeably and refer to microscale particles having a size measured in micrometers, e.g., microscale particles having at least one dimension less than about 10 micrometers, less than 5 micrometers, or less than 2 micrometers.

[0108] The term "wound dressing" refers to a material placed adjacent to a wound that has absorbent, adhesive, protective, osmoregulatory, pH-regulatory, or pressure-inducing properties. Wound dressings may directly or indirectly contact the wound. Wound dressings are not limited by size or shape. Indeed, many wound dressing materials may be cut or configured to fit the dimensions of the wound. Examples of wound dressing materials include, but are not limited to, gauze, adhesive tape, bandages, and commercially available wound dressings, including, but not limited to, the Band-Aid® line of wound dressings adhesive bandages and pads, the Nexcare® line of wound dressings adhesive bandages and pads, the Kendall Curity Tefla® line of wound dressings adhesive bandages and non-adhesive pads, the Tegaderm® line of wound dressings adhesive bandages and pads, the Steri-Strip® line of wound dressings adhesive bandages and pads, the COMFEEL® line of wound dressings, adhesive bandages and pads, the Duoderm® line of wound dressings, adhesive bandages and pads, the TEGADERM™ line of wound dressings, adhesive bandages and pads, the OPSITE® line of wound dressings, adhesive bandages and pads, and biological wound dressings. A "biological wound dressing" is a type of wound dressing that includes, e.g., is coated with or incorporates, cells and / or one or more biomolecules or fragments of biomolecules that can be placed in contact with the wound surface. The biomolecules may be provided in the form of an artificial tissue matrix. Examples of such biomolecules include, but are not limited to, collagen, hyaluronic acid, glycosaminoglycans, laminin, vitronectin, fibronectin, keratin, antimicrobial polypeptides, and combinations thereof. Examples of suitable biological wound dressings include, but are not limited to, BIOBRANE™, Integra™, Apligraf™, Dermagraft™, Oasis™, Transcyte™, Cryoskin™, and Myskin™.

[0109] As used herein, the term "antimicrobial silver composition" refers to a composition that includes silver as an active antimicrobial agent. Examples of "antimicrobial silver compositions" include, but are not limited to, silver nanoparticles, elemental silver, zero-valent silver, zirconium phosphate-supported polyvalent silver ion (ZP-Ag) (see, e.g., Wound Repair and Regeneration, 16:800-804), and silver-containing compounds such as silver sulfadiazine, and related compounds. The term "releasable antimicrobial silver composition" refers to an antimicrobial silver composition that can be released from a material, e.g., a polymeric multi-layer solid carrier, such that antimicrobial activity can be observed. The release of an antimicrobial silver composition can be defined as the amount of composition released from a defined area or space in the material.

[0110] [Mode for carrying out the invention] Due to the complex nature of wounds and the lack of significant clinical and technological advances based on current medical practice, new and unconventional approaches are urgently needed. The microenvironment of pathological / chronic wound beds is dysregulated by altered activity of extracellular matrix constituents, degradative enzymes, growth factors and other cell activators. The present invention provides compositions and methods to engineer the wound bed itself, for example by altering the surface chemistry / structure of the wound bed to promote favorable cell behaviors such as accelerating wound healing. In some embodiments, the wound bed is first treated with a priming agent (i.e., primer) that provides a uniform, reactive bed at the wound surface. The primed wound bed is then treated with the desired agent (e.g., wound activator).

[0111] In normal wound healing, the coordinated interaction between fibroblasts, vascular cells, extracellular matrix components, and epithelial cells results in uninterrupted progression through inflammatory response, wound repair, contracture, and epithelial barrier coverage. However, in many subjects with dysregulated wound microenvironment, systemic disease, or other confounding conditions, the wound healing process becomes asynchronous and painless ulcers develop (Pierce, 2001, Am. J. Pathol. 159:399). In other subjects, the loss or absence of the control response to properly regulate cellular behavior during healing leads to a hyperproliferative response that is essentially harmful to the subject. This is especially true in patients with a tendency to form keloids or who have suffered burns, where excessive fibroblast proliferation and collagen production leads to the formation of disfiguring and dysfunctional scars.

[0112] It is clear that there are various triggering mechanisms and wound microenvironments across a wide range of non-healing wounds. These wounds exhibit pathology at many junctions in their progression towards closure. Lack of angiogenesis, fibroblast response, and re-epithelialization all play important roles in chronic wounds. Thus, treating chronic wounds with a single agent is unlikely to be a beneficial approach across the many different wounds present in clinical settings. In such heterogeneous environments, better strategies may include identifying specific aspects of the cellular response, components that can modulate the reaction in the wound environment, thereby resulting in a customized healing response appropriate for each individual wound and patient.

[0113] Since the wound environment is heterogeneous, it is contemplated that the best way to stimulate a "desirable" healing response is to specifically modulate the cellular response within the wound. The present invention offers the selection of a subset of cellular active components from a list of candidates fixed to the wound bed to specifically modulate endothelial, fibroblastic, and epithelial components within the wound response. Thus, the present invention offers the possibility of obtaining high-quality wound responses in various clinical conditions, thereby offering a wound bed manipulation strategy for personalized therapy for the individual wound healing challenges faced by clinicians. Specific examples where specific modulation of cellular responses within the wound can provide substantial benefits include chronic wounds in diabetes or venous stasis ulcers, where promotion of an overall cellular healing response is desirable, but in particular, a vigorous angiogenic response is required to support all other aspects of wound healing. In other words, where the strength of the healed wound is a major concern, modulation to promote fibroblastic responses with normal angiogenesis and epithelial components is desirable.

[0114] In contrast, in some burns (e.g., severe second-degree burns, where components of the dermis and hair shaft epithelium continue to replace lost tissue), vigorous angiogenesis and epithelial responses are required, but a reduced fibroblastic response is desirable to reduce scar hypertrophy, contracture, and disfigurement. A similar reduction is desirable in the healing of subjects prone to keloid formation, where the proliferative fibroblastic response must be inhibited. Also, in wounds near joints or orifices, rapid healing and epithelial coverage are desirable, but the fibroblastic response is desirably modulated to maintain improved tissue flexibility. Thus, modulating the fibroblastic response may result in better clinical outcomes, thereby obviating the need for reconstructive procedures aimed at restoring limbs or other vital bodily functions. The feasibility of such methods has been shown previously, for example, by Muehlberger et al. on the effect of tretinoin on incisional wounds (Muehlberger et al., 2003). (Eds. et al., 2005, J. Am. Acad. Derm. 52:583). In this study, application of tretinoin increased fibroblast proliferation while decreasing collagen production.

[0115] Surface modification has become an important issue for the application in implants, prostheses and artificial organs in the last decade, which allows a wide range of medical applications for implantation and tissue engineering (Langer and Vacanti, 1993, Science 260:920; Peppas and Langer, 1994, Science 263:1715; Angelova and Hunkeler, 1999, Trends Biotechnol. 17:409). Several methods have been investigated to improve the fusion efficiency of implants, including modification of the physicochemical, morphological and biochemical properties of the device surface, aiming at obtaining a suitable bone-implant interface. Self-assembled monolayers (SAMs) or Langmuir-Blodgett techniques are commonly used to generate new interfaces (Mrksich, 1997, Curr. Opin. Colloid Interface Sci. 2:83; Loesche, 1997, Curr. Opin. Solid State Mater. Sci. 2:546).

[0116] Recently, a new versatile method of self-assembly structures based on layer-by-layer deposition of polyanions and polycations has been developed for the assembly of multilayered polyelectrolyte films (Decher, 1997, Science 277:1232). In addition to varying film thickness, roughness, and porosity, it is also possible to incorporate functionalized polymers into the film structures (Caruso et al., 1997, Langmuir 13:3427; Cassier et al., 1998, Supramol. Sci. 5:309). It has also been shown that the multilayer deposition process is not limited to its applicability to polyelectrolytes, but can also be applied to viruses, nanoparticles, non-ionic polymers, proteins, and other small material (micro- and nano-level) forms. Recently, information has been reported on a wide range of species and interfacial structures that can be formed by the multilayer deposition method. The scope of the invention described herein is not limited to polyelectrolytes, but includes all species that have been shown to be incorporated into interfacial structures by the multilayer deposition process.

[0117] The present invention provides various embodiments for altering the composition of a wound bed. In some embodiments, a wound modifying agent is applied to prime the wound bed. As detailed below, a wound modifying agent is an agent that is applied to the wound bed and modifies the wound bed either covalently or non-covalently. Examples of wound modifying agents include homogeneous and heterogeneous bifunctional linkers, polyelectrolytes, non-ionic polymers, combinations of polyelectrolytes and non-ionic polymers, and nanoparticles and microparticles, including beads and needles. In some embodiments, the wound modifying agent alters the properties of the wound bed selected from the group consisting of compliance, pH, alkalinity, and oxidative or reductive strength, net charge, hydrophilicity, osmotic power, nanoscale or submicron tissue distribution, electrical conductivity, MMP production, phagocytosis, and transglutaminase activity. In a preferred embodiment, the wound modifying agent is used to incorporate and position the wound active agent in the wound bed. The wound active agent may be covalently or non-covalently bound to the wound modifying agent. Additionally, the wound active agent may form a gradient through the wound modifying agent. In further embodiments, the wound modifying agent alters the compliance of the wound bed. In these embodiments, the polymer or nanoparticles or microparticles have a predefined hardness. In further embodiments, the polymer, nanoparticles, or microparticles may form a compliance gradient with different levels of hardness.

[0118] In some embodiments of the present invention, the wound active agent is silver or a form of silver.Silver is widely used as a non-specific biocide that acts against a wide range of bacterial species (Yin et al., 1999, J. Burn Care Rehabil. 20:195, incorporated herein by reference in its entirety), yeast species, fungal species (Wright et al., 1999, Am. J Infect. Control 27:344, incorporated herein by reference in its entirety), and viruses (Hussain et al., 1991, Biochem. Biophys. Res. Comm. 189:1444, incorporated herein by reference in its entirety), including some antibiotic-resistant strains (Wright et al., 1998, Am. J. Infect. Control 26:572, incorporated herein by reference in its entirety). However, due to the highly reactive nature of silver ions, topically applied silver preparations are rapidly inactivated in wounds, and frequent application to wounds can introduce excessive amounts of silver ions into the wound, resulting in overdose toxicity. In vitro experiments have demonstrated the cytotoxic effects of silver ions on fibroblasts (Poon et al., 2004, Burns 30:140; Hildago et al., Skin Pharmacol. Appl. Skin Physiol. 11:140, each of which is incorporated herein by reference in its entirety), keratinocytes (Poon et al., 2004, Burns 30:140, each of which is incorporated herein by reference in its entirety), hepatocytes (Baldi et al., 1988, Toxicol. Lett. 41:261, each of which is incorporated herein by reference in its entirety), and lymphocytes (Hussain et al., 1991, Biochem. Biophys. Res. Comm. 189:1444, each of which is incorporated herein by reference in its entirety).

[0119] The highly reactive nature of silver ions makes their delivery to the wound bed difficult: released silver ions readily bind to proteins and chloride in complex wound fluids, causing rapid inactivation (Mooney et al., 2006, Plastic and Reconstr. Surg. 117:666, each of which is incorporated herein by reference in its entirety), and leads to undesirable adsorption of silver ions to epithelial cells and sweat glands (Klasen, 2000, Burns 26:117, each of which is incorporated herein by reference in its entirety). Silver-based topical solutions, such as 0.5% silver nitrate, or ointments, such as 1% silver sulfadiazine cream, currently used clinically for wound healing release silver at concentrations up to 3200 ppm, most of which is rapidly inactivated by chemical complex formation in the wound (Dunn et al., Burns, 2004, 30(supplement 1):S1, incorporated herein by reference in its entirety), and therefore require frequent application (up to 12 times per day for silver nitrate solutions and at least twice per day for silver sulfadiazine cream). Frequent application introduces excessive amounts of silver ions into the wound, which results in toxic effects and discoloration resulting from overdosing (Atiyeh et al., 2007, Burns 33:139; Trop et al., 2006, J. Trauma 60:648, each of which is incorporated herein by reference in its entirety). Wound dressings with silver incorporated into dressings have been introduced in recent years, prolonging the release of silver into the wound and reducing the frequency of dressing changes. However, these dressings must be impregnated with large amounts of silver ions, which can lead to cytotoxicity. The leading commercially available wound dressing is Acticoat® (containing nanocrystalline silver) (Dunn et al., Burns, 2004, 30(supplement 1):S1).Silver released from topical silver antimicrobials (Poon et al., 2004, Burns 30:140; Trop et al., 2006, J. Trauma 60:648, each of which is incorporated herein by reference in its entirety) has been shown to be toxic to in vitro monolayer cell cultures of keratinocytes and fibroblasts (Poon et al., 2004, Burns 30:140; Trop et al., 2006, J. Trauma 60:648, each of which is incorporated herein by reference in its entirety). Thus, challenges with current topically applied silver antimicrobials include low levels of silver release, lack of penetration, rapid loss of silver ions, and the presence of silver nitrate or cream bases that are pro-inflammatory and negatively impact wound healing. Challenges such as wound contamination, electrolyte imbalance, and patient discomfort also exist.

[0120] In certain embodiments, the present invention includes a novel method for controlled topical application of non-cytotoxic levels of antimicrobial silver compositions to surfaces that maintains antimicrobial activity and reduces cytotoxicity while avoiding the use of excessive amounts of silver in wounds. In experiments conducted in the course of developing certain embodiments of the present invention (Example 13), nanometer thick polymer films were assembled that were incorporated with silver nanoparticles at levels that produced a bacteria-killing effect, but did not produce a cytotoxic effect on the attachment and growth of mouse fibroblast cells on the films. In some embodiments, polymer films are incorporated with antimicrobial silver compositions by incubating the films in the antimicrobial silver compositions described in Example 13. In other embodiments, antimicrobial silver compositions are incorporated directly into the polymer multilayer during the synthesis of the multilayer. See, for example, Langmuir. 2005 Dec 6;21(25):11915-21.

[0121] The silver nanoparticle-impregnated thin film in some embodiments of the present invention utilizes a different principle for the delivery of silver to the wound matrix. The film can be applied directly to the exposed wound bed, which releases silver ions locally into the wound. This reduces the amount of bactericidal silver that needs to be incorporated into the film by several orders of magnitude, and significantly reduces the toxicity of silver ions, compared to local silver delivery agents. Although the present invention is not limited to any particular mechanism, and an understanding of the mechanism is not necessary to practice the present invention, it is contemplated that while silver-impregnated dressings and ointments must deliver high levels of silver ions into the wound bed to overcome the rapid loss of silver ions in the wound fluid, which limits the penetration of released silver, the local release of silver to the wound matrix by some polymer thin film embodiments presented herein can avoid the use of high silver loadings.

[0122] Some molecularly thin synthetic films of the present invention have a molecular weight of 0.4 μg / cm 2 The films can be formulated to contain as little as soluble silver and release less than 1 ppm total silver ions into the buffer solution. Such films exhibit 99.9999% bactericidal efficacy without any measurable cytotoxicity to mammalian cells. Furthermore, films containing these levels of silver allow attachment and proliferation of mammalian cells (e.g., NIH-3T3 mouse fibroblast cells). In some embodiments, the releasable antimicrobial silver composition is present in a concentration of 1 or 10 to about 50, 100, 200, 300, 400, 500, or 1000 μg / cm of the polymeric multilayer. 2 and / or about 0.01 to 100 μg / cm of the polymer multilayer per day. 2 In some embodiments, the releasable antimicrobial silver composition is capable of being released in an amount of about 0.05-100 μg / cm of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is capable of being released in an amount of about 0.05-20 μg / cm of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is capable of being released in an amount of about 0.05-5 μg / cm of the polymeric multilayer.2 In some embodiments, the releasable antimicrobial silver composition is capable of being released in an amount of about 0.05-2 μg / cm of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is capable of being released in an amount of about 0.05-1 μg / cm of the polymeric multilayer. 2 In some embodiments, the releasable antimicrobial silver composition is capable of being released in an amount of about 0.1-0.5 μg / cm of the polymeric multilayer. 2 It is possible to release in amounts of

[0123] Experiments conducted during the course of developing some embodiments of the present invention have shown that the silver concentration in the films can be systematically varied, and that their cytotoxicity and antimicrobial efficacy are dependent on the silver loading. By comparison, the amount of soluble silver in the commercially available wound dressing Acticoat® is approximately 100 μg / cm 2 (Dunn et al., 2004, Burns 30(supplement 1):S1, which are incorporated herein by reference in their entireties. Acticoat® has been shown to release more than 120 ppm total dissolved silver in water in 24 hours (Taylor et al., 2005, Biomaterials 26:7221, which are incorporated herein by reference in their entireties) and to be cytotoxic to keratinocytes and fibroblasts (Poon et al., 2005, Burns 30:140; Trop et al., 2006, J. Trauma 60:648, each of which are incorporated herein by reference in their entireties).

[0124] There have been several reports of polyelectrolyte composite films that contain silver and exhibit antibacterial activity by releasing silver into solution (Lee et al., 2005, Langmuir 21:9651; Li et al., 2006, Langmuir 22:9820; Grunlan et al., 2005, Biomacromolecules 6:1149; Yu et al., 2007, Bioconj. Chem. 18:1521; Shi et al., 2006, J. Biomed. Mat. Res. Part A 76A:826, each of which is incorporated herein by reference in its entirety). However, all of these experiments were focused on controlling the volume fraction and concentration of silver in the film. Films containing high silver loading (approximately 5.5 μg / cm) 2 Polyelectrolyte films, such as those described above, have been reported to exhibit antibacterial activity (Wang et al., 2002, Langmuir 18:3370; Logar et al., 2007, Nanotechnol. 18:325601, each of which is incorporated by reference in its entirety herein). Such polyelectrolyte films, when loaded with silver at these levels, exhibited strong cytotoxicity, killing 100% of NIH-3T3 cells seeded on them (e.g., Example 13).

[0125] In experiments conducted in the course of developing certain embodiments of the present invention (e.g., Example 13), silver loading levels in PEM were identified and obtained that lead to silver-impregnated antimicrobial molecular thin films that allow mammalian cell attachment without exhibiting cytotoxicity. Such films find use for localized delivery of antiseptic silver to wounds, reducing the risk of toxicity from silver overdose as seen with other topical delivery agents. In some embodiments, implantable medical devices are coated with these silver-impregnated thin films, which are sterilized during initial attachment to these surfaces and inhibit bacterial colonization, a major cause of implant failure.

[0126] Thus, the silver-releasing molecular thin layer mixed films of some embodiments of the present invention have advantages over 1) other topical silver delivery agents currently in clinical use, 2) wound dressings containing high amounts of silver, and 3) other antiseptic thin layer mixed films containing high amounts of silver, which are cytotoxic to mammalian cells and on which mammalian cells cannot attach and grow.

[0127] The use of silver nanoparticle molecular thin films for local administration of bactericidal silver in wounds overcomes the silver-related toxicity issues faced by topical silver delivery agents for wound healing (Poon et al., 2004, Burns 30:140; Baldi et al., 1988, Toxicol. Lett. 41:261; Atiyeh et al., 2007, Burns 33:139; Coombs et al., 1992, Burns 18:179, each of which is incorporated herein by reference in its entirety). Moreover, these polyelectrolyte multilayers (PEMs) are homogeneous, highly permeable, ultrathin nanomixed films, typically less than 1 μm thick (Decher, 1997, Science 277:1232;Hammond, 1999, Curr. Opin. Colloid Interface Sci. 4:430. Each of which is incorporated herein by reference in its entirety). Their permeable and supramolecular structures allow the incorporation of a variety of molecules, including DNA, enzymes, viruses, dendrimers, colloids, inorganic particles, and dyes (Decher, 1997, Science 277:1232. Each of which is incorporated herein by reference in its entirety). Thus, in some embodiments, they can be used for the simultaneous local delivery of other bioactive agents (e.g., cell-recruiting growth factors, DNA plasmids encoding such growth factors, etc.) to the wound matrix along with the bactericidal silver. Because PEMs can conformally coat substrates of any type, size, or shape, including natural and synthetic polymers (Hammond, 1999, Curr. Opin. Colloid Interface Sci. 4:430, incorporated herein by reference in its entirety), they can be constructed onto any wound bed or implantable medical device.

[0128] In one embodiment, the present invention provides for the deposition and fixation of cell active factors and extracellular matrix (ECM) onto a wound bed, for example by using polyelectrolyte multilayers or beads. In FIG. 1, a schematic diagram 100 of a wound bed 110 onto which a polyelectrolyte multilayer 130 has been deposited is shown. The schematic diagram 100 shows that the wound bed 110 contains a heterogeneous surface depicted by shapes 120 representing different chemical moieties. The polyelectrolyte multilayer 130 provides a homogeneous surface to which functional groups 140 can be attached to form a homogeneous functionalized surface 150. In the illustrated embodiment, the functional groups are homogeneous, but in some preferred embodiments, different functional groups are used. Various active agents may then be attached to the surface via the functional groups 140. In other embodiments, the wound bed is covalently modified with a covalent modifying agent. The covalent modifying agents include, but are not limited to, homogeneous and heterogeneous bifunctional crosslinkers, as well as photoactivated crosslinkers. In Figure 2, a schematic diagram 200 is presented of a wound bed 210 containing a heterogeneous surface depicted by shapes 220 representing different chemical moieties. The wound bed is covalently modified by reacting a covalent modifying agent 230 with different chemical moieties to provide a relatively homogenously functionalized surface 250. In a preferred embodiment, the covalent modifying agent 230 provides functional groups 240. In the illustrated embodiment, the functional groups are uniform, however, in some preferred embodiments, different functional groups are used. Various active agents may then be attached to the surface via the functional groups 240. These embodiments are described in more detail below.

[0129] It is expected that the wound bed is a highly heterogeneous environment. The compositions and methods of the present invention are designed to modify the wound bed to provide a homogenous environment that provides uniform and predictable delivery to the wound bed or uniformly incorporates active agents into the wound bed. Surprisingly, it has been found that modifying the wound bed in this manner significantly reduces the amount of active agent required (i.e., the effective amount of active agent required is reduced). Surface functionalization allows for precise control of the amount of active agent used or delivered, and also allows for the formation of a gradient of active agent on the wound bed. In some preferred embodiments, the priming agent is optimized to react with the wound bed. In some embodiments, the priming agent provides an optimal surface for enhancing or optimizing the delivery of active agents. In some embodiments, the chemical parameters of the wound bed are changed. For example, the wound bed may be modified to be more or less acidic, basic, alkaline, reducing, or oxidizing, or to have high or low ionic strength.

[0130] There are various candidate molecules for improving the healing of chronic wounds. For example, basement membrane constituents and growth factors promote wound healing. In some embodiments, the deposited and immobilized extracellular matrix is ​​a constituent of a natural basement membrane. Natural ECM contains a mixture of glycoproteins, proteoglycans, and hyaluronic acid. These glycoproteins and proteoglycans include, but are not limited to, fibrin, elastin, fibronectin, laminin, glycosaminoglycans, nidogen, and collagen. Cell activating factors, such as growth factors, are also part of the ECM. In some embodiments, extracellular matrix components, such as collagen, laminin, glycosaminoglycans, or hyaluronic acid, are deposited and immobilized on the wound bed. In some embodiments, a synthetic matrix, such as MATRIGEL™, is deposited on the wound bed. MATRIGEL™ is a commercially available basement membrane-like complex that has many of the characteristics of natural basement membranes, including a three-dimensional nanoscale topography. The present invention is not limited to a particular mechanism. Indeed, an understanding of the mechanisms is not necessary to practice the present invention. However, it is contemplated that the nanoscale topographical features of the basement membrane regulate fundamental cell behaviors, including migration, attachment, proliferation and differentiation (Abrams et al., 2002, Biomimetic Materials and Design: Interactive Biointerfacial, Tissue Engineering, and Drug Delivery, Eds. Dillow and Lowman; Diehl et al., 2003). et al., 2005, J. Biomed. Mater. Res. A 75:603;Foley et al., 2005, Biomaterials 26:3639;Karuri et al., 2004, J. Cell Sci. 117:3153;Liliensiek et al., 2006, J. Biomed. Mater. Res. A 79:185). In some embodiments, the present invention further provides methods, formulations, compositions and kits for modifying the compliance of a wound surface. In some embodiments, local compliance (compliance at the cellular level) is modified by immobilizing a thin layer of an extracellular matrix component, such as MATRIGEL™, or a suitable hydrogel, or other synthetic matrix, or by treating the wound bed with an enzyme. In other embodiments, compliance is modified by adding a crosslinking agent to the wound bed to crosslink components already present in the wound bed or components intentionally introduced into the wound bed. Picart et al. also demonstrate that the compliance of multilayer structures formed from polyelectrolytes can be controlled by the addition of crosslinkers.

[0131] In some embodiments, the cell active factors deposited and immobilized on the wound bed include, but are not limited to, epithelial and vascular endothelial cell mitogens and other factors that contribute to wound closure. For example, in some embodiments, growth factors such as platelet-derived growth factor (PDGF) and / or epidermal growth factor (EGF), known to promote epithelial cell division, are deposited on the wound bed. In other embodiments, vascular endothelial growth factor (VEGF), known to promote vascular endothelial cell division, constitutes the cell active factor immobilized on the wound bed. It is contemplated that the present invention is not limited to ECM components or cell active factors immobilized on the wound bed, and in fact, any extracellular matrix components and / or cell active factors that improve wound healing are equally applicable. Additional cell active and wound active agents that can be incorporated are presented below.

[0132] I. Priming the Wound Bed In some embodiments, the present invention provides compositions and methods for priming a wound bed to provide a homogenous reactive surface for subsequent modification. Suitable compositions for priming a wound bed include, but are not limited to, polyelectrolytes and chemical crosslinkers that covalently react with functional groups present in the wound bed, such as, for example, carboxy, thiol, amide groups and sugars.

[0133] A. Multi-layer deposition on the wound bed In some embodiments, the present invention provides compositions, formulations, methods and kits for the deposition of multi-layer structures on wound beds. In some embodiments, the multi-layer structures contain layers of polymers that form polyelectrolytes, while in other embodiments, the multi-layers contain uncharged polymers (i.e., non-ionic polymers) or a combination of charged and uncharged polymer layers. In some embodiments, it is contemplated that the assembly of polyelectrolyte films by alternating the adsorption of cationic and anionic polyelectrolyte layers establishes a novel and promising technology for modifying wound surfaces in a controlled manner (Decher et al., 1992, Thin Solid Films 210 / 211:831; Decher, 1997, Science 277:1232). One of the most important properties of such multilayers is that they exhibit excessive alternating positive and negative charges (Caruso et al., 1999, J Am Chem Soc 121:6039; Ladam et al., 2000, Langmuir 16:1249). This not only drives their assembly (Joanny, 1999, Eur. Phys. J. Biol. 9:117), but also allows the simple contact of, for example, pigments, particles (Cassagneau et al., 1998, J. Am. Chem. Soc. 120:7848;Caruso et al., 1999, Langmuir 15:8276;Lvov et al., 1997, Langmuir 13:6195), clay microplates (Ariga et al., 1999, Appl. Clay Sci. 15:137), and proteins (Keller et al., 1994, J. Am. Chem. Soc. 116:8817;Lvov et al., 1995, J. Am. Chem. Soc. 117:6117;Caruso et al., It is possible to adsorb a wide variety of components such as cellulose acetate, cellulose esters, and cellulose acetate phosphate esters (Citromers, 1997, Langmuir 13:3427).

[0134] In some embodiments, the polymeric multilayer, such as a polyelectrolyte multilayer, is of nanoscale dimensions. Thus, in some embodiments, the polymeric multilayer is about 1 nm to 1000 nm thick, about 1 nm to 500 nm thick, about 1 nm to 100 nm thick, about 1 nm to 25 nm thick, about 1 nm to 10 nm thick, or less than about 500 nm, 100 nm, 25 nm, or 10 nm thick. It is contemplated that the nanoscale dimensions (i.e., nanoscale thickness) of the polymeric multilayer allow for the loading of a reduced total amount of active agent, while still allowing for the delivery of an effective amount of active agent (i.e., the amount of active agent that accelerates wound healing compared to a control), compared to a matrix structure of greater thickness. It is contemplated that the reduced total loading level reduces toxicity in the wound environment, particularly when antimicrobial components are incorporated into the polymeric multilayer.

[0135] In some embodiments, the compliance of the polymeric multilayer is adjusted to facilitate wound cell migration, hi some embodiments, the polymeric multilayer exhibits a compliance (measured in kilopascals (kPa)) of about 3 to about 500 kPa, about 7 to about 250 kPa, about 10 to about 250 kPa, or about 10 to about 200 kPa.

[0136] 1. Formation of Polyelectrolyte Layer The cationic polyelectrolyte poly(L-lysine) (PLL) interacts with anionic sites on cell surfaces and in the extracellular matrix (Elbert and Hubbell, 1998, J. Biomed. Mater. Res. 42:55). In some embodiments, the present invention provides a method of treating a wound comprising sequentially applying a cationic polyelectrolyte, an anionic polyelectrolyte, and a wound active agent to the wound. In other embodiments, the treatment includes sequential and repeated application of a cationic polyelectrolyte, an anionic polyelectrolyte, and a wound active agent to the wound.

[0137] The polyelectrolyte layer is formed by alternately applying anionic and cationic polyelectrolytes to a surface to form a polyelectrolyte layer. The layer can be used to deliver wound active agents to the wound. Preferably, at least four layers, and more preferably at least six layers, are used to form the polyelectrolyte multilayer. In some embodiments, more than six layers are used (e.g., 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more layers). In some preferred embodiments, the polyelectrolyte multilayer contains 10.5 layers (e.g., 10 bilayers of two components and an additional layer of one of the two components).

[0138] The treatment methods of the present invention are not limited to use on wound surfaces: the wound active agent-containing polyelectrolyte layer structure may be formed on any surface to which delivery of the wound active agent is desired.

[0139] In some embodiments, the cationic polyelectrolyte used is PLL, and the anionic polyelectrolyte used is poly(L-glutamic acid) (PGA).In practice, various polyelectrolytes are contemplated for use, including, but not limited to, poly(ethyleneimine) (PEI), poly(allylamine hydrochloride) (PAH), poly(sodium 4-styrenesulfonate) (PSS), poly(acrylic acid) (PAC), poly(maleic acid-co-propylene) (PMA-P), poly(acrylic acid) (PAA), and poly(vinyl sulfate) (PVS).It is also possible to use natural polyelectrolytes, including hyaluronic acid and chondroitin sulfate.

[0140] In still further embodiments, the polymer is a dendrimer, a graft polymer, or a star structure polymer. In other embodiments, the multilayer is structured in the presence of or responsive to an electric field (e.g., an electric field created by placing electrodes on either side of the wound).

[0141] In some embodiments (see FIG. 1), the polymer multilayer 130 is composed of polystyrene sulfonate, an amphiphilic polyelectrolyte (which has an affinity for hydrophobic regions of the wound bed), and an amphoteric polymer. The polymer multilayer is preferably functionalized with one or more crosslinkers presenting alkynes (e.g., 140 in FIG. 1, where x represents an alkyne group) so that a homogenous surface is presented. From this state, the desired wound active agent can be added to the modified surface of the wound using widely used click chemistry. In some embodiments, the wound modifying agent is an azide complex or contains an azide group and reacts with the alkyne groups presented on the wound bed in a Huisgen cycloaddition reaction.

[0142] Other suitable methods for preparing polyelectrolyte multilayers include those described, for example, in Cho and Char, Langmuir 20:4011-4016, 2004; Okamura et al., Adv. Mater. 21, 4388-92 (2009); Cho et al., Adv. Mat. 13(14):1076-1078 (2001); and U.S. Patent Application Publication No. 2010 / 0062258, the entire contents of each of which are incorporated herein by reference. Suitable methods include multilayer deposition, formation on a SAM, and spin-coating assisted assembly.

[0143] 2. Cationic polymers Cationic polymers useful in the present invention may be any biocompatible, water-soluble polycationic polymer (e.g., any polymer having protonated heterocycles attached as pendant groups). As used herein, "water-soluble" means that the polymer as a whole is soluble in aqueous solutions (e.g., buffered saline or buffered saline with small amounts of added organic solvent as a co-solvent, etc.) at temperatures between 20 and 37°C. In some embodiments, the material is not itself sufficiently soluble in aqueous solutions (defined herein as soluble to the extent of at least 1 g per liter), but can be rendered water-soluble by grafting the polycationic polymer with a water-soluble polynonionic material, such as polyethylene glycol.

[0144] Representative cationic polymers include non-natural and natural polyamino acids with a net positive charge at neutral pH, positively charged polysaccharides, and positively charged synthetic polymers. Examples of suitable polycationic substances include polyamines having amine groups on either the polymer backbone or the polymer side chains (e.g., poly-L-lysine (PLL)) and other positively charged polyamino acids of natural or synthetic amino acids or mixtures of amino acids (including but not limited to, poly(D-lysine), poly(ornithine), poly(arginine), and poly(histidine)), and non-peptide polyamines (e.g., poly(aminostyrene), poly(aminoacrylate), poly(N-methylaminoacrylate), poly(N-ethylaminoacrylate), poly(N,N-dimethylaminoacrylate), poly(N,N-di ... (amino methacrylate), poly(N-methylamino-methacrylate), poly(N-ethylamino methacrylate), poly(N,N-dimethylamino methacrylate), poly(N,N-diethylamino methacrylate), poly(ethyleneimine), polymers of quaternary amines such as poly(N,N,N-trimethylamino acrylate chloride), poly(methylacrylamidopropyl trimethylammonium chloride), and natural or synthetic polysaccharides such as chitosan. In some embodiments, PLL is the preferred material. In some preferred embodiments, the cationic polymer is poly(allylamine hydrochloride) (PAH).

[0145] Generally, the polymer must contain at least five charges and the molecular weight of the polycationic material must be sufficient to provide the desired degree of binding to tissue or other surfaces (having a molecular weight of at least 1000 g / mol).

[0146] 3. Anionic polymers The polyanionic material useful in the present invention may be any biocompatible water-soluble polyanionic polymer (e.g., any polymer having carboxylic acid groups attached as pendant groups). Suitable materials include alginate, powdered agar, furcellaran, pectin, xanthan, hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, dextran sulfate, poly(meth)acrylic acid, oxidized cellulose, carboxymethylcellulose, and crosmarmelose, synthetic polymers, and copolymers containing pendant carboxyl groups (e.g., those containing maleic or fumaric acid in the backbone). Polyamino acids that are predominantly negatively charged are also suitable. Examples of these materials include polyaspartic acid, polyglutamic acid, and other natural and unnatural amino acids and their copolymers. Polyphenolic materials, such as tannins and lignins, may also be used if sufficiently biocompatible. Preferred materials include alginate, pectin, carboxymethylcellulose, heparin and hyaluronic acid. In some preferred embodiments, the anionic polymer is poly(acrylic acid) (PAA).

[0147] 4.Nonionic polymers In some embodiments, the multi-layer structure is formed from uncharged polymers or a combination of charged and uncharged polymers. Examples of uncharged polymers include, but are not limited to, dextran, dextran sulfate, diethylaminoethyl (DEAE)-dextran, hydroxyethyl cellulose, ethyl(hydroxyethyl) cellulose, acrylamide, polyethylene oxide, polypropylene oxide, polyethylene oxide-polypropylene oxide copolymers, PAAN, etc. a , Ficoll, polyvinylpyrrolidone, and polyacrylic acid.

[0148] 5. Amphoteric polymers In some embodiments, the multilayer structure is formed from one or more amphoteric polymers, alone or in combination with other polymers described herein.In some embodiments, the amphoteric polymer comprises one or more of acrylic acid (AA), DMAEMA (dimethylaminoethyl methacrylate), APA (2-aminopropyl acrylate), MorphEMA (morpholinoethyl methacrylate), DEAEMA (diethylaminoethyl methacrylate), t-butylAEMA (t-butylaminoethyl methacrylate), PipEMA (piperidinoethyl methacrylate), AEMA (aminoethyl methacrylate), HEMA (2-hydroxyethyl methacrylate), MA (methyl acrylate), MAA (methacrylic acid) APMA (2-aminopropyl methacrylate), AEA (aminoethyl acrylate).In some embodiments, the amphoteric polymer comprises (a) a carboxylic acid, (b) a primary amine, and (c) a secondary amine and / or a tertiary amine. The amphoteric polymer has an isoelectric point of 4 to 8, preferably 5 to 7, and a number average molecular weight in the range of 10,000 to 150,000.

[0149] 6.Multi-layer application Wound modifying agents, such as polymeric multilayers, may be applied to the wound by a variety of methods. In some embodiments, it is contemplated that the polymer or polymeric multilayer is applied, preferably continuously, to the wound using either a pump (including syringes, inkjet printers, and electronic jets) or an aerosol spray. In other embodiments, particle bombardment is used. In other embodiments, the use of a brush, including an airbrush, is contemplated. In other embodiments, a sponge is used. In other embodiments, a solid support or stamp, such as an elastomeric material (e.g., PDMS (polydimethylsiloxane), silicone, hydrogel, or latex, etc.), is used to support the wound modifying agent and mechanically transfer the agent to the wound bed. In these embodiments, the polymeric multilayer is preformed on the stamp. In further embodiments, nanoparticles or microparticles are placed on the stamp for delivery to the wound. In other methods, an electric or magnetic field is used to facilitate transfer of the wound modifying agent to the wound bed.

[0150] In some embodiments, the polymeric multilayer is fabricated on a support substrate (e.g., PDMS), removed from the support substrate, and then placed on the wound. In some embodiments, the polymeric multilayer is fabricated on a support substrate (e.g., PDMS) and covered with a support layer (e.g., a sacrificial support layer (e.g., a water-soluble sacrificial support layer)) that contains, for example, a biocompatible polymer (e.g., polyvinyl alcohol (PVA)). In these embodiments, the sacrificial support layer facilitates removal of the polymeric multilayer from the support substrate, facilitates manual manipulation of the polymeric multilayer, and / or facilitates application of the polymeric multilayer onto the wound. Then, in some embodiments, after placement, the support layer is dissolved, thereby facilitating adhesion of the polymeric multilayer to the micro- and nano-topography of the wound.

[0151] In some embodiments, the polymer is applied to the wound by spraying (e.g., via a pump or aerosol device). In some embodiments, the polymer layers are applied sequentially. In one embodiment, a solution, dispersion, or suspension of the wound modifier and wound active agent is sprayed onto the wound to form multiple layers of polyelectrolytes. In embodiments where the wound modifier and wound active agent are delivered as an aerosol, a propellant is used to provide the force of ejection from the container. In some embodiments, the wound modifier or wound active agent and the propellant form a single liquid phase so that the composition is delivered consistently.

[0152] Generally, for aerosol delivery, the components of the composition are mixed to form a substantially homogenous solution, slurry, dispersion, etc. For two-part systems, the parts are mixed. The composition is placed in a suitable container and the propellant is added using standard techniques (e.g., cold-fill or pressure-fill). The composition may be delivered using a commercially available aerosol sprayer (e.g., Preval™ aerosol spray unit (available from Precision Valve Corporation, NY, USA), which has a modular power supply and a refillable reservoir bottle). The propellant is a mixture of propane, isobutane, and dimethyl ether.

[0153] The composition may also be delivered using a syringe equipped with a spray head or a dual spray device equipped with a spray head and, optionally, a mixing chamber. The device may include a meter so that the amount of composition applied can be controlled.

[0154] Any of the many propellants known in the art may be used, provided they are chemically inert to the other components of the composition. Suitable propellants include vinyl chloride and mixtures of vinyl chloride and dichlorodifluoromethane, other fluorochlorohydrocarbons (known as Freons and Genetrons), and blends of fluorochlorohydrocarbons, chlorinated hydrocarbons, and hydrocarbons. Examples of fluorochlorohydrocarbons include trichloromonofluoromethane, dichlorodifluoromethane, dichloromonofluoromethane, 2-tetrafluoroethane, 1,1-dichloro-1,2,2-tetrafluoroethane, 1-chloro-1,1-difluoroethane, 1,1-difluoroethane, and octofluorocyclobutane, and mixtures thereof. Examples of hydrocarbons include liquefied petroleum gases, such as propane, isobutane, and N-butane, and mixtures thereof. Dimethyl ether is another propellant. Compressed gas propellants may be used, preferably non-toxic, non-flammable, and inert. Examples include carbon dioxide, nitrous oxide, and N 2 Mixtures of the above are also commonly used.

[0155] The amount of propellant used is important only if an insufficient amount is used, there will be a lack of driving force to expel the entire composition from the container. Typically, the composition contains 75-95% by weight of propellant.

[0156] In some embodiments, the present invention contemplates a kit containing a container with cationic polyelectrolyte, a second container containing an anionic polyelectrolyte, and a third container containing at least one wound active agent.In yet other embodiments, in addition to the container with cationic polyelectrolyte, the second container containing an anionic polyelectrolyte, and the third container containing at least one wound active agent, the kit provides an application device for administering the polyelectrolyte and at least one wound active agent to a wound.In some preferred embodiments, the container contains a propellant.In other embodiments, the container contains a pump.

[0157] In some embodiments, the contacting includes delivering the polymer and at least one wound active agent to the wound using a reaction chamber dressing (RCD). In some embodiments, the RCD is contemplated to contain a solid barrier attached to an area that completely surrounds the wound. Within the solid barrier are inflow and outflow openings to which tubes from a solution container are connected. A variety of solid barriers are contemplated for use, including, but not limited to, Gortex, latex, Teflon, PVDF, plastic and rubber.

[0158] In some embodiments, the wound modifying agent is applied to the wound by microfluidics printing, microstamping (U.S. Pat. Nos. 5,512,131, 5,731,152, both of which are incorporated herein by reference in their entirety), or microcontact printing (PCWO 96 / 29629, incorporated herein by reference in their entirety). In other embodiments, the wound modifying agent is applied to the wound via a pulse jet, such as, for example, an inkjet printer. Examples of suitable inkjet printers for application of biological liquids include those described in U.S. Pat. Nos. 7,128,398, WO 95 / 25116, and WO 98 / 41531, each of which is incorporated herein by reference in its entirety. In other embodiments, the wound modifying agent is applied by a droplet dispenser, such as, for example, the tip of a pin or an open capillary, and the pin or capillary touches the substrate surface. Such methods are described in U.S. Pat. No. 5,807,522. When the liquid touches the surface, some of the liquid is transferred. In another embodiment, the wound modifying agent is applied by pipetting, micropipetting, or a positive displacement pump, such as a Biodot instrument (commercially available from Bio-Dot Inc., Irvine Calif., USA).

[0159] Preferably, one or more wound active agents are applied to the wound together with the wound modifier. In some embodiments, the wound active agent is covalently attached to the wound modifier. In other embodiments, the wound active agent is incorporated into the wound modifier, for example, by application during the successive application of polymer layers in a polymer multilayer. In other embodiments, the wound active agent is delivered by a microarrayer, a pipette, a positive displacement pump, an inkjet printer, a microneedle array, an elastomeric stamp, a gene gun, an electron jet, or an airbrush, as described above in connection with the wound modifier.

[0160] B. Wound Bed Modification with Biocompatible Particles In some embodiments, the wound modifying agent is a nanoparticle or a microparticle. In some embodiments, nanometer to submicron sized biocompatible particles, such as spherical particles (e.g., beads) and / or non-spherical particles (e.g., ellipsoidal, acicular, cubic, tetrahedral, mushroom, haystack structures), or electrospun polymers are applied (either directly or indirectly) to the wound bed, thereby generating a three-dimensional topographical wound bed. For example, application of biocompatible particles to the wound bed generates bumps, protrusions, spikes, ripples, etc. in the wound bed. Microbeads typically have a size in the range of about 1 to about 500 micrometers, and nanobeads typically have a size in the range of about 1 to about 1000 nanometers. Microbeads may further include microscale (i.e., 1 to 100 micrometers) or nanoscale (0.1 to 1000 nanometers) features on the bead surface. Nanobeads may further contain nanoscale features (ie features between 0.1 and 500 nanometers) on the surface of the bead. In some embodiments, the wound active agent is present in the form of beads or particles, such as, for example, silver nanoparticles.

[0161] In some embodiments, the biocompatible particles are biodegradable. In some embodiments, the biocompatible particles are not biodegradable. The biocompatible particles are modified with interfacial chemical crosslinkers that allow for attachment and immobilization of, for example, wound active agents, extracellular matrix components, polyelectrolytes, etc., as further described herein. It is contemplated that the incorporation of modified biocompatible particles facilitates the presentation of ECM constituents that support, for example, epithelial coverage of the wound, provides cytoactive factors for wound healing, and introduces topographical features that support cellular behaviors that promote wound healing. In some embodiments, the biocompatible particles are functionalized with mesoscopic crosslinkers, for example, to allow widespread covalent interactions with the wound bed. In some embodiments, the crosslinkers are attached to negatively charged biocompatible particles. In some embodiments, the biocompatible particles contain layers of multiple different constituents for wound healing or contain only one constituent for wound healing. For example, spherical particles, such as beads, placed on the wound bed contain one or more of the above-mentioned polyelectrolytes for wound healing, ECM agents, proteins with hydrolyzable bonds, proteins with enzyme-cleavable bonds, or mixed species, or layered. In some embodiments, antimicrobial agents are also applied to the biocompatible particles, alone or in combination with other wound healing compositions. Antimicrobial agents include, but are not limited to, antibiotics, metal-based antimicrobial compositions containing silver (e.g., ionic silver, elemental silver, silver nanoparticles), copper, selenium, triclosan-based antimicrobials, thiabendazole-based antimicrobials, isothiazolinone-based antimicrobials, zinc-pyrithione-based antimicrobials, and / or 10'-oxybisphenoxarsine-based antimicrobials (OBPA). The present invention is not limited to the type of antimicrobial agent used.

[0162] In some embodiments, the size of biocompatible particles, such as beads, is at least 1 nm, at least 5 nm, at least 10 nm, at least 20 nm, at least 50 nm, at least 100 nm, at least 200 nm, at least 300 nm, at least 500 nm, or at least 800 nm in diameter. In some embodiments, beads and other spherical or non-spherical particles contain their own surface texture. For example, the bead surface may contain undulations, indentations, tunnels, holes, bumps, protrusions, etc. Spherical particles, such as beads, may or may not be inert and may be, for example, magnetic. Magnetic beads contain, for example, magnetic cores or particles. Examples of different bead compositions can be found, for example, in U.S. Patent Nos. 5,268,178, 6,458,858, 6,869,858, and 5,834,121, each of which is incorporated herein by reference in its entirety.

[0163] In some embodiments, the biocompatible particles of the present invention used for wound healing are coated with a layer of polyelectrolytes, ECM components, antimicrobials, proteins with hydrolyzable bonds, proteins with enzyme-cleavable bonds, etc., and other wound healing compositions, where the surface compliance of the beads is maintained to be optimal for wound healing. For example, the compliance of the layer for wound healing deposited on the biocompatible particles is contemplated to be optimally stiff (e.g., not too soft, not too hard) for optimal anchoring and spreading of cells in the wound bed. Engler et al. (2004, Biophys. J. 86:617-628) discusses substrate compliance for cell anchoring and spreading. In some embodiments, the biocompatible particles are layered with polyelectrolytes, ECM components, antimicrobials, etc., resulting in a substrate stiffness of at least 1 kPa, at least 5 kPa, at least 8 kPa, at least 10 kPa, at least 20 kPa, at least 40 kPa, at least 60 kPa, at least 80 kPa, as measured using the method of Engler et al. (2004). In preferred embodiments, the substrate compliance of the wound healing composition, as applied to biocompatibility, is at least 8 kPa to about 80 kPa, or 100 kPa. Hardnesses within these limits are contemplated even if not all such hardnesses are specifically listed, e.g., 10, 20, 30, 40, 50, 60, or 70 kPa are all contemplated by the present invention as upper or lower range limits. In some embodiments, the ECM composition used with the polyelectrolytes, antimicrobials, and other wound healing compositions is preferably collagen.

[0164] In some embodiments, the layer applied to the wound bed or biocompatible particles contains a gradient of wound healing composition (e.g., wound active agent). For example, the concentration of the composition is layered in the wound bed or on the biocompatible particles in a gradient such that vertically, there is a higher concentration of a particular composition proximal to the wound bed than distal to the wound bed. The reverse is also contemplated, where the composition concentration is higher distal to the wound bed than proximal to the wound bed. The concentration of the composition in the wound bed or the biocompatible particles is also contemplated to provide a horizontal gradient. Topographical gradients are also contemplated, where the composition is deposited in the wound bed or biocompatible particles such that the composition concentration follows the topography of the substrate, e.g., a higher concentration of the composition is deposited in the valleys of a typical substrate waviness compared to the peaks of the waviness. Similarly, the present invention contemplates the controlled application of microbeads or nanobeads of varying hardness to create a compliance gradient in the wound bed. For example, beads having one, two, three, four or more different hardnesses may be applied to form a vertical gradient (i.e., a depth gradient) over the wound, or to form a horizontal gradient (i.e., a gradient along the length or width of the wound), or to form a combination of vertical and horizontal gradients. Horizontal and vertical gradients may also be formed with beads functionalized with one, two, three, four or more different wound active agents.Ichinose et al., Biomaterials. Volume 27, Issue 18, June 2006, Pages 3343-3350;Stefonek et al., Immobilized gradients of epidermal growth factor promote accelerated and directed keratinocyte migration. Wound Repair and Regeneration (OnlineEarly Articles). doi:10.1111 / j.1524-475X.2007.00288.x;Kapur et al., Immobilized concentration gradients of nerve growth factor guide neurite outgrowth. Journal of Biomedical Materials Research Part A. Volume 68A, Issue 2, Pages 235-243;DeLong et al., Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials 26 (2005) 3227-3234;Liu, et al., 2007 Sep 25; 17892312 Endothelial Cell Migration on Surface-Density Gradients of Fibronectin, VEGF, or Both Proteins, see

[0165] In some embodiments, the wound healing composition applied to the wound bed or biocompatible particles (e.g., beads, needles, etc.) is time-released such that the wound healing composition applied to the wound bed or biocompatible particles is released over a period of time (e.g., 3 hours, 5 hours, 10 hours, 1 day, several days, 1 week, several weeks, etc.), thereby treating the wound bed over a short and / or long term period.

[0166] In some embodiments, the biocompatible particles used in wound bed healing applications of the invention are not, for example, spherical as described above, but are, for example, ellipsoidal, needles, mushroom-like structures, haystack-like structures. In some embodiments, the shape of the biocompatible particles is preferably needle-like. Fabrication of needles useful in embodiments of the invention can be performed using microfabrication techniques, for example, as described in McAllister et al., 2003, Proc. Natl. Acad. Sci. 100:13755-13760. In some embodiments, the biocompatible particles are coated and / or layered with wound healing compositions, antimicrobials, hydrolytically cleavable proteins, enzymatically cleavable proteins, antimicrobials, etc., as described herein. In some embodiments, the coated and / or layered biocompatible particles are applied to the wound bed by stamping, spraying, or other methods as described herein.

[0167] In some embodiments, a layer of the wound healing composition described herein is deposited on the wound bed or biocompatible particles by electrostatic bonding. In other compositions, non-electrostatic interactions (e.g., van der Waals interactions, metal ion-ligand coordination, or hydrogen bonding, etc.) are utilized. In some embodiments, a layer of the wound healing composition described herein is deposited by piezoelectric application, for example, using the methods and systems described in U.S. Pat. No. 6,368,079 and Sumerel et al., 2006, Biotechnol. J. 1:976-987. In other embodiments, the wound healing composition is deposited directly or indirectly on the wound bed by using electrojet techniques (including electroextrusion, and electrospraying and electrospinning). In some embodiments, the deposited layer contains one or more wound healing compositions. In some embodiments, the layer is a biocompatible particle (e.g., spherical beads, needles, etc.) mixed with the wound healing composition. In other embodiments, the layered deposition is continuous. For example, sequential deposition of the wound healing composition alone, or sequential deposition of the wound healing composition followed by the biocompatible particles followed by the wound healing composition, etc. The present invention is not limited to the components that make up the deposited layer on the biocompatible particles, and many permutations of layering the wound healing composition and the biocompatible particles will be apparent to one skilled in the art.

[0168] In some embodiments, layer deposition onto the wound bed or onto biocompatible particles or onto other substrates to be added to the wound bed is performed by "stamping" (also referred to as "contact printing"). The stamp substrate is any substrate that can be used for the transfer of one or more entities or compositions (such as polyelectrolytes, ECM components, proteins with hydrolyzable or enzymatically cleavable bonds, etc.) covalently or non-covalently bound to the surface of the stamp substrate to other surfaces. Examples of suitable stamp substrates include, but are not limited to, polydimethylsiloxane (PDMS) and other elastomeric (e.g., flexible) materials. In some embodiments, different concentrations of the same wound healing composition are placed on different regions of the stamp substrate. In other embodiments, a variety of different compositions are placed on the stamp substrate surface. In some embodiments, multiple wound healing compositions at multiple concentrations are placed on the stamp substrate surface. The wound healing compositions are then introduced onto the stamp substrate surface, which in turn are stamped onto the wound bed or onto other substrates (e.g., biocompatible particles) for introduction into the wound bed.

[0169] In other embodiments, biocompatible particles, such as needles, are coated and / or layered with a wound healing composition, antimicrobial, hydrolytically cleavable protein, enzymatically cleavable protein, etc., and applied to a pad that is subsequently applied to the wound. The pad includes, but is not limited to, band-aids, gauze, surgical packing, etc. In some embodiments, the pad is impregnated with the wound healing composition, antimicrobial, hydrolytically cleavable protein, enzymatically cleavable protein, etc. In some embodiments, the biocompatible particles (e.g., coated and / or layered with the wound healing composition, antimicrobial, hydrolytically cleavable protein, enzymatically cleavable protein, etc.) are affixed to the pad in a removable or non-removable manner prior to application of the pad to the wound. In some embodiments, the biocompatible particles remain on the pad (e.g., are not removed) when the pad is removed from the wound, while in other embodiments, the nanostructures remain in the wound bed (e.g., are removed) when the pad is removed from the wound. For example, a pad is impregnated with the described composition and is further affixed with biocompatible particles that are coated and / or layered with the described composition for wound healing. The pad with the biocompatible particles is applied to the wound, and while the pad is on the surface of the wound bed, the biocompatible particles thereon reach closer to the wound bed compared to the location of the pad. The pad releases the impregnated wound healing composition (e.g., either in a short-term or sustained release manner) on or near the surface of the wound, while the affixed biocompatible particles release the coated and / or layered wound healing composition (e.g., either in a short-term or sustained release manner) further closer to the wound bed. Alternatively, a pad with affixed biocompatible particles (both the pad containing the wound healing composition described above and the nanostructures) is first applied to the wound bed. The pad is then removed, but the removable biocompatible particles remain in the wound bed. The pad not only serves the purpose of delivering the wound healing composition to the wound bed, but also of delivering biocompatible particles, such as needles, into the wound bed.The biocompatible particles left on the wound bed continue to release the wound healing composition to the wound bed, for example, for further healing. In some embodiments, a new (second, third, fourth, etc.) pad containing the impregnated wound healing composition described above is reapplied to the wound, with the biocompatible particles retained in the wound from the original application of the first pad / nanostructure. Application of the new pad, for example, not only brings new wound healing composition to the wound, but also recoats the biocompatible particles with the new wound healing composition released (either in a short-term or sustained release manner) in close proximity to the wound bed.

[0170] The present invention is not limited to a particular mechanism. Indeed, understanding of the mechanism is not necessary to practice the present invention. However, it is contemplated that negatively charged polymeric species and beads do not easily cross cell membranes and therefore provide a non-toxic means of wound bed healing. Similarly, the size of the beads used will determine the nanostructure of the wound bed, thereby allowing for personalized wound bed healing therapy. In FIG. 6, an exemplary embodiment of the use of beads for wound bed healing is presented. However, the present invention is not limited to the size of the beads, the reactive groups present on the beads (e.g., carboxylic acid groups, thiol groups, amine groups, etc.), the crosslinking agents or cell activators used, and other wound healing compositions associated with the beads. Indeed, an infinite number of combinations of compounds for wound healing (e.g., small molecules, peptides, proteins, drugs, etc.) are contemplated for use with the beads applied to the wound bed.

[0171] In some embodiments, the particles modulate wound response after application of an electric or magnetic field to the wound bed. Thus, in some embodiments, the particles are charged or magnetic, so that they move or reorganize in an electric or magnetic field. In other embodiments, the beads are dielectric, so that they undergo dielectrophoresis in an AC electric field. In other embodiments, the beads are magnetic, so that they move and / or transmit mechanical forces when exposed to a magnetic field. In other embodiments, the beads are charged, so that a mechanical force is applied to the wound bed when an electric field is applied, for example, by placing electrodes on either side of the wound.

[0172] In some embodiments, the nanobeads or microbeads are applied to the wound by microfluidics printing, microstamping (U.S. Pat. Nos. 5,512,131 and 5,731,152, both of which are incorporated herein by reference in their entirety), or microcontact printing (PCT Publication WO 96 / 29629, which is incorporated herein by reference in its entirety). In other embodiments, the nanobeads or microbeads are applied to the wound via a pulse jet, such as an inkjet printer. Examples of inkjet printers suitable for applying biological liquids include those described in U.S. Pat. No. 7,128,398, WO 95 / 25116, and WO 98 / 41531, each of which is incorporated herein by reference in its entirety. In other embodiments, the nanobeads or microbeads are applied by a droplet dispenser, such as the tip of a pin or an open capillary tube, and the pin or capillary tube touches the substrate surface. Such methods are described in US Patent No. 5,807,522. When the liquid touches the surface, a portion of the liquid is transferred. In other embodiments, the wound modifying agent is applied by pipetting, micropipetting, or a positive displacement pump, such as, for example, a Biodot instrument (available from Bio-Dot Inc., Irvine Calif., USA). In yet other embodiments, nanobeads or microbeads are applied to the wound via a microneedle array.

[0173] C. Modification with Covalent Modifiers In some embodiments, the present invention provides for the covalent immobilization of factors to wound beds. In some preferred embodiments, the covalent modification occurs via homobifunctional linkers or heterobifunctional linkers. In some embodiments, the covalent modifying agent is used to directly modify the wound bed by covalently binding to the wound bed. In some embodiments, the covalent modifying agent is used to covalently bind one, two, three, four or more different wound active agents to the wound bed. In some embodiments, the covalent modifying agent is used to establish a gradient of one, two, three, four or more different wound active agents in the vertical or horizontal plane across the wound. In some embodiments, the covalent modifying agent is used in conjunction with the polymer layer or beads described above. In some embodiments, the covalent modifying agent is used to attach the wound active agent to the polymer layer or beads, while in other embodiments, the covalent modifying agent is used to crosslink the polymer or beads.

[0174] In some embodiments, the present invention provides a method of treatment comprising providing at least one covalent modifying agent and at least one wound active agent to a subject having a wound, and contacting the wound with the at least one covalent modifying agent and the at least one wound active agent under conditions such that the at least one wound active agent is covalently bound to the wound. In some embodiments, the subject is a human. In other embodiments, the subject is a non-human vertebrate. In some embodiments, the at least one covalent modifying agent is a homogeneous bifunctional crosslinking agent. In other embodiments, the at least one covalent modifying agent is a heterogeneous bifunctional crosslinking agent. For example, in some embodiments, homogeneous bifunctional crosslinkers include N-hydroxysuccinimidyl esters (such as, but not limited to, disuccinimidyl ester, dithiobis(succinimidyl propionate), 3,3′-dithiobis(sulfosuccinimidyl propionate), disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, disuccinimidyl tartarate, disulfosuccinimidyl tartarate, bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfo, Examples of suitable crosslinkers include N,N'-disuccinimidyl carbonate, ...In other embodiments, at least one covalent modification agent is a heterobifunctional crosslinker (such as, but not limited to, N-succinimidyl 3-(2-pyridyldithio)propionate, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate, sulfosuccinimidyl 6-(3'-[2-pyridyldithio]-propionamido)hexanoate, succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio) ... thio)toluene, sulfosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio)toluamide]hexanoate, succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-maleimidobenzoyl-N-hydroxysuccinimide ester, m-maleimidobenzoyl-N-hydroxysuccinimide ester ter, N-succinimidyl (4-iodoacetyl)aminobenzoate, sulfo-succinimidyl (4-iodoacetyl)aminobenzoate, succinimidyl-4-(p-maleimidophenyl)butyrate, sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, N-(γ-maleimidobutyryloxy)succinimide ester, N-(γ-maleimidobutyryloxy)sulfosuccinimide ester, succinimidyl 6-((iodoacetyl)aminobenzoate Examples of suitable heterobifunctional crosslinkers include succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoate, succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoyl)amino)hexanoate, succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate, succinimidyl 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate, and p-nitrophenyl iodoacetate). In some embodiments, the heterobifunctional crosslinkers are modified with functional groups, thereby making them soluble in aqueous solvents and delivered as aqueous solutions. Additionally, in some embodiments, the aqueous solutions contain additives, such as, but not limited to, surfactants and block copolymers.In other embodiments, a variety of heterobifunctional crosslinkers can be attached to molecules, polymers, or particles and function as crosslinkers. In other embodiments, the heterobifunctional crosslinkers are dissolved in an organic solvent (e.g., but not limited to, dimethylsulfoxide). In some embodiments, the at least one wound active agent contains, but is not limited to, trophic factors, extracellular matrices, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infective agents (including, but not limited to, silver (e.g., ionic silver, elemental silver, silver nanoparticles)), buffers, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anti-cancer agents. In some embodiments, the at least one wound active agent contains one or more free -SH groups.

[0175] In some embodiments, the covalent modification agent is a photoactivatable crosslinking agent.Suitable photoactivatable crosslinking agents include, but are not limited to, aryl azido N-((2-pyridyldithio)ethyl)-4-azido salicylamide, 4-azido-2,3,5,6-tetrafluorobenzoic acid, succinimidyl ester, 4-azido-2,3,5,6-tetrafluorobenzoic acid, STP ester, benzophenone maleimide, succinimidyl ester of 4-benzoylbenzoic acid, N-5-azido-2-nitrobenzoyloxysuccinimide, N-hydroxysulfosuccinimidyl-4-azidobenzoate, N-hydroxysuccinimidyl-4-azido salicylic acid, and (4-[p-azido salicylamide]butylamine).

[0176] Referring again to FIG. 2, spatial heterogeneity is depicted in the wound by shapes 720, which depict the different chemical moieties present in the wound bed, such as amine and sulfhydryl groups. Typical areas in the wound are rich in amines and / or sulfhydryls. In some embodiments, a crosslinker containing an activated acid (e.g., 230 in FIG. 2) is used to react with the amine groups, such as nHS (n-hydroxysuccinimidyl), and a second crosslinker containing a malemide (e.g., 235 in FIG. 2) is used to react with the sulfhydryl groups. In some embodiments, the malemide and the activated acid are coupled to an alkyne (e.g., 240 in FIG. 2, where x represents an alkyne group) to present a homogenous surface. From this state, the desired wound active agent can be added to the modified surface of the wound using widely used click chemistry. In some embodiments, the wound modifying agent is an azide conjugate or contains an azide group, which reacts with alkyne groups presented on the wound bed in a Huisgen cycloaddition reaction.

[0177] The present invention also provides a kit for treating a subject with a wound, the kit comprises at least one covalent modifier, at least one wound active agent, and instructions for using the kit to covalently bind at least one wound active agent to wound.In some embodiments, the at least one covalent modifier is the homogeneous bifunctional crosslinker, heterogeneous bifunctional crosslinker, or photoactivatable crosslinker described above.In some embodiments, the at least one wound active agent comprises, but is not limited to, the wound active agent described in detail below.

[0178] The present invention also provides a kit for treating a subject having a wound, the kit containing at least one covalent modifying agent, at least one wound active agent, and instructions for using the kit to covalently attach the at least one wound active agent to the wound, in some embodiments, the at least one covalent modifying agent is a homogeneous bifunctional crosslinker. In some embodiments, the homogeneous bifunctional crosslinker is an N-hydroxysuccinimidyl ester (for example, including but not limited to, disuccinimidyl ester, dithiobis(succinimidyl propionate), 3,3′-dithiobis(sulfosuccinimidyl propionate), disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, disuccinimidyl tartarate, disulfosuccinimidyl tartarate, bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfone, bis[2-(sulfosuccinimidyloxycarbonyloxy)ethyl]sulfone, ethylene glycol bis(succinimidyl succinate), ethylene glycol bis(sulfosuccinimidyl-succinate), disuccinimidyl glutarate, and N,N′-disuccinimidyl carbonate).In some embodiments, the at least one covalent modification agent is a heterobifunctional crosslinker (such as, but not limited to, N-succinimidyl 3-(2-pyridyldithio)propionate, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate, sulfosuccinimidyl 6-(3′-[2-pyridyldithio]-propionamido)hexanoate, succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio) e) Toluene, sulfosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio)toluamide]hexanoate, succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-maleimidobenzoyl-N-hydroxysuccinimide ester, m-maleimidobenzoyl-N-hydroxysuccinimide ester , N-Succinimidyl (4-iodoacetyl)aminobenzoate, Sulfo-Succinimidyl (4-iodoacetyl)aminobenzoate, Succinimidyl-4-(p-maleimidophenyl)butyrate, Sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, N-(γ-maleimidobutyryloxy)succinimide ester, N-(γ-maleimidobutyryloxy)sulfosuccinimide ester, Succinimidyl 6-((iodoacetyl)aminobenzoate, cetyl)amino)hexanoate, succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoyl)amino)hexanoate, succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate, succinimidyl 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate, and p-nitrophenyl iodoacetate).In some embodiments, the at least one wound active agent is selected from the group consisting of trophic factors (including, but not limited to, polypeptide growth factors, neuropeptides, neurotrophins), extracellular matrices and their individual natural components (including, but not limited to, laminin, fibronectin, vitronectin, collagen), and selected amino acid sequences present in these proteins known to promote cellular behaviors favorable to wound healing (including, but not limited to, RGD, EILDV, VCAM-1 and recombinant or synthetic analogs thereof). In another embodiment, the kit contains small interfering RNA (siRNA, also referred to as microRNA) that can promote cellular behaviors conducive to the wound healing process. In another embodiment, the kit contains compounds (i.e., inhibitors / promoters) that promote / stabilize favorable pH, osmotic environment, surface energy, surface charge, surface functionality that enhances favorable electro-magnetic effects on wound healing, or the equilibrium of MMP / other peptidase / protease activity.

[0179] II. Wound Active Agents In some embodiments, the wound active agent is delivered to or incorporated into the wound bed using the systems described above. In some embodiments, the wound active agent is covalently or non-covalently bound to the polyelectrolyte layer, beads, non-covalent modifiers, etc. The present invention is not limited to a particular mechanism by which the wound active agent is bound to the polyelectrolyte layer, beads, non-covalent modifiers, etc.

[0180] In some embodiments, the polyelectrolyte layer, beads or non-covalent modifiers may act as a drug delivery scaffold for delivering one or more wound active agents to the wound. Wound active agents that may be desired to be delivered include, but are not limited to, trophic factors, extracellular matrix (ECM), ECM fragments or synthetic constructs, enzymes, enzyme inhibitors, defensins, polypeptides, anti-infective agents (including antibacterial, antiviral, and antifungal agents), buffers, vitamins and minerals, analgesics, anticoagulants, clotting factors, anti-inflammatory agents, vasoconstrictors, vasodilators, diuretics, and anticancer agents. Additionally, wound active agents include chlorhexidine, iodine-based antibacterial agents (e.g., PVP-iodine); selenium-based antibacterial agents (e.g., 7-azabenzisoselenazole-3(2H)-one, selenium disulfide, and selenide); and silver-based antibacterial agents (e.g., silver sulfadiazine, ionic silver, elemental silver, silver nanoparticles). With regard to selenides, standard and modified versions of typical protein and carbohydrate attachment chemistries may be used to routinely attach carboxyl and amino-containing selenides to many polymers, peptides, antibodies, steroids and drugs. Selenide-attached polymers and other molecules generate superoxide in a dose-dependent manner in biological solutions, in cells, or when attached to insoluble matrices such as silicones.

[0181] A variety of wound active agents can be incorporated into the polyelectrolyte layer, beads, or covalent or non-covalent modifiers. The present invention is not limited to a particular mechanism by which one or more wound active agents are released from the polyelectrolyte layer, beads, or covalent or non-covalent modifiers to the wound. Indeed, understanding of the mechanism is not necessary to practice the present invention. However, in some embodiments, the present invention contemplates that one or more incorporated agents are released from the polyelectrolyte layer, beads, or non-covalent modifiers to the wound by diffusion from the polyelectrolyte layer. In other embodiments, one or more wound active agents may be released from the polyelectrolyte layer, beads, or non-covalent modifiers over time or in response to environmental conditions. One or more wound active agents may be attached by a degradable bond, such as a bond that is susceptible to degradation via hydrolysis or enzymatic degradation. The bond may be susceptible to degradation at a certain pH, for example.

[0182] In some embodiments, one or more wound active agents are applied to form a gradient with respect to the wound modifier. In general, the gradient is such that a higher concentration of wound active agent is present at one or more of the first desired locations in the wound after the wound modifier is applied to the wound, and a lower concentration of wound active agent is present at one or a second location in the wound after the wound modifier is applied to the wound. For example, the concentration of wound active agent is layered in the wound bed in a vertical gradient such that a higher concentration of a particular composition is proximal to the wound bed than distal to the wound bed. The reverse is also contemplated, such that the composition concentration is higher distal to the wound bed than proximal to the wound bed. The composition concentration in the wound bed is also contemplated to provide a horizontal gradient. Topographical gradients are also contemplated, where the composition is deposited in the wound bed or on the biocompatible particles such that the composition concentration follows the topography of the substrate, for example, a higher concentration of the composition is deposited in the valley of a typical substrate undulation compared to the peak of the undulation.

[0183] In some embodiments, the gradient has a higher concentration of wound active agent at the center of the wound modifier and a lower concentration of wound active agent away from the center of the wound modifier. Thus, when the wound modifier is applied to a wound, the gradient will result in a higher concentration of wound active agent at the center of the wound and a lower concentration of wound active agent towards the edge of the wound. In some embodiments, the gradient has a lower concentration of wound active agent at the center of the wound modifier and a higher concentration of wound active agent away from the center of the wound modifier. Thus, the gradient will result in a lower concentration of wound active agent at the center of the wound and a higher concentration of wound active agent towards the edge of the wound. If more than one wound active agent is used, they may be present in the same gradient or the gradient may vary such that the concentrations of the two or more wound active agents vary across the wound. The gradient of high or low concentrations may be any shape, such as a circle, a square, a rectangle, an oval, an ellipse, etc., so that the matrix and gradient can fit various wound shapes. For example, for long incision type wounds, the gradient can be centered on the long axis extending along the length of the wound and can be in the center of the wound. In another example, the gradient can be circular or oval when applied to open wounds, burns, sores, and ulcers, which are generally circular or oval. In other embodiments, the gradient has a series of properties arranged in a pattern. For example, the gradient can form a series of stripes or high and low concentrations of one or more wound active agents along the long axis of the matrix. Alternatively, the gradient can form a checkerboard pattern, an array, concentric circles, overlapping circles, or ovals, etc.

[0184] The present invention contemplates the delivery of a variety of wound active agents to the wound. In some embodiments, the present invention provides for the delivery of trophic factors (including but not limited to agrin, amphiregulin, artemin, cardiotrophin-1, epidermal growth factor (EGF); fibroblast growth factors (e.g., FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, and FGF-7); LIF, CSF-1, CSF-2, CSF-3, erythropoietin, endothelial cell growth factors (including ECGF); FGF-related growth factors and ECGF-related growth factors (e.g., endothelial cell growth factors, FGF-related growth factors, and ECGF-related growth factors). cell-stimulating angiogenesis factors, tumor angiogenesis factors, retina-derived growth factor (RDGF), vascular endothelial growth factor (VEGF), brain-derived growth factor (BDGF-A and B), astrocyte growth factor (AGF1 and 2), omentum-derived growth factor, fibroblast-stimulating factor (FSF), and embryonic carcinoma-derived growth factor (ECDGF); neurotrophic growth factors (e.g., nerve growth factor (NGF), neurturin, brain-derived neurotrophic factor (BDNF), neurotrophin 3, neurotrophin 4, and ciliary neurotrophic factor ( glial growth factors (e.g., GGF-I, GGF-II, GGF-III, glial maturation factor (GMF), and glial-derived neurotrophic factor (GDNF)); hepatic growth factors (e.g., including hepatopoietin A, hepatopoietin B, and hepatocyte growth factor (HGF)); prostate growth factors (including prostate-derived growth factor (PGF)); mammary growth factors (including mammary derived growth factor 1 (MDGF-1) and mammary tumor-derived growth factor (MTGF)); cardiac growth factors (including non-myocyte-derived growth factor (NMDGF) ); melanocyte growth factors (including melanocyte stimulating hormone (MSH) and melanoma growth stimulating activity (MGSA)); angiogenic factors (e.g., angiogenin, angiotropin, platelet-derived ECGF, VEGF, and pleiotrophin); transforming growth factors (including TGFα, and TGFβ); TGF-like growth factors (e.g., TGFβ1, TGFβ2, TGFβ3, GDF1, CDGF, tumor-derived TGF-like factor, ND-TGF, and human epithelial cell transforming factor);Regulatory peptides with growth factor-like properties (e.g., bombesin and the bombesin-like peptides ranatensin and litorin, angiotensin, endothelin, atrial natriuretic factor, vasoactive intestinal peptide, and bradykinin); platelet-derived growth factors (including PDGF-A, PDGF-B, and PDGF-AB); neuropeptides (e.g., substance P, calcitonin gene regulatory peptide (CGRP), and neuropeptide Y); neurotransmitters and their analogs (including norepinephrine, acetylcholine, and carbachol); hedgehog, heregulin / neuregulin, IL-1, osteoclast-activating factor (OAF), lymphocyte-activating factor (LAF), hepatocyte-stimulating factor (HSF), B cell-activating factor (BAF), and other cellular and biologically active substances (C-C-C). ), tumor inhibitory factor 2 (TIF-2), keratinocyte-derived T-cell growth factor (KD-TCGF), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, stromal cell-derived cytokines (SCDCs), IL-12, IL-13, IL-14, IL-15, insulin, insulin-like growth factors (including IGF-1, IGF-2, and IGF-BP); interferons including INF-α, INF-β, and INF-γ; leptin, midkine, tumor necrosis factors (TNFα and β), netrin, saposin, semaphorins, somatremes, somatropins, stem cell factor, VVGF, bone macrophage proteins (BMPs), adhesion molecules, other cytokines, heparin-binding growth factors, and tyrosine kinase receptor ligands) are presented for delivery. In some embodiments, the wound active agent is a peptide such as, for example, AcEEED, an N-terminal peptide to alpha smooth muscle actin that has been shown to inhibit the contractile ability of myofibroblasts;

[0185] In some embodiments, the present invention provides for the delivery of ECM (including but not limited to: extracellular matrix proteins, reconstituted basement membrane-like complexes from eukaryotic cell lines, collagen, fibronectin, laminin, VCAM-1, vitronectin and gelatin, bacterial extracellular matrix, gel matrix, and polymeric matrix). In some embodiments, wound active agents are integrin binding sequences, enzymes, enzyme inhibitors, and polypeptides, exemplified by but not limited to RGD, EILDV, VCAM-1, and recombinant or synthetic analogs thereof.

[0186] In some embodiments, the present invention provides a method for the preparation of a proteinase inhibitor, such as an enzyme (including but not limited to exopeptidases and endopeptidases (also known as proteases and proteinases) (including but not limited to serine proteinases, chymotrypsin, trypsin, elastase, and kallikrein), bacterial enzymes, cysteine ​​proteases papain, actinin, bromelain, cathepsin, cytosolic calpain, parasitic proteases, asparagine proteinases, and the like. , the pepsin family of proteases pepsin, and chymosin, lysosomal cathepsin D, renin, fungal proteases, viral proteases, AIDS viral retropepsin, and metalloproteinases (MMPs), collagenase, Maggott enzyme, MMP1, MMP2, MMP8, MMP13, gelatinase, MMP2, MMP9, MMP3, MMP7, MMP10, MMP11, and MMP12 are presented.

[0187] In some embodiments, the present invention provides for the delivery of enzyme inhibitors, including but not limited to captopril, thiorphan, phosphoramidon, teprotide, protease and proteinase inhibitors, metalloproteinase inhibitors, and exopeptidase inhibitors.

[0188] In some embodiments, the present invention provides for the delivery of defensins, including but not limited to alpha defensins HNP1, 2, 3 and 4, and beta defensins HBD-1 and HBD-2.

[0189] In some embodiments, the present invention provides for the delivery of polypeptides, including but not limited to, fibronectin, serotonin, PAF, PDEGF, TNFa, IL1, IL6, IGF, IGF-1, IGF-2, IL-1, PDGF, FGF, KGF, VEGF, bradykinin, prothymosin alpha, and thymosin alpha 1.

[0190] In some embodiments, the present invention provides antibacterial agents, including but not limited to, magainins (e.g., magainin I, magainin II, xenopsin, xenopsin precursor fragment, caerulein precursor fragment), analogs of magainin I and II (e.g., PGLa, magainin A, magainin G, pexiganin, Z-12, pexiganin acetate, D35, MSI-78A, MG0 (K10E, K11E, F12W-magainin 2), MG2+ (K10E, F12W-magainin-2), MG4+ (F12W-magainin 2), MG6+ (f12W, E19Q-magainin 2 amide), MSI-238, inverted magainin II analogs (e.g., 53D, 87-ISM, and A87-ISM), Ala-magainin II amide, magainin II amide, cecropin P1, cecropin A, cecropin B, indolicidin, nisin, ranalexin, lactoferricin B, poly-L-lysine, cecropin A(1-8)-magainin II(1-12), cecropin A(1-8)-melittin(1-12), CA(1-13)-MA(1-13), CA(1-13)-ME(1-13), gramicidin, gramicidin A, gramicidin D, gramicidin S, alamethicin, protegrin, histatin, dermaseptin, lentiviral amphipathic peptides or analogs, paracin I, lycotoxin I or II, globomycin ... indane), PM2c ((+ / -)-6-benzyl-1-(3-carboxypropyl)indane), PM3 ((+ / -)-1-benzyl-6-(4-aminobutyl)indane), tachyplesin, buforin I or II, misgurin, melittin, PR-39, PR-26, 9-phenylnonylamine, (KLAKKLA)n, (KLAKLAK)n (where n=1, 2, or 3), (KALKALK)3, KLGKKLG)n, and KAAKKAA)n (where N=1, 2, or 3), paradaxin, Bac 5, Bac7, ceratoxin, mdelin 1 and 5, bombin-like peptide, PGQ, cathelicidin, HD-5, Oabac5 alpha, ChBac5, SMAP-29, Bac7.5, lactoferrin, granulysin, thionin, hevein and knottin-like peptide, MPG1, 1bAMP, snakin, lipid transfer protein, and plant defensin are presented. Exemplary sequences of the above-mentioned compounds are shown in Table 1. In some embodiments, the antimicrobial peptide is synthesized from L-amino acids, while in other embodiments, the peptide is synthesized from or contains D-amino acids. Additional antimicrobial polypeptides for use in the present invention are listed in FIG. 7.

[0191] [Table 1]

[0192] TIFF0007586654000002.tif229169

[0193] TIFF0007586654000003.tif235169

[0194] TIFF0007586654000004.tif233169

[0195] TIFF0007586654000005.tif229169

[0196] TIFF0007586654000006.tif237169

[0197] TIFF0007586654000007.tif233169

[0198] TIFF0007586654000008.tif217169

[0199] TIFF0007586654000009.tif227169

[0200] TIFF0007586654000010.tif170169

[0201] In some embodiments, the present invention provides an antibacterial agent, including but not limited to, loracarbef, cephalexin, cefadroxil, cefixime, ceftibuten, cefprozil, cefpodoxime, cephradine, cefuroxime, cefaclor, neomycin / polymyxin / bacitracin, dicloxacillin, nitrofurantoin, nitrofurantoin macrocrystals, nitrofurantoin / nitrofuran mac, dirithromycin, gemifloxacin, ampicillin, gatifloxacin, penicillin V potassium, ciprofloxacin, enoxacin, amoxicillin ... , amoxicillin / clavulanate potassium, clarithromycin, levofloxacin, moxifloxacin, azithromycin, sparfloxacin, cefdinir, ofloxacin, trovafloxacin, lomefloxacin, methenamine, erythromycin, norfloxacin, clindamycin / benzoyl peroxide, quinupristin / dalfopristin, doxycycline, amikacin sulfate, vancomycin, kanamycin, netilmicin, streptomycin, tobramycin sulfate, gentamicin sulfate, tetracycline, framycin tin, minocycline, nalidixic acid, demeclocycline, trimethoprim, miconazole, colistimethate, piperacillin sodium / tazobactam sodium, paromomycin, colistin / neomycin / hydrocortisone, amoebic drugs, sulfisoxazole, pentamidine, sulfadiazine, clindamycin phosphate, metronidazole, oxacillin sodium, nafcillin sodium, vancomycin hydrochloride, clindamycin, cefotaxime sodium, cotrimoxazole, ticarcillin disodium, piperacillin sodium thorium, ticarcillin disodium / clavulanate potassium, neomycin, daptomycin, cefazolin sodium, cefoxitin sodium, ceftizoxime sodium, penicillin G potassium and sodium, ceftriaxone sodium, ceftazidime, imipenem / cilastatin sodium, aztreonam, cinoxacin, erythromycin / sulfisoxazole, cefotetan disodium, ampicillin sodium / sulbactam sodium, cefoperazone sodium, cefamandole nafate, gentamicin,Sulfisoxazole / phenazopyridine, tobramycin, lincomycin, neomycin / polymyxin B / gramicidin, clindamycin hydrochloride, lansoprazole / clarithromycin / amoxicillin, alatrofloxacin, linezolid, bismuth subsalicylate / metronidazole / tetracycline, erythromycin / benzoyl peroxide, mupirocin, fosfomycin, pentamidine isethionate, imipenem Nem / cilastatin, troleandomycin, gatifloxacin, chloramphenicol, cycloserine, neomycin / polymyxin B / hydrocortisone, ertapenem, meropenem, cephalosporins, fluconazole, cefepime, sulfamethoxazole, sulfamethoxazole / trimethoprim, neomycin / polymyxin B, penicillin, rifampin / isoniazid, erythromycin estolate, erythromycin Synethylsuccinate, Erythromycin stearate, Ampicillin trihydrate, Ampicillin / probenecid, Sulfasalazine, Sulfanilamide, Sodium sulfacetamide, Dapsone, Doxycycline hyclate, Trimethoprim / sulfa, Methenamine mandelate, Antiplasmodials, Pyrimethamine, Hydroxychloroquine, Chloroquine phosphate, Antitrichomonas, Anthelmintics, Atovaquone, Bacitracin, Bacitracin Delivery of silver ion compounds including thoracin / polymyxin b, gentamicin, neomycin / polymyxin / dexameth, neomycin sulf / dexameth, sulfacetamide / prednisolone, sulfacetamide / phenylephrine, tobramycin sulfate / dexameth, bismuth tribromophenate, silver ion compounds, silver nanoparticles, zero-valent silver, multivalent silver, elemental silver, and silver-containing compounds such as, for example, silver sulfadiazine and related compounds, is presented.

[0202] In some embodiments, the present invention provides for the treatment of patients with antiviral drugs, including but not limited to amantadine, acyclovir, foscarnet, indinavir, ribavirin, enfuvirtide, emtricitabine, lamivudine, abacavir sulfate, fomivirsen, valacyclovir, tenofovir, cidofovir, atazanavir, amprenavir, delavirdine mesylate, famciclovir, adefovir, didanosine, efavirenz, trifluridine, inidinavir, lamivudine, vidarabine, Delivery of antivirals including lopinavir / ritonavir, ganciclovir, zanamivir, abacavir / lamivudine / zidovudine, lamivudine / zidovudine, nelfinavir, nelfinavir mesylate, nevirapine, ritonavir, saquinavir, saquinavir mesylate, rimantadine, stavudine, docosanol, zalcitabine, idoxuridine, zidovudine, zidovudine / didanosine, valganciclovir, penciclovir, lamivudine, and oseltamivir is presented.

[0203] In some embodiments, the present invention provides the use of antifungal drugs, including but not limited to, amphotericin B, nystatin, nystatin / triamcinolone, itraconazole, ketoconazole, miconazole, sulconazole, clotrimazole, clotrimazole / betamethasone, enilconazole, econazole, oxiconazole, tioconazole, terconazole, butoconazole, thiabendazole, flucytosine, butenafine, ciclopirox, cyclopyrrolidone ... Delivery of topical azoles (including, but not limited to, cyclosporine, haloprogin, naftifine, tolnaftate, natamycin, undecylenic acid, mafenide, dapsone, clioquinol, clioquinol / hydrocortisone, potassium iodide, silver sulfadiazine, gentian violet, carbofuchsin, cilofungin, sertaconazole, voriconazole, fluconazole, terbinafine, caspofungin, other topical azole drugs, and griseofulvin, are presented.

[0204] In some embodiments, the present invention provides for the use and delivery of buffers including, but not limited to, maleic acid, phosphate, glycine, chloroacetic acid, formic acid, benzoic acid, acetic acid, pyridine, piperazine, MES, Bis-Tris, carbonate, ACES, ADA MOPSO, PIPES, phosphate, BES, MOPS, TES, HEPES, DIPSO, TAPSO, triethanolamine, HEPSO, Tris, Tricine, Bicine, TAPS, borate, ammonia, CHES, ethanolamine, CAPSO, glycine, carbonate, CAPS, methylamine, piperidine, and phosphate.

[0205] In some embodiments, the present invention provides for the delivery of vitamins and minerals, including but not limited to Vitamin A, carotenoids, Vitamin D, Vitamin E, Vitamin K, Vitamin C / ascorbic acid, B1 / thiamine, B2 / riboflavin, B3 / niacin, B5 / pantothenic acid, B6 / pyridoxine, B12 / cobalamin, biotin, calcium, magnesium, phosphorus, sodium, chloride, potassium, boron, chromium, copper, iodine, iron, manganese, selenium, and zinc.

[0206] In some embodiments, the present invention provides for the delivery of analgesics, including but not limited to acetaminophen, anileridine, acetylsalicylic acid, buprenorphine, butorphanol, fentanyl, fentanyl citrate, codeine, rofecoxib, hydrocodone, hydromorphone, hydromorphone hydrochloride, levorphanol, alfentanil hydrochloride, meperidine, meperidine hydrochloride, methadone, morphine, nalbuphine, opium, levomethadyl, sodium hyaluronate, sufentanil citrate, capsaicin, tramadol, leflunomide, oxycodone, oxymorphone, celecoxib, pentazocine, propoxyphene, benzocaine, lidocaine, dezocine, clonidine, butalbital, phenobarbital, tetracaine, phenazopyridine, sulfamethoxazole / phenazopyridine, and sulfisoxazole / phenazopyridine.

[0207] In some embodiments, the present invention provides for the delivery of anticoagulants, including but not limited to coumarin, 1,3-indandione, anisindione, fondaparinux, heparin, lepirudin, antithrombin, warfarin, enoxaparin, dipyridamole, dalteparin, ardeparin, nadroparin, and tinzaparin.

[0208] In some embodiments, the present invention provides for the delivery of clotting factors, including but not limited to Factor I (fibrinogen), Factor II (prothrombin), Factor III (thromboplastin, tissue factor), Factor IV (calcium), Factor V (labile factor), Factor VII (stable factor), Factor VIII (antihemophilic globulin, antihemophilic globulin, antihemophilic factor A), Factor IX (plasma thromboplastin component, Christmas factor, antihemophilic factor B), Factor X (Stuart factor, Prower factor, Stuart-Prower factor), Factor XI (plasma thromboplastin precursor, antihemophilic factor C), Factor XII (Hageman factor, surface factor, contact factor), and Factor XIII (fibrin stabilizing factor, fibrin stabilizing enzyme, fibrinase).

[0209] In some embodiments, the present invention provides an anti-inflammatory agent (including but not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs) (Diclofenac (also known as Voltaren, Abitren, Allvoran, Almiral, Alonpin, Anfenax, Artrites, Betaren, Blesin, Bolabomin, Cataflam, Clofec, Clofen, Cordralan, Curinflam, Diclomax, Diclosian, Dicsnal, Difenac, Ecofenac, Hizemin, Inflamac, Inflanac, Klotaren, Lidonin, Monoflam, Naboal, Oritaren, Remethan, Savismin, Silino, Staren, Tsudohmin, Voltarol, Voren, Voveran, and Vurdon)), Diflunisal (Dolobid, Adomal, Diflonid, Diflu Nil, Dolisal, Dolobis, Dolocid, Donobid, Dopanone, Dorbid, Dugodol, Flovacil, Fluniget, Fluodonil, Flusar, Ilacen, Noaldol, Reuflos, and Unisal), Etodolac (also known as Lodine), Fenoprofen (also known as Nalfon, Fenoprex, Fenopron, Fepron, Nalgesic, and Progesic), Flurbiprofen (also known as Ansaid and Ocuflur), Ibuprofen (Rufen, Motrin, Aches-N-Pain, Advil, Nuprin, Dolgesic, Genpril, Haltran, Ibifon, Ibren, Ibumed, Ibuprin, Ibupro-600, Ibuprohm, Ibu-Tab, Ibutex, Ifen, Medipren, Midol 200, Motrin-IB, Cramp End, Profen, Ro-Profen, Trendar, Alaxan, Brofen, Alfam, Brufen, Algofen, Brufort, Amersol, Bruzon, Andran, Buburone, Anflagen, Butacortelone,Apsifen, Deflem, Artofen, Dolgit, Artril, Dolocyl, Bloom, Donjust, Bluton, Easifon, Ebufac, Emflam, Emodin, Fenbid, Fenspan, Focus, Ibosure, Ibufen, Ibufug, Ibugen, Ibumetin, Ibupirac, Imbun, Inabrin, Inflam, Irfen, Librofen, Limidon, Lopane, Mynosedin, Napacetin, Nobafon, Nobgen, Novogent, Novoprofen, Nurofen, Optifen, Paduden, Paxofen, Perofen, Proartinal, Prontalgin, Q-Profen, Relcofen, Remofen, Roidenin, Seclodin, Tarein, and also known as Zofen), indomethacin (Indameth, Indocin, Amuno, Antalgin, Areumatin, Argilex, Artherexin, Arthrexin, Artrinovo, Bavilon, Bonidon, Boutycin, Chrono-Indocid, Cidalgon, Confortid, Confortind, Domecid, Durametacin, Elemetacin, Idicin, Imbrilon, Inacid, Indacin, Indecin, Indocap, Indocen, Indocid, Indoflex, Indolag, Indolar, Indomed, Indomee, Indometacinum, Indometicina, Indometin, Indovis, Indox, Indozu, Indrenin, Indylon, Inflazon, Inpan, Lauzit, Liometace, Metacen, Metindon, Metocid, Mezolin, Mobilan, Novomethacin, Peralgon, Reflox, Rheumacid, Rheumacin, Salinac, Servindomet, Toshisan, and also known as Vonum), ketoprofen (Orudis, Alrheumat, Alrheumun, Alrhumat, Aneol, Arcental,Dexal, Epatec, Fastum, Keeduril, Kefenid, Keprofen, Ketofen, Ketonal, Ketosolan, Kevadon, Mero, Naxal, Oruvail, Profenid, Salient, Tofen, and Treosin), Ketorolac (also known as Toradol), Meclofenamic Acid (also known as Meclofen, Meclomen, and Movens), Mefenamic Acid (Ponstel, Alpain, Aprostal, Benost, etc.) an, Bonabol, Coslan, Dysman, Dyspen, Ecopan, Lysalgo, Manic, Mefac, Mefic, Mefix, Parkemed, Pondex, Ponsfen, Ponstan, Ponstyl, Pontal, Ralgec, and Youfenam), nabumetone (also known as Relafen), naproxen (Naprosyn, Anaprox, Aleve, Apranax, Apronax, Arthrisil, Artrixen, Artroxen, Bonyl, Congex, Danaprox, Diocodal, Dysmenalgit, Femex, Flanax, Flexipen, Floginax, Gibixen, Headlon, Laraflex, Laser, Leniartil, Nafasol, Naixan, N alyxan, Napoton, Napren, Naprelan, Naprium, Naprius, Naprontag, Naprux, Napxen, Narma, Naxen, Naxid, Novonaprox, Nycopren, Patxen, Prexan, Pr odexin, Rahsen, Roxen, Saritilron, Sinartrin, Sinton, Sutony, Synflex, Tohexen, Veradol, Vinsen, and Xenar), Oxaprozin (also known as Daypro), Piroxicam (Feldene, Algidol, Antiflog, Arpyrox, Atidem, Bestocam, Butacinon, Desinflam, Dixonal, Doblexan, Dolonex, Feline, Felrox, Fuldin,Indene, Infeld, Inflamene, Lampoflex, Larapam, Medoptil, Novopirocam, Osteral, Pilox, Piraldene, Piram, Pirax, Piricam, Pirocam, Pirocaps, Piroxan, Piroxedol, Piroxim, Piton, Posidene, Pyroxy, Reucam, R exicam, Riacen, Rosic, Sinalgico, Sotilen, Stopen, and Zunden), Sulindac (Clinoril, Aflodac, Algocetil, Antribid, Arthridex, Arthrocine, Biflace, Citireuma, Clisundac, Imbaral, Lindak, Lyndak, Mobi The delivery of anti-inflammatory drugs including steroids, such as lin, Reumofil, Sudac, Sulene, Sulic, Sulindal, Suloril, and Sulreuma, tolmetin (also known as Tolectin, Donison, Midocil, Reutol, and Safitex), celecoxib (also known as Celebrex), meloxicam (also known as Mobic), rofecoxib (also known as Vioxx), valdecoxib (also known as Bextra), aspirin (also known as Anacin, Ascriptin, Bayer, Bufferin, Ecotrin, and Excedrin), and steroidal anti-inflammatory drugs, such as cortisone, prednisone, and dexamethasone, are suggested.

[0210] In some embodiments, the present invention provides for the delivery of vasoconstrictors, including but not limited to epinephrine (adrenaline, Susphrine), phenylephrine hydrochloride (Neo-Synephrine), oxymetazoline hydrochloride (Afrin), norepinephrine (Levophed), and caffeine.

[0211] In some embodiments, the present invention provides the use of vasodilators, including but not limited to, bosentan (Tracleer), epoprostenol (Flolan), treprostinil (Remodulin), sitaxsentan, nifedipine (Adalat, Procardia), nicardipine (Cardene), verapamil (Calan, Covera-HS, Isoptin, Verelan), diltiazem (Dilacor XR, Diltia XT, Tiamate, Tiazac, Cardizem), Isradipine (DynaCirc), Nimodipine (Nimotop), Amlodipine (Norvasc), Felodipine (Plendil), Nisoldipine (Sular), Bepridil (Vascor), Hydralazine (Apresoline), Minoxidil (Loniten), Isosorbide dinitrate (Dilatrate-SR, Iso-Bid, Isonate, Isorbid, Isordil, Isotrate, Sorbitrate), Sosorbide mononitrate (IMDUR), Prazosin (Minipress), Cilostazol (Pletal), Treprostinil (Remodulin), Cyclanderate, Isoxsuprine (Vasodilan), Nylidrin (Arlidin), Nitrate (Deponit, Minitran, Nitro-Bid, Nitrodisc, Nitro-Dur, Nitrol, Transderm-Nitro) Benazepril (Lotensin), Benazepril and Hydrochlorothiazide (LotensinHCT), Captopril (Capoten), Captopril and hydrochlorothiazide (Capozide), Enalapril (Vasotec), Enalapril and hydrochlorothiazide (Vaseretic), Fosinopril (Monopril), Lisinopril (Prinivil, Zestril), Lisinopril and hydrochlorothiazide (Prinzide, Zestoretic), Moexipril (Univasc), Moexipril and hydrochlorothiazide (Uniretic), Perindopril (Aceon), Quinapril (Accupril), Quinapril and hydrochlorothiazide (Accuretic), Ramipril (Altace), Trandolapril (Mavik), Papaverine (Cerespan, Genabid, Pavabid, Pavabid) Delivery of anticoagulants (including HP, Pavacels, Pavacot, Pavagen, Pavarine, Pavased, Pavatine, Pavatym, Paverolan) is suggested.

[0212] In some embodiments, the present invention provides the use of diuretics, including but not limited to, acetazolamide (Diamox), dichlorphenamide (Daranide), methazolamide (Neptazane), bendroflumethiazide (Naturetin), benzthiazide (Exna), chlorothiazide (Diuril), chlorthalidone (Hygroton), hydrochlorothiazide (Esidrix, HydroDiuril, Microzide), hydroflumethiazide (Diucardin), indapamide (Lozol), methyclothiazide (Enduron), metolazone (Zaroxolyn, Mykrox), povidone-2-one (Povidone), benzodiazepine (Povidone), benzothiazide ... Delivery of lithiazide (Renese), quinethazone (Hydromox), trichlormethiazide (Naqua), bumetanide (Bumex), ethacrynic acid (Edecrin), furosemide (Lasix), torsemide (Demadex), amiloride (Midamor), amiloride and hydrochlorothiazide (Moduretic), spironolactone (Aldactone), spironolactone and hydrochlorothiazide (Aldactazide), triamterene (Dyrenium), triamterene and hydrochlorothiazide (Dyazide, Maxzide) are suggested.

[0213] In some embodiments, the present invention provides an anti-cancer drug (including but not limited to, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anagrelide, anastrozole, arsenic trioxide, asparaginase, bexarotene, bicalutamide, bleomycin, busulfan, calsterone, capecitabine, carboplatin, carmustine, celecoxib, chlorambucil, cisplatin, cladribine, cyclophosphatase ... amide, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, daunorubicin, daunomycin, dexrazoxane, docetaxel, doxorubicin, epoetin alfa, estramustine, etoposide, etoposide phosphate, exemestane, filgrastim, floxuridine, fludarabine, flutamide, fulvestrant, gemcitabine, gemtuzumab, ozogamicin, goserelin acetate, hydroxyurea, ibritumomab Tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alpha-2a, interferon alpha-2b, irinotecan, leflunomide, letrozole, leucovorin, levamisole, lomustine, mechlorethamine (nitrogen mustard), megestrol acetate, melphalan, mercaptopurine, mesna, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, mycophenolate mofetil, nandrolone phenpropionate, nilutamide, nofetumomab, oprelvekin, oxaliplatin, paclitaxel, pamid Delivery of drugs such as rituximab, sargramostim, streptozocin, tacrolimus, tamoxifen, temozolomide, teniposide, testolactone, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, and zoledronate is suggested.

[0214] In another embodiment, the wound active agent is an siRNA. The RNAi construct of the present invention is a gene or genes that express base-paired RNA forming a ds RNA RNA region. The RNA may be part of the same molecule or different molecules. In a preferred embodiment, the RNAi construct contains a promoter operably linked to a nucleic acid sequence that encodes two complementary sequences separated by a loop sequence. The complementary regions correspond to a target RNA sequence separated by a loop sequence. When the RNAi construct is expressed, the complementary regions of the resulting pair of RNA molecules pair with each other to form a double-stranded RNA region. The present invention is not limited to any particular length of loop sequence. In some preferred embodiments, the loop sequence is in the range of about 4 to about 20 nucleotides in length. In more preferred embodiments, the loop sequence is about 6 to about 12 nucleotides in length. In other preferred embodiments, the dsRNA region is about 19 to about 23 nucleotides in length.

[0215] In other embodiments, dsRNA is formed from RNA transcribed from a vector as two different strands. In other embodiments, the two strands of DNA used to form dsRNA may belong to the same duplex, or two different duplexes, each forming with a DNA strand of at least partially complementary sequence. When dsRNA is generated in this way, the transcribed DNA sequence is flanked by two promoters, one controlling the transcription of one of the strands and the other controlling its complementary strand. These two promoters may be the same or different. In some embodiments, the DNA duplex with a promoter sequence at each end may directly generate RNA of a defined length, and they pair up to form dsRNA. See, for example, U.S. Patent No. 5,795,715 (incorporated herein by reference). The formation of the RNA duplex may be initiated either inside or outside the cell.

[0216] It is recognized that after processing, the resulting siRNA may contain two blunt ends, one blunt end and one overhang end, or two overhang ends.In some embodiments, the overhang end(s) contain either one or two nucleotide overhangs.As a non-limiting example, a 23 nucleotide long siRNA contains two 19mers with two nucleotide overhangs at each end.As another non-limiting example, a 21 nucleotide long siRNA contains two 19mers with one nucleotide overhang at each end.As yet another non-limiting example, a 22 nucleotide long siRNA contains two 22mers with no overhangs at each end.

[0217] Inhibition is sequence-specific in that the nucleotide sequence corresponding to the double-stranded region of the RNA is targeted for genetic inhibition. Preferred for inhibition are RNA molecules that contain nucleotide sequences identical to a portion of the target gene. RNA sequences with insertions, deletions, and single base mutations compared to the target sequence have also been found to be effective for inhibition. Thus, sequence identity may be optimized by using sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991 and references cited therein) and calculating the percent difference between nucleotide sequences using the Smith-Waterman algorithm (e.g., University of Wisconsin Genetic Computing Group), for example, implemented in the BESTFIT software program with default parameters. It is preferred that there is more than 90% sequence identity, or 100% sequence identity, between the inhibitory RNA and the portion of the target gene. Alternatively, the double-stranded region of the RNA may be defined functionally as a nucleotide sequence capable of hybridizing with a portion of a target gene transcript.

[0218] There is no upper limit to the length of the dsRNA that can be used. For example, the dsRNA may range from about 21 base pairs (bp) of the gene to the full length of the gene or more. In one embodiment, the dsRNA used in the methods of the invention is about 1000 bp in length. In another embodiment, the dsRNA is about 500 bp in length. In yet another embodiment, the dsRNA is about 22 bp in length. In some preferred embodiments, the sequence mediating RNAi is about 21 to about 23 nucleotides. The isolated iRNA of the invention mediates degradation of a target RNA.

[0219] The double-stranded RNA of the present invention only needs to be sufficiently similar to natural RNA so that it has the ability to mediate RNAi against target RNA.In one embodiment, the present invention relates to RNA molecules of various lengths, whose sequences guide the cleavage of specific mRNAs that correspond to them.The sequence does not need to be completely complementary, but there must be sufficient similarity so that the RNA can guide the RNAi cleavage of target mRNA.In a particular embodiment, the RNA molecule of the present invention contains a 3' hydroxyl group.

[0220] III. Nanoscale Polymer Matrix Compositions In some embodiments, the present invention provides compositions containing nanoscale polymer matrices that can be applied to wounds, biological tissues, corneas, lenses, bones, tendons, surgical meshes, wound dressings, biomedical devices, devices used in health care, or other surfaces. In some embodiments, the nanoscale polymer matrices are functionalized. In some embodiments, the nanoscale polymer matrices are not functionalized. In some embodiments, the nanoscale polymer matrices contain one or more polymers, preferably biocompatible or formed from one or more proteins, or a combination of polymers and proteins. In some embodiments, the nanoscale polymer layer is formed from synthetic polymers, such as synthetic polyelectrolytes. In other embodiments, the nanoscale polymer layer is synthesized from natural polymers, such as polysaccharides. In some embodiments, the nanoscale polymer matrix is ​​functionalized to allow for covalent interactions and / or to allow for binding to wound beds or tissue surfaces, or to allow for the application of bioactive agents to the nanoscale polymer matrix. In some embodiments, a bioactive agent, such as an antimicrobial agent (such as silver, polyhexamethylene biguanide (PHMB), chlorhexidine or iodine compounds, or antibiotics), is incorporated into the nanoscale polymer matrix. The bioactive agent is preferably impregnated, contained, or interspersed throughout the three-dimensional structure of the nanoscale polymer matrix. For example, if the nanoscale polymer matrix is ​​a polyelectrolyte multilayer (PEM), the bioactive agent is preferably incorporated between or within the polymer multilayers.

[0221] In some embodiments, the polymer matrix (e.g., the nanoscale polymer matrix and / or the second (e.g., sacrificial and / or non-sacrificial) polymer layer) contains an anti-biofilm agent. The technology is not limited to the anti-biofilm agents used in the device and related methods, kit embodiments, and method of treatment embodiments. For example, in some embodiments, the anti-biofilm agent is a small molecule anti-biofilm agent, a charged small molecule anti-biofilm agent, an anti-biofilm polypeptide, an anti-biofilm enzyme (e.g., Dispersin B), a metallic particle, or a metal ion anti-biofilm agent (e.g., a metal ion, a salt of a metal ion, or a nanoparticle of a metal ion). Further, in some embodiments, the metal ion anti-biofilm agent is a gallium ion, a salt of a gallium ion, a nanoparticle of a gallium ion, a gallium alloy, or an alloy of gallium and silver.

[0222] In some embodiments, the nanoscale polymer matrix, e.g., the polymer multilayer, is nanoscale to microscale in size. Thus, in some embodiments, the nanoscale polymer matrix is ​​about 1 nm to 1000 nm thick, about 1 nm to 500 nm thick, about 1 nm to 100 nm thick, about 1 nm to about 25 nm thick, about 1 nm to about 10 nm thick, or less than about 500 nm, 100 nm, 25 nm, or 10 nm thick. It is contemplated that nanoscale size matrices (i.e., nanoscale thickness) can lower the total amount of active agent loaded while still delivering an effective amount of active agent (i.e., the amount of active agent that accelerates wound healing compared to a control) compared to matrix structures of greater thickness. Lower total loading levels reduce toxicity in the wound environment, especially when antimicrobial compounds are incorporated into the polymer multilayer.

[0223] In some embodiments, the compliance of the nanoscale polymer matrix, e.g., polymer multilayers, is adjusted to facilitate cell migration through the wound. In some embodiments, the matrix has a compliance (measured in kilopascals (kPa)) of 100 Pa to about 500 kPa, about 7 to about 250 kPa, about 10 to about 250 kPa, or about 10 to about 200 kPa. In some embodiments, the matrix, e.g., polymer multilayers, has a compliance of about 3 kPa to 5, 4, 3, 2, 1, 0.5, 0.1, and 0.05 GPa (gigapascals).

[0224] In some embodiments, the nanoscale polymer matrix is ​​formed or placed on a solid support. The solid support can form an external permeable, semi-permeable, or impermeable barrier after the matrix is ​​applied to the wound, or can serve as a removal support for removing the support after transferring and applying the matrix to the wound. The present invention is not limited to any particular solid support. Indeed, a variety of solid supports are contemplated, including, but not limited to, solid supports formed from elastomeric materials such as PDMS, nylon, Teflon®, Gortex®, silk, polyurethane, silicone, preferably medical grade silicone, glass, plastic, PVDF, and solid supports formed from polyvinyl alcohol (PVA), polyvinyl acetate (PVAc), polystyrene (PS), polymethyl methacrylate (PMMA), polyvinyl acetate (PVAc), and polyethylene oxide.

[0225] In some embodiments, the nanoscale polymer matrix is ​​supported by a second polymer layer (e.g., a non-sacrificial polymer layer). For example, in some embodiments, the nanoscale polymer matrix is ​​supported by a second polymer layer (e.g., a non-sacrificial polymer layer) that contains a hydrogel, a hydrocolloid, and / or collagen as a support. In some embodiments, the second (e.g., non-sacrificial) polymer matrix support is peeled off the device before and / or after application.

[0226] In other embodiments, the nanoscale polymer matrix is ​​supported on a sacrificial polymer layer, preferably a sacrificial polymer layer formed from a degradable or dissolvable support material, such as a dissolvable polymer. In some embodiments, the nanoscale polymer matrix is ​​first formed on a solid support, and then a sacrificial polymer layer is formed on the nanoscale polymer matrix by, for example, spin-coating, spraying, or casting the sacrificial polymer layer material on the nanoscale polymer matrix. In preferred embodiments, the sacrificial polymer layer material is dissolvable in an aqueous environment or in an environment where moisture is present (e.g., a moist surface such as a wound bed, an internal body surface, an epithelial surface, etc.). In preferred embodiments, the sacrificial polymer layer material is dissolvable in an aqueous solution after application of the nanoscale polymer matrix on the surface. In some embodiments, the sacrificial polymer layer is microscale in size and may range from 0.2 μm to 1000 μm, 0.2 μm to 500 μm, 0.2 μm to 200 μm, 0.2 μm to 100 μm, 1 μm to 50 μm, 1 μm to 20 μm, 0.2 μm to 10 μm, or 1 μm to 10 μm, and is preferably less than 100, 50, 20, or 10 μm thick. Thus, the present invention provides an article containing two layers, a first nanoscale polymer matrix layer adjacent to a sacrificial polymer layer. This article may also be referred to as a microsheet. In some embodiments, when applied to a wet surface, the sacrificial polymer layer dissolves such that the nanoscale polymer matrix remains in contact with the wet surface. In some embodiments, when attached to a surface, the nanoscale polymer matrix forms a barrier against entry of foreign pathogens from the environment to the surface. In some embodiments, the microsheet contains at least two layers, a first layer being a sacrificial polymer layer and a second layer being a nanoscale polymer matrix, the nanoscale polymer matrix being exposed (i.e., the nanoscale polymer matrix is ​​not sandwiched between additional layers).In preferred embodiments, when a desired surface is contacted with the microsheet, the exposed nanoscale polymer matrix contacts the surface. In some embodiments, the microsheets of the present invention consist essentially of a sacrificial polymer layer and a nanoscale polymer layer.

[0227] In some embodiments of the invention, a nanoscale polymer matrix is ​​transferred to a wound or tissue using a sacrificial polymer layer, which is placed on top of the nanoscale polymer matrix after being transferred to the wound or tissue. In some embodiments of the invention, a nanoscale polymer matrix is ​​transferred to a wound or tissue using a sacrificial polymer layer, which is placed on the bottom of the nanoscale polymer matrix after being transferred to the wound or tissue. In some embodiments, a wound dressing is placed on top of the sacrificial polymer layer before or after the sacrificial polymer layer is dissolved or partially dissolved in an aqueous liquid. In some embodiments, a nanoscale polymer matrix is ​​transferred to a wound or tissue surface, and there is no insoluble polymer microfilm between the wound dressing placed on the treated wound or tissue and the nanoscale polymer matrix on the wound or tissue. In some embodiments, the nanoscale polymer matrix made of PEM and the soluble sacrificial cast are transferred to a wound or tissue surface, the sacrificial cast dissolves completely in the wound, and the PEM comes into direct contact with the wound tissue and a first / second wound dressing placed on the wound. In some embodiments, the first dressing is a biological dressing and the nanoscale polymer matrix does not interfere with the integration of the biological dressing in the wound bed.

[0228] In some embodiments, a nanoscale polymer matrix is ​​transferred to a surface of a biomedical device using a soluble polymer microfilm without an insoluble polymer microfilm covering the nanoscale polymer matrix.

[0229] In some embodiments of the present invention, the nanoscale polymer matrix containing one or more bioactive agents is transferred to the wound or tissue using a sacrificial polymer layer, which is placed on top of the nanoscale polymer matrix after being transferred to the wound or tissue. In some embodiments, a wound dressing is placed on top of the sacrificial polymer layer before or after the sacrificial polymer layer is dissolved or partially dissolved in an aqueous liquid. In some embodiments, the nanoscale polymer matrix containing one or more bioactive agents is transferred to the wound or tissue surface, and there is no insoluble polymer microfilm between the wound dressing placed on the treated wound or tissue and the nanoscale polymer matrix containing one or more bioactive agents on the wound or tissue. In some embodiments, the nanoscale polymer matrix containing one or more bioactive agents made of PEM and a soluble sacrificial cast is transferred to the wound or tissue surface, the sacrificial cast dissolves completely in the wound, and the PEM comes into direct contact with the wound tissue and the first / second wound dressing placed on the wound. In some embodiments, the first dressing is a biological dressing and the nanoscale polymer matrix does not interfere with the integration of the biological dressing in the wound bed.

[0230] In some embodiments, a nanoscale polymer matrix containing one or more bioactive agents is transferred to the surface of a biomedical device using a soluble microfilm that does not have an insoluble polymer microfilm covering the nanoscale polymer matrix containing one or more bioactive agents.

[0231] In some embodiments of the nanoscale polymer matrices described in this patent application, the nanoscale polymer matrices are polyelectrolyte multilayers (PEMs).

[0232] In some embodiments, the nanoscale polymer matrix is ​​used to modify medical devices, such as wound dressings. Examples of commercially available wound dressings that can be modified by the addition of the matrix described below include, but are not limited to, Biobrane®, Integra™ Matrix Wound Dressing, gauze, adhesive tape, bandages such as Band-Aids®, and other commercially available wound dressings, including, but not limited to, COMPEEL®, DUODERM®, TAGADERM®, and OPSITE®. In some preferred embodiments, a microsheet with a nanoscale polymer matrix is ​​first applied to a surface (e.g., a wound or other wet body surface), and then a wound dressing is applied.

[0233] In some embodiments, nanoscale polymer matrices are used to modify medical devices, such as surgical meshes. Examples of commercially available surgical meshes that can be modified by the addition of the matrices described below include, but are not limited to, polypropylene, polyester, polytetrafluoroethylene meshes, or absorbable biomesh, or biological meshes (biomeshes), including, but not limited to, ULTRAPRO (trademark) mesh, PROCEED (trademark) mesh, PROLENE (trademark) polypropylene mesh, Ethicon Physiomesh (trademark), MERSILENE (trademark) polyester mesh, PARIETEX (trademark) mesh, DOLPHIN (trademark) polypropylene mesh, GORE INFINIT (trademark) mesh, PERFIX (trademark), KUGEL (trademark), 3DMAX (trademark), BARD (trademark), VISILEX (trademark), XENMATRIX (trademark), ALLOMAX (trademark), SURGISIS BIODESIGN (trademark), and TIGR MATRIX (trademark).

[0234] In some embodiments, the sacrificial polymer layer of the microsheet contains a bioactive agent, an antibacterial agent, an antibiofilm agent, a microparticle, a nanoparticle, a magnetic particle, In some embodiments, the microparticle or nanoparticle in the sacrificial polymer layer contains a bioactive agent or an antibacterial agent.

[0235] In some embodiments, the polymer matrix (e.g., the second (e.g., sacrificial and / or non-sacrificial) polymer matrix) contains an anti-biofilm agent. The technology is not limited to the anti-biofilm agents used in the device and related method, kit embodiments, and method of treatment embodiments. For example, in some embodiments, the anti-biofilm agent is a small molecule anti-biofilm agent, a charged small molecule anti-biofilm agent, an anti-biofilm polypeptide, an anti-biofilm enzyme (e.g., Dispersin B), a metallic particle, or a metal ion anti-biofilm agent (e.g., a metal ion, a salt of a metal ion, or a nanoparticle of a metal ion). Further, in some embodiments, the metal ion anti-biofilm agent is a gallium ion, a salt of a gallium ion, a nanoparticle of a gallium ion, a gallium alloy, or an alloy of gallium and silver.

[0236] In a preferred embodiment, the sacrificial polymer layer of the microsheet is water-soluble. In some embodiments, the sacrificial polymer layer is made of a non-toxic polymer, and in some embodiments, the sacrificial polymer layer is polyvinyl alcohol (PVA). In some embodiments, the sacrificial polymer layer is made of polyacrylic acid (PAA), polystyrene (PS), PMMA polymethyl methacrylate (PMMA), or polyvinyl acetate (PVAc).

[0237] A. Polymer matrix materials In some embodiments, the matrix is ​​a polymer multilayer. In some embodiments, the multilayer structure contains a layer of polyelectrolyte (i.e., forms a polyelectrolyte multilayer), while in other embodiments, the multilayer contains an uncharged polymer (i.e., a nonionic polymer) or a combination of charged and uncharged polymer layers. In some embodiments, it is contemplated that the assembly of polyelectrolyte films by alternating the adsorption of cationic and anionic polyelectrolyte layers establishes a novel and promising technique for modifying wound surfaces in a controlled manner (Decher et al., 1992, Thin Solid Films 210 / 211:831; Decher, 1997, Science 277:1232). One of the most important properties of such multilayers is that they exhibit excessive alternating positive and negative charges (Caruso et al., 1999, J Am Chem Soc 121:6039; Ladam et al., 2000, Langmuir 16:1249). This not only drives their assembly (Joanny, 1999, Eur. Phys. J. Biol. 9:117), but also allows the simple contact of, for example, pigments, particles (Cassagneau et al., 1998, J. Am. Chem. Soc. 120:7848;Caruso et al., 1999, Langmuir 15:8276;Lvov et al., 1997, Langmuir 13:6195), clay microplates (Ariga et al., 1999, Appl. Clay Sci. 15:137), and proteins (Keller et al., 1994, J. Am. Chem. Soc. 116:8817;Lvov et al., 1995, J. Am. Chem. Soc. 117:6117;Caruso et al., It is possible to adsorb a wide variety of components such as cellulose acetate, cellulose esters, and cellulose acetate phosphate esters (Citromers, 1997, Langmuir 13:3427).

[0238] The polyelectrolyte layer is formed by applying alternating anionic and cationic polyelectrolytes to a surface to form a polyelectrolyte multilayer. In some embodiments, one or more wound active agents, such as those described above, are incorporated into the multilayer. Preferably, at least four layers, more preferably at least six layers, are used to form the polyelectrolyte multilayer.

[0239] Cationic polyelectrolytes useful in the present invention can be, for example, any biocompatible, water-soluble polycationic polymer (e.g., any polymer having protonated heterocycles attached as pendant groups). As used herein, "water-soluble" means that the polymer as a whole is soluble in aqueous solutions (e.g., buffered saline or buffered saline with small amounts of added organic solvent as a co-solvent, etc.) at temperatures between 20 and 37°C. In some embodiments, the material is not itself sufficiently soluble in aqueous solutions (defined herein as soluble to the extent of at least 1 g per liter), but can be rendered water-soluble by grafting the polycationic polymer with a water-soluble polynonionic material, such as polyethylene glycol.

[0240] Representative cationic polyelectrolytes include non-natural and natural polyamino acids with a net positive charge at neutral pH, positively charged polysaccharides, and positively charged synthetic polymers. Examples of suitable polycationic substances include polyamines having amine groups either on the polymer backbone or on the polymer side chains (e.g., poly-L-lysine (PLL)) and other positively charged polyamino acids of natural or synthetic amino acids or mixtures of amino acids (including but not limited to, poly(D-lysine), poly(ornithine), poly(arginine), and poly(histidine)), and non-peptide polyamines (e.g., poly(aminostyrene), poly(aminoacrylate), poly(N-methylaminoacrylate), poly(N-ethylaminoacrylate), poly(N,N-di ... Examples of suitable polysaccharides include poly(N,N-methylaminoacrylate), poly(N,N-diethylaminoacrylate), poly(amino methacrylate), poly(N-methylamino methacrylate), poly(N-ethylamino methacrylate), poly(N,N-dimethylamino methacrylate), poly(N,N-diethylamino methacrylate), poly(ethyleneimine), polymers of quaternary amines such as poly(N,N,N-trimethylaminoacrylate chloride), poly(methylacrylamidopropyltrimethylammonium chloride), and natural or synthetic polysaccharides such as chitosan.

[0241] Generally, the polymer must contain at least five charges and the molecular weight of the polycationic material must be sufficient to provide the desired degree of binding to tissue or other surfaces (having a molecular weight of at least 1000 g / mol).

[0242] The polyanionic material useful in the present invention may be any biocompatible water-soluble polyanionic polymer (e.g., any polymer having carboxylic acid groups attached as pendant groups). Suitable materials include alginate, powdered agar, furcellaran, pectin, xanthan, hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate, polyacrylic acid (PAA), dermatan sulfate, dextran sulfate, poly(meth)acrylic acid, oxidized cellulose, carboxymethylcellulose, and crosmarmelose, synthetic polymers, and copolymers containing pendant carboxyl groups (e.g., those containing maleic or fumaric acid in the backbone). Polyamino acids that are predominantly negatively charged are also suitable. Examples of these materials include polyaspartic acid, polyglutamic acid, and other natural and unnatural amino acids and their copolymers. Polyphenolic materials, such as tannins and lignins, may also be used if sufficiently biocompatible. Preferred materials include alginate, pectin, carboxymethylcellulose, heparin and hyaluronic acid.

[0243] In some embodiments, the cationic polyelectrolyte used is PLL, and the anionic polyelectrolyte used is poly(L-glutamic acid) (PGA).In practice, the use of various polyelectrolytes is contemplated, including, but not limited to, poly(ethyleneimine) (PEI), poly(allylamine hydrochloride) (PAH), poly(sodium 4-styrenesulfonate) (PSS), poly(acrylic acid) (PAC), poly(maleic acid-co-propylene) (PMA-P), and poly(vinyl sulfate) (PVS).It is also possible to use natural polyelectrolytes, including hyaluronic acid and chondroitin sulfate.In yet further embodiments, the polymer is a dendrimer, a graft polymer, or a star-structured polymer.

[0244] In some embodiments, the multi-layer structure is formed from uncharged polymers or a combination of charged and uncharged polymers. Examples of uncharged polymers include, but are not limited to, dextran, dextran sulfate, diethylaminoethyl (DEAE)-dextran, hydroxyethyl cellulose, ethyl(hydroxyethyl) cellulose, acrylamide, polyethylene oxide, polypropylene oxide, polyethylene oxide-polypropylene oxide copolymers, PAAN, etc. a , Ficoll, polyvinylpyrrolidone, and polyacrylic acid.

[0245] In some embodiments, the multilayer structure is formed from one or more amphoteric polymers, alone or in combination with other polymers described herein.In some embodiments, the amphoteric polymer comprises one or more of acrylic acid (AA), DMAEMA (dimethylaminoethyl methacrylate), APA (2-aminopropyl acrylate), MorphEMA (morpholinoethyl methacrylate), DEAEMA (diethylaminoethyl methacrylate), t-butylAEMA (t-butylaminoethyl methacrylate), PipEMA (piperidinoethyl methacrylate), AEMA (aminoethyl methacrylate), HEMA (2-hydroxyethyl methacrylate), MA (methyl acrylate), MAA (methacrylic acid) APMA (2-aminopropyl methacrylate), AEA (aminoethyl acrylate).In some embodiments, the amphoteric polymer comprises (a) a carboxylic acid, (b) a primary amine, and (c) a secondary amine and / or a tertiary amine. The amphoteric polymer has an isoelectric point of 4 to 8, preferably 5 to 7, and a number average molecular weight in the range of 10,000 to 150,000.

[0246] The polymer layer may be formed by a variety of methods. In some embodiments, the polymer layer is formed on a solid support as detailed below. In some embodiments, it is contemplated that the polymer, or polymer multilayer, is formed by sequential application of the polymer using either a pump (including syringes, inkjet printers, and electronic jets), or a spray (e.g., aerosol spray), or dip coating. In other embodiments, particle bombardment is used. In other embodiments, the use of a brush, including an airbrush, is contemplated. In other embodiments, a sponge is used. In other embodiments, a solid support or a stamp, such as an elastomeric material (e.g., PDMS (polydimethylsiloxane), silicone, hydrogel, or latex, etc.), is used to support the polymer layer and mechanically transfer the polymer layer into or onto the wound bed. In yet other embodiments, a nanoscale polymer matrix is ​​formed on a solid support, a sacrificial polymer layer is formed on the nanoscale polymer matrix, and the resulting microsheet is peeled off from the solid support.

[0247] In some embodiments, the matrix contains one or more proteins. In preferred embodiments, the proteins form a hydrogel. In some preferred embodiments, the matrix contains one or more extracellular matrix proteins. In some embodiments, the matrix contains at least one of collagen, laminin, vitronectin, fibronectin, keratin, and combinations thereof. As mentioned above, the protein matrix may be preferably formed by a variety of methods. In some embodiments, the protein matrix is ​​formed on a solid support as detailed below. In some embodiments, it is contemplated that the protein matrix is ​​formed by applying the protein, or a solution or gel of the protein, using either a pump (including syringe, inkjet printer, and electronic jet) or a spray (such as an aerosol spray). In other embodiments, the use of a brush (including an airbrush) is contemplated. In other embodiments, a sponge is utilized. In other embodiments, a solid support or a stamp, such as an elastomeric material (such as PDMS (polydimethylsiloxane), silicone, hydrogel, or latex), is used to support the protein matrix and mechanically transfer the protein matrix into or onto the wound bed.

[0248] In some embodiments, the matrix is ​​further modified to include cells (including but not limited to stem cells, keratinocytes, 3-D skin constructs, corneal epithelial cells, conjunctival cells, limbal stem cells, human embryonic stem cells, pluripotent stem cells, adult inducible stem cells, hematopoietic stem cells, hepatocytes, pancreatic cells, etc.). In some embodiments, the compositions and methods described herein are used to functionalize harvested and processed (frozen, lyophilized, fixed, and wet or dry stored, fresh tissue for direct transplantation) animal and human tissues (porcine / human aortic valves, harvested human amniotic membrane, human cadaver skin, harvested sclera and cornea, harvested cadaver bone, harvested blood vessels, etc.). In some embodiments, the compositions and methods described herein are used to functionalize skin constructs (including but not limited to autologous skin (i.e., skin is harvested from a patient, functionalized as described herein, and returned to the patient), organotypic cultured human skin equivalents, and other keratinocyte products, such as Dermagraft™).

[0249] B. Polymer Multilayers Associated with Micro- or Nano-Scale Beads In some embodiments, the present invention provides a polymeric multilayer containing nanoscale particles or microscale particles. In some embodiments, the particles are dispersed in the polymeric multilayer (e.g., between the polymeric layers). In other embodiments, the particles are presented on a surface, such as a top surface or a bottom surface, of the polymeric multilayer. In some embodiments, the particles are associated with the polymeric multilayer in a manner selected from the group consisting of: interspersed or dispersed in the polymeric multilayer; presented on the polymeric multilayer; and the bottom surface of the polymeric multilayer.

[0250] In some embodiments, the polymer multilayer is formed as described above. In some preferred embodiments, the particles have a diameter or other linear measurement characteristic, such as, for example, length or width, that is greater than the thickness of the polymer multilayer. In some embodiments, the diameter or other linear measurement is about 1, 1.5, 2, 3 or 4 times, to about 5, 10 or 20 times, greater than the thickness of the polymer multilayer.

[0251] In some embodiments, nanometer to micrometer sized biocompatible particles (e.g., spherical particles (e.g., beads) and / or non-spherical particles (e.g., ellipsoidal, acicular, cubic, tetrahedral, mushroom, haystack structures, etc.) particles or electrospun polymers) are used in or on the polymer multilayer. Microbeads typically have a size in the range of about 1 to about 500 micrometers, while nanobeads typically have a size in the range of about 1 to about 1000 nanometers. Microbeads may further contain microscale (e.g., 1 to 100 micrometers) or nanoscale (e.g., 0.1 to 1000 nanometers) features on the bead surface. Nanobeads may further contain nanoscale (e.g., 0.1 to 500 nanometers) features on the bead surface. In some embodiments, the wound active agent is present in the form of beads or particles, such as, for example, silver nanoparticles. In some embodiments, the biocompatible particles are biodegradable. In some embodiments, the biocompatible particles are modified with surface chemical crosslinkers that can attach and immobilize, for example, wound active agents, cell matrix components, etc., as described elsewhere herein. In some embodiments, the size of the biocompatible particles, for example, beads, is at least 1 nm, at least 5 nm, at least 10 nm, at least 20 nm, at least 50 nm, at least 100 nm, at least 200 nm, at least 300 nm, at least 500 nm, or at least 800 nm in diameter. In some embodiments, beads and other spherical or non-spherical particles contain their own surface texture. For example, bead surfaces may contain undulations, indentations, tunnels, holes, bumps, protrusions, etc. Spherical particles, such as beads, may or may not be inert and may be, for example, magnetic. Magnetic beads contain, for example, magnetic cores or magnetic particles. Examples of different bead compositions can be found, for example, in US Pat. Nos. 5,268,178, 6,458,858, 6,869,858, and 5,834,121, each of which is incorporated by reference herein in its entirety.In some embodiments the particles contain or are impregnated with a wound active agent.

[0252] It is contemplated that polymer multilayers, such as those described above, provide the opportunity to chemically and topographically engineer substrate surfaces. With existing techniques, nanostructures or organic films (such as polymer multilayers) must be constructed on these surfaces and active agents must be added to them. These procedures are time-consuming and laborious (it takes 6 hours to assemble a multilayer film containing 20 layers, which is prohibitively long for wound treatment, for example), can involve harsh chemicals, solutions with non-physiological pH, and can involve mechanical shear forces that can damage and injure the substrates on which they are formed (especially biological tissues and delicate biomedical devices). To overcome these limitations, in some embodiments, the polymer multilayers of the present invention are pre-assembled on an elastomeric stamp (e.g., a PDMS stamp) and then mechanically transferred onto the substrate of interest by stamping on the substrate of interest. Although the concept of contact printing prefabricated nano- and microstructures on rigid substrates (microscope slides, silicon wafers) has been used for the microfabrication of electromechanical systems, such methods do not work well when applied to soft substrates, especially those with mechanical properties often found in the range of biological tissues.

[0253] The present invention provides methods and compositions that allow the transfer of thin organic and inorganic films, including polymer multilayers, onto compatible substrates, including soft substrates with mechanical properties comparable to biological tissues (elastic modulus E' of about 1-500 kPa, preferably about 10-100 kPa). Existing methods described in the literature that allow the transfer of thin organic layers onto hard substrates such as glass (E' of about 65 GPa) with various surface chemistries, do not work well when used on soft surfaces (E' of about 100 kPa). Figure 11 illustrates these observations. The method shown in Example 14 and Figure 12 facilitates the transfer of polymer multilayers onto soft surfaces, including biological tissues, including skin grafts and mouse skin. When stamping onto human skin grafts or onto soft biomedical grade silicone elastomers (E', ~100 kPa), the incorporation of polymer microspheres (E', ~3 GPa) into the assembly of polymer multilayers on the elastomeric stamp allows for substantially complete transfer of the hard microspheres and the polymer multilayers in contact with the microspheres.

[0254] This method allows engineering the surface of soft substrates (E', approx. 100 kPa) by contact printing preassembled functionalized polymer multilayers onto the surface. This opens up a huge opportunity to chemically and topographically modify the surfaces of biological tissues and soft implantable biomedical devices such as biomedical grade silicones, and to generate surfaces with tailored functionality, chemistry, and topography at the nanometer scale. This is a versatile solution for engineering or patterning wound beds, for example, from two perspectives. First, from a product development perspective, the assembly and functionalization of the polymer multilayers used in this method can be easily automated in a robotic manufacturing environment. Second, from an application perspective, the end user simply contact prints material from a stamp onto a substrate instead of preparing the multilayer on the substrate.

[0255] Thus, the present invention provides a method to tailor the surface chemistry and nanostructured morphology of soft substrates by mechanically transferring prefabricated nanometer-thick organic films (impregnated with active agents) onto substrates. This technology offers unprecedented advantages over some existing competing technologies. First, the previously described techniques of stamping prefabricated polymer multilayer films onto substrates in conjunction with the microfabrication of electromechanical systems are unable to transfer them onto soft substrates with mechanical strengths related to biological tissues. Thus, the present invention opens up the possibility of engineering a whole new range of soft substrate surfaces by contact printing prefabricated functionalized polymer films. Some of such soft substrates that are relevant for the immediate commercialization of this technology include biological tissues, wound beds, and implantable biomedical devices (such as biomedical grade silicone). Furthermore, experiments conducted during the present invention have led to the new insight that the mechanical properties of the substrate affect the mechanical transfer of organic films onto them - these new mechanical transfer properties can be used to selectively transfer organic films onto substrates having, for example, patterned soft and hard regions.

[0256] Secondly, to chemically or topographically modify the surface of soft substrates (E', approx. 100 kPa) using existing techniques, one must build nanostructures or organic films (such as polymer multilayers) on these surfaces and immerse them in active agents. These procedures often involve harsh chemicals, non-physiological pH, and potentially mechanical shear forces that can destroy delicate substrates, especially biological tissues and delicate biomedical devices. The invention described herein allows contact printing of pre-assembled polymer multilayers impregnated with active agents onto soft substrates instead of assembling them on the substrate. Furthermore, direct stamping of pre-assembled polymer multilayers onto substrates provides precise control over the two- and three-dimensional arrangement of the polymer multilayers. By using the technique to stamp multiple pre-assembled polymer multilayers in succession, multi-level and multi-component pattern structures can be conveniently introduced onto device surfaces. Thus, the invention provides novel control over the surface modification of soft substrates at the nanometer level.

[0257] Third, with regard to wound healing, current clinical wound management methods include delivery of active agents to the wound in ointments or dressings. The wound dressing is a reservoir for the active agent, and high loading concentrations are required to allow the active agent to diffuse through the wound fluid and reach the wound bed where activity is required. High concentrations of the active agent are cytotoxic, thereby causing tissue toxicity and inhibiting wound healing.

[0258] The present invention allows for the immobilization of active agents on the surface of the wound bed by stamping prefabricated nanostructured polymer multilayers impregnated with the active agent. Such immobilization of active agents in polymer multilayers on the wound bed 1) allows for precise delivery and minimal loading of the active molecule on the wound bed, resulting in effective wound treatment at low cost and without cytotoxic effects, and 2) prolongs the bioavailability of the active agent in the wound bed, eliminating the need for frequent dressing, thus reducing pain for the patient and reducing the overall cost of wound management. This is especially relevant in the treatment of chronic wounds that take months to heal. 3) The delivery of bioactive molecules is controlled both spatially and temporally, allowing for controlled distribution of the active molecules throughout the wound bed and creating gradients of them. For example, in vitro experiments have shown that gradients of growth factors promote the migration of cells involved in wound healing to the wound bed, speeding up wound closure. 4) The active molecule can be placed directly into the cellular microenvironment, thereby increasing the local concentration and avoiding the problems of mass transport limitations or complex aggregation encountered in release systems, and 5) The active molecule can be maintained locally in the matrix, limiting potential undesirable diffusion to distant sites or any loss of permeability.

[0259] This approach to wound healing using the present invention is fundamentally novel in the sense that it attempts to "engineer the wound bed." The surface of the wound bed is chemically and topographically modified with nanometer thick organic films that are impregnated with minimal concentrations of active agents. This contrasts with current approaches, which attempt to treat wounds by dusting the entire wound with high concentrations of bioactive agents. Thus, in some embodiments, the present invention provides a polymeric multilayer comprising at least one polymer, the polymeric multilayer being associated with particles selected from the group consisting of nanoscale particles and microscale particles. In some embodiments, the polymeric multilayer is 1 nm to 1000 nm thick, and in preferred embodiments, about 1 to about 250 nm thick. In some embodiments, the polymeric multilayer has a compliance of 3 to 500 kPa. In some embodiments, the polymeric multilayer is disposed on a support. In some embodiments, the polymeric multilayer is formed on a support. In some preferred embodiments, the support is an elastomeric support.

[0260] In some embodiments, the present invention provides a method of modifying a surface comprising contacting the surface with the polymeric multilayer described above under conditions such that the polymeric multilayer is transferred to the surface. In some embodiments, the surface is a soft surface. In some embodiments, the surface has an elastic modulus of about 1 to about 500 kPa, preferably about 10 to about 100 kPa. In some embodiments, the surface is a biological surface. In some embodiments, the biological surface contains proteins, lipids, and / or carbohydrates. In some embodiments, the biological surface is selected from the group consisting of skin, wound beds, hair, tissue surfaces, and organ surfaces. In some embodiments, the surface is a biologically compatible surface or a surface of a biomedical device. In some embodiments, the surface is a silicone surface.

[0261] C. Microsheets Containing Nanoscale Polymer Matrix and Sacrificial Polymer Layers As detailed above, in some embodiments, the present invention provides a microsheet containing at least two layers, the first layer being a nanoscale polymer matrix and the second layer being a sacrificial polymer layer. Exemplary microsheets and methods for making the microsheets are shown in Figures 13, 16, and 17. With reference to Figure 13, the nanoscale polymer matrix may preferably be formed on a solid support, such as PDMS. The nanoscale polymer matrix may contain any of the polymers detailed above. Additional support materials are detailed below. In some embodiments, the wound active agent is incorporated into the nanoscale polymer matrix during the formation of the matrix. Impregnation of the matrix may also be performed after the formation of the matrix to provide a bioactive nanoscale polymer matrix. As described above, the wound active agent is preferably incorporated or interspersed within the three-dimensional structure of the matrix. Figure 16 illustrates a preferred embodiment of the present invention in which silver ions and nanoparticles are interspersed within the three-dimensional structure of a PAH / PAA nanoscale polyelectrolyte multilayer (PEM) matrix. In a preferred embodiment, the nanoscale polymer matrix is ​​soaked in a silver nitrate solution to impregnate it with silver ions; the matrix is ​​then incubated in a reducing agent solution to form silver nanoparticles within the matrix. In Figure 17, another preferred embodiment of the present invention is illustrated in which a positively charged antimicrobial agent, chlorhexidine, is interspersed between the negatively charged polyelectrolyte (PAA) layers of a PAH / PAA nanoscale polyelectrolyte multilayer (PEM) matrix.

[0262] With reference to FIG. 13, in some embodiments, a sacrificial polymer layer is then cast onto the nanoscale polymer matrix. The sacrificial polymer layer preferably contains a decomposable or dissolvable material, as described above. In some preferred embodiments, the sacrificial polymer layer contains polyvinyl alcohol (PVA). In some embodiments, the sacrificial polymer layer is made of polyacrylic acid (PAA), polystyrene (PS), polymethyl methacrylate (PMMA), or polyvinyl acetate (PVAc). In some embodiments, the sacrificial polymer layer is preferably cast by dip coating, spin coating, or spraying. It is contemplated that dip coating, spin coating, or spraying will result in a sacrificial polymer layer of uniform thickness. In some preferred embodiments, the microsheet is about 0.2 cm thick. 2 ~about 600cm 2 In some embodiments, the sacrificial polymer layer has a thickness variation across the microsheet of less than 500, 400, 300, 200, 100, 50, 20, or 10% of the average thickness when measured in cross section. With further reference to FIG. 13, the microsheet may be peeled off from the solid support to provide a free-standing microsheet that can be applied to a surface such as a device or wound tissue (as illustrated in FIGS. 13 and 14, respectively). The microsheets of the present invention, even though microscopically thin, have excellent mechanical strength and can be handled by hand or machine. In some embodiments, the microsheet has a Young's modulus of about 0.1 GPa to about 10 GPa. As is evident from FIGS. 13 and 14, the exposed nanoscale polymer matrix is ​​in direct contact with the device surface or wound surface. In the presence of moisture, the sacrificial polymer layer dissolves leaving the nanoscale polymer matrix exposed or attached to the surface.

[0263] D. Functionalizing Agents In some embodiments, the matrix is ​​functionalized. In preferred embodiments, the matrix is ​​functionalized with one or more covalent modifiers. In some preferred embodiments, the crosslinker contains either an azide group or an alkyne group to allow for suitable click chemistry. In some embodiments, at least one covalent modifier is a homogeneous bifunctional crosslinker. In other embodiments, at least one covalent modifier is a heterogeneous bifunctional crosslinker. For example, in some embodiments, the homogeneous bifunctional crosslinker is selected from the group consisting of N-hydroxysuccinimidyl esters (such as, but not limited to, disuccinimidyl esters, dithiobis(succinimidyl propionate), 3,3'-dithiobis(sulfosuccinimidyl propionate), disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, disuccinimidyl tartarate, disulfosuccinimidyl tartarate, bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfone ... , bis[2-(sulfosuccinimidooxycarbonyloxy)ethyl]sulfone, ethylene glycobis(succinimidyl-succinate, ethylene glycobis(sulfosuccinimidyl-succinate), disuccinimidyl glutarate, and N,N'-disuccinimidyl carbonate). In some embodiments, the homogeneous bifunctional crosslinker is at a concentration of 1 nanomolar to 10 millimolar. In some preferred embodiments, the homogeneous bifunctional crosslinker is at a concentration of 10 micromolar to 1 millimolar.In other embodiments, at least one covalent modification agent is a heterobifunctional crosslinker (such as, but not limited to, N-succinimidyl 3-(2-pyridyldithio)propionate, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate, sulfosuccinimidyl 6-(3'-[2-pyridyldithio]-propionamido)hexanoate, succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio) ... thio)toluene, sulfosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio)toluamide]hexanoate, succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-maleimidobenzoyl-N-hydroxysuccinimide ester, m-maleimidobenzoyl-N-hydroxysuccinimide ester ter, N-succinimidyl (4-iodoacetyl)aminobenzoate, sulfo-succinimidyl (4-iodoacetyl)aminobenzoate, succinimidyl-4-(p-maleimidophenyl)butyrate, sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, N-(γ-maleimidobutyryloxy)succinimide ester, N-(γ-maleimidobutyryloxy)sulfosuccinimide ester, succinimidyl 6-((iodoacetyl)aminobenzoate Examples of suitable heterobifunctional crosslinkers include succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoate, succinimidyl 6-(6-(((4-iodoacetyl)amino)hexanoyl)amino)hexanoate, succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate, succinimidyl 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate, and p-nitrophenyl iodoacetate). In some embodiments, the heterobifunctional crosslinkers are modified with functional groups, thereby making them soluble in aqueous solvents and delivered as aqueous solutions. Additionally, in some embodiments, the aqueous solutions contain additives, such as, but not limited to, surfactants and block copolymers.In other embodiments, a variety of heterobifunctional crosslinkers can be attached to molecules, polymers, or particles and function as crosslinkers, hi other embodiments, the heterobifunctional crosslinkers are dissolved in an organic solvent (such as, but not limited to, dimethylsulfoxide).

[0264] In some embodiments, the covalent modification agent is a photoactivatable crosslinking agent.Suitable photoactivatable crosslinking agents include, but are not limited to, aryl azido N-((2-pyridyldithio)ethyl)-4-azido salicylamide, 4-azido-2,3,5,6-tetrafluorobenzoic acid, succinimidyl ester, 4-azido-2,3,5,6-tetrafluorobenzoic acid, STP ester, benzophenone maleimide, succinimidyl ester of 4-benzoylbenzoic acid, N-5-azido-2-nitrobenzoyloxysuccinimide, N-hydroxysulfosuccinimidyl-4-azidobenzoate, N-hydroxysuccinimidyl-4-azido salicylic acid, and (4-[p-azido salicylamide]butylamine).

[0265] The covalent modifying agent may be applied to the matrix by any suitable method. In some embodiments, it is contemplated that the covalent modifying agent is applied using a pump (including syringe, inkjet printer, and electronic jet) or a spray, such as an aerosol sprayer. In other embodiments, the use of a brush, including an airbrush, is contemplated. In other embodiments, a sponge is used.

[0266] After applying the covalent modifying agent to the matrix, a functionalized matrix is ​​formed, which in some embodiments presents one or more reactive moieties (e.g., azide moieties, succinimidyl moieties, alkyne moieties, or any other reactive group of the compounds described above, etc.).

[0267] In some embodiments, the matrix is ​​modified by PEGylation with polyethylene glycol.It is contemplated that PEGylation can be used to control the interaction between the matrix and wound bed, and if desired, prevent non-specific adsorption.PEGylation can also be used to control the delivery of wound active agents from the matrix.

[0268] E. Wound activators In some embodiments, the matrix contains one or more wound active agents as detailed above. In some embodiments, the wound active agent(s) are non-covalently incorporated into the matrix. In some preferred embodiments, the silver-containing antimicrobial material is incorporated into a functionalized matrix (e.g., the polyelectrolyte multilayers described above). In some embodiments, the wound active agent(s) are covalently immobilized onto the matrix, for example, via a covalent modifier.

[0269] In some embodiments, one or more wound active agents are applied to form a gradient with respect to the wound modifier. Typically, the gradient is such that after applying the wound modifier to the wound, there is a higher concentration of the wound active agent at one or more of the first desired locations in the wound, and after applying the matrix to the wound, there is a lower concentration of the wound active agent at one or a second location in the wound. For example, the concentration of the wound active agent is layered in the wound bed in a vertical gradient such that there is a higher concentration of a particular composition proximal to the wound bed than distal to the wound bed. The reverse is also contemplated, such that the composition concentration is higher distal to the wound bed than proximal to the wound bed. The composition concentration in the wound bed is also contemplated to provide a horizontal gradient. Topographical gradients are also contemplated, where the composition is deposited in the wound bed or on the biocompatible particles such that the composition concentration follows the topography of the substrate, for example, a higher concentration of the composition is deposited in the valley of a typical substrate undulation compared to the peak of the undulation.

[0270] In some embodiments, the gradient has a higher concentration of wound active agent in the center of the matrix and a lower concentration of wound active agent away from the center of the matrix. Thus, when the matrix is ​​applied to a wound, the gradient will provide a higher concentration of wound active agent in the center of the wound and a lower concentration of wound active agent toward the wound edge. In some embodiments, the gradient has a lower concentration of wound active agent in the center of the matrix and a higher concentration of wound active agent away from the center of the matrix. Thus, the gradient will provide a lower concentration of wound active agent in the center of the wound and a higher concentration of wound active agent toward the wound edge. If more than one wound active agent is used, they may be present in the same gradient or the gradient may vary such that the concentration of the two or more wound active agents varies across the wound. The high or low concentration gradient may be any shape, such as a circle, square, rectangle, oval, ellipse, etc., so that the matrix and gradient can fit a variety of wound shapes. For example, for long incision type wounds, the gradient may be centered on the long axis extending along the length of the wound and may be in the center of the wound. In another example, the gradient may be circular or oval when applied to open wounds, burns, sores, and ulcers, which are generally circular or oval. In other embodiments, the gradient has a series of properties arranged in a pattern. For example, the gradient may form a series of stripes or high and low concentrations of one or more wound active agents along the long axis of the matrix. Alternatively, the gr...

Claims

1. 1. A wound active nanoscale polymer matrix microsheet comprising: a wound-active nanoscale polymer layer having an anti-biofilm agent incorporated therein; a second polymer layer adjacent to said wound active nanoscale polymer layer; Including, the anti-biofilm agent is selected from gallium ions, gallium ion salts, or gallium ion nanoparticles; said anti-biofilm agent being incorporated into said wound active nanoscale polymer layer at a concentration of 1-10 μg / cm 2 ; the second polymer layer being a dissolvable sacrificial polymer layer; When the microsheet is applied to a surface, the second polymer layer dissolves upon exposure to moisture, leaving the nanoscale polymer layer on the surface; said wound active nanoscale polymer layer being a polymer multilayer; A wound active nanoscale polymer matrix microsheet, wherein said polymer multilayer is formed by alternating at least one layer of positively charged polyelectrolyte with at least one layer of negatively charged polyelectrolyte.

2. The microsheet of claim 1, wherein the wound active nanoscale polymer layer is about 0.5 nm to 1000 nm thick.

3. 10. The microsheet of claim 1, wherein the wound active nanoscale polymer layer comprises a polymer selected from the group consisting of polyelectrolytes, lipids, proteins, collagen, hyaluronic acid, chitosan, keratin, fibronectin, vitronectin, laminin, polysaccharides, polyanhydrides, poly(lactic-co-glycolic acid) (PLGA), poly(L-lactic acid) (PLLA), and combinations or fragments thereof.

4. the at least one positively charged polyelectrolyte is selected from the group consisting of poly(allylamine hydrochloride) (PAH), poly-L-lysine (PLL), poly(ethyleneimine) (PEI), poly(histidine), poly(N,N-dimethylaminoacrylate), poly(N,N,N-trimethylaminoacrylate chloride), poly(methylacrylamidopropyltrimethylammonium chloride), and natural or synthetic polysaccharides such as chitosan; 2. The microsheet of claim 1, wherein the at least one negatively charged polyelectrolyte is selected from the group consisting of poly(acrylic acid) (PAA), poly(styrene sulfonate) (PSS), alginate, hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate, dextran sulfate, poly(meth)acrylic acid, oxidized cellulose, carboxymethyl cellulose, polyaspartic acid, and polyglutamic acid.

5. 2. The microsheet of claim 1, wherein the anti-biofilm agent incorporated into the wound active nanoscale polymer layer is incorporated into the nanoscale polymer multilayer such that the anti-biofilm agent is interspersed within the layer of the nanoscale polymer multilayer.

6. 10. The microsheet of claim 1, wherein the second polymer layer comprises a polymer selected from the group consisting of polyvinyl alcohol (PVA), polyacrylic acid (PAA), polystyrene (PS), polymethyl methacrylate (PMMA), or polyvinyl acetate (PVAc).

7. A medical device comprising the microsheet of claim 1.

Citation Information

Patent Citations

  • Methods of enhancing wound healing and tissue repair

    JP1993503924A

  • Methods and compositions for wound healing

    US20110189287A1

  • Gallium inhibits biofilm formation

    JP2007521112A

  • Antimicrobial composition for biofilm removal and its use

    JP2012515726A